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TIIVISTELMÄ
Hiilihappoanhydraasit (CA:t) ovat metalloentsyymejä, jotka katalysoivat
reversiibelisti hiilidioksidin hydraatiota bikarbonaatiksi ja protoniksi. CA-
entsyymejä tuotetaan monissa kudoksissa, joissa ne osallistuvat useisiin
fysiologisiin prosesseihin, kuten pH:n säätelyyn, CO2:n ja HCO3?:n kuljetukseen,
elimistössä olevien nesteiden tuotantoon, luun hajotukseen ja
aineenvaihduntareaktioihin. Nisäkkäiden CA-entsyymiperhe koostuu 13 aktiivisesta
isoentsyymistä, joista CA I, II, III, VII ja XIII sijaitsevat solulimassa, CA IV, IX,
XII, XIV ja XV ovat liittyneet solukalvoon, CA VA ja VB ovat mitokondriaalisia ja
CA VI on ainoa soluista erittyvä CA-entsyymi.
Tällä työllä oli neljä päätavoitetta. Ensimmäinen tavoite oli löytää CA IX:n ja CA
XII:n säätelijöitä, sillä hypoksiaa lukuun ottamatta niiden säätelijät tunnetaan
huonosti. Toinen tavoite oli tutkia näiden kahden isoentsyymin ilmentymistä hiiren
sikiönkehityksen aikana. Kolmas tavoite oli karakterisoida Car9-poistogeenisen
hiiren mahalaukussa tapahtuvia koko genomin laajuisia geenien transkriptiotasojen
muutoksia. Näillä hiirillä on havaittu mahalaukun epiteelin hyperplasiaa, mutta
tähän fenotyyppiin johtavat tarkat mekanismit ovat olleet tuntemattomia. Neljäs
tavoite oli tutkia tarkemmin proteiineja, joiden ilmentyminen on muuttunut Car9-
poistogeenisten hiirten mahalaukun limakalvolla.
Kvantitatiivisella reaalikaikaisella PCR -menetelmällä tehty tutkimuksemme
osoitti, että kasvutekijät IGF-1, TGF-?, TGF-?1 ja EGF nostivat CA IX:n ja CA
XII:n lähetti-RNA:n (mRNA) tasoja syöpäsolulinjoissa. CA IX:n mRNA:n taso
nousi vain yhdessä syöpäsolulinjassa, kun taas CA XII:n mRNA:n taso nousi
neljässä syöpäsolulinjassa. Näyttää siis siltä, että CA XII:n ilmentymisen tärkein
säätelijä ei ole hypoksia, kuten CA IX:n.
CA IX:n ja CA XII:n ilmentymistä hiiren organogeneesin aikana tutkittiin
immunohistokemiallisella värjäyksellä. Molempia isoentsyymejä ilmennettiin
useissa kehittyvän hiiren kudoksissa; osa näistä oli sellaisia, jotka eivät ilmennä
12
kyseisiä proteiineja aikuisella hiirellä. Siksi onkin mahdollista, että CA IX:ää ja CA
XII:ta tarvitaan tiettyjen kudosten muodostumiseen.
Car9-poistogeenisyyden aiheuttamia geenien transkriptiotasojen muutoksia
hiirten mahalaukuissa tutkittiin cDNA-mikrosirutekniikalla. Analyysi osoitti, että 86
geenin mRNA-taso oli noussut ja 46 geenin laskenut. Näiden geenien joukossa oli
sellaisia, jotka ovat mukana kehitykseen liittyvissä prosesseissa, solujen
erilaistumisessa ja immuunivasteissa. Nämä tulokset ja muiden tutkijoiden
aikaisemmat havainnot viittaavat siihen, että CA IX:n ensisijainen tehtävä mahassa
ei liity pH:n säätelyyn tai vaihtoehtoisesti CA IX on korvattavissa tätä toimintoa
ajatellen.
cDNA-mikrosirutekniikalla tehty tutkimus osoitti, että NCCRP1 (non-specific
cytotoxic cell receptor protein 1) -geenin mRNA-taso oli noussut tilastollisesti
merkitsevästi Car9-poistogeenisten hiirten mahalaukussa. Koska kyseinen geeni on
huonosti tunnettu, se valittiin jatkoanalyyseihin. Kun CA9 hiljennettiin
syöpäsolulinjassa, ei NCCRP1:n mRNA-taso muuttunut, mikä viittaa siihen, ettei
CA9 säätele suoraan NCCRP1:tä. Tutkimus osoitti myös, että NCCRP1 ilmentyy
sytosolissa. Bioinformatiikka-analyysit ehdottivat NCCRP1-proteiinin kuuluvan F-
box-proteiinien lektiini-tyypin alaperheeseen (FBXO-perhe). Kyseiset proteiinit
ovat E3-ubikitiiniligaasikompleksin osia. Koetulostemme mukaan NCCRP1 ei ole
solukalvoon kiinnittynyt immuunivasteita välittävä proteiini, kuten on ajateltu
aiemmin. Näin ollen NCCRP1:n nimi tulisi muuttaa FBXO50:ksi.
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ABSTRACT
The carbonic anhydrases (CAs) are a family of metalloenzymes that catalyze the
reversible hydration of carbon dioxide to bicarbonate and a proton. The CAs are
produced in a variety of tissues where they participate in several physiological
processes, such as pH regulation, CO2 and HCO3? transport, the production of body
fluids, bone resorption, and metabolic processes. The CA family consists of 13
active isozymes in mammals: CA I, II, III, VII, and XIII are cytoplasmic; CA IV,
IX, XII, XIV, and XV are anchored to plasma membranes; CA VA and VB are
mitochondrial; and CA VI is the only secreted protein.
This study had four specific aims. The first aim was to identify new regulators of
CA IX and CA XII. This aim was proposed because, besides hypoxia, the regulation
of these proteins is poorly characterized. The second goal was to examine the
expression profiles of these isozymes during mouse embryonic development. The
third aim was to investigate the whole-genome expression changes that occur in
response to CA IX deficiency in the mouse stomach. These mice exhibit gastric
hyperplasia, but the exact mechanisms leading to this disturbed cell lineage
phenotype remain unknown. The fourth and final goal was to elucidate further the
properties of some selected proteins that are dysregulated in the gastric mucosa of
Car9?/? mice.
Our studies demonstrate that the growth factors IGF-1, TGF-?, TGF-?1, and
EGF increase CA9 and CA12 mRNA expression in cancer-derived cell lines as
determined by quantitative real-time PCR (QRT-PCR). In the case of CA9, this
effect was observed in only one cell line, whereas CA12 was elevated by growth
factors in four cell lines. Thus, hypoxia may not be the primary regulator of CA12 in
contrast to CA9.
Immunohistochemistry was used to study CA IX and CA XII expression during
mouse organogenesis. These isozymes were detected in several tissues of which a
portion are negative for expression in adult mice. Therefore, it is possible that CA
IX and CA XII have specific roles in the assembly of certain tissues.
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The changes caused by CA IX deficiency in the mouse stomach were explored
using a cDNA microarray, which revealed the induction of 86 genes and the
repression of 46 genes. Among the genes with altered regulation were those
involved in developmental processes, cell differentiation and immune responses.
These data and previous findings by others suggest that the primary role of CA IX in
the stomach is not related to pH regulation or, alternatively, that its function in this
tissue is compensated for by other CA isozymes.
The microarray data indicated significant upregulation of non-specific cytotoxic
cell receptor protein 1 (Nccrp1), a poorly characterized gene that was selected for
further analyses. Silencing of CA9 in HeLa cells did not affect NCCRP1 levels,
suggesting that NCCRP1 is not directly regulated by CA9 and that its upregulation is
secondary to Car9 gene disruption. Moreover, it was demonstrated that human
recombinant NCCRP1 is expressed intracellularly. Bioinformatic analyses revealed
that NCCRP1 belongs to the lectin-type subfamily of F-box (FBXO) proteins, which
are components of the E3 ubiquitin ligase complex. In conclusion, our data clearly
demonstrate that NCCRP1 is not a transmembrane protein responsible for the
cytolytic function of nonspecific cytotoxic cells as has been previously suggested.
Therefore, the name of Nccrp1 should be changed to FBXO50.
15
1. INTRODUCTION
Carbonic anhydrases (CAs) (EC 4.2.1.1) are zinc-containing metalloenzymes that
catalyze the reversible hydration of carbon dioxide in the following reaction: CO2 +
H2O ? H+ + HCO3?. The importance of CA enzymes is emphasized by the fact that
they are found in a wide variety of organisms within the phylogenetic tree (Hewett-
Emmett 2000). In mammals, each characterized CA enzyme is a member of the ?-
CA family. This family consists of 13 active isozymes, 12 of which are expressed
and functional in humans (Hilvo et al. 2005). Each isozyme has a characteristic
subcellular localization, distribution within the body, enzymatic activity, and
affinity for inhibitors.
CA IX is a transmembrane protein with many unique properties compared to the
other CA isozymes. CA IX is expressed in only a few normal human tissues, but its
ectopic expression is induced in several cancers (Pastorekova and Zavada 2004).
Tissue oxygen content has been considered the primary regulatory mechanism of
CA IX. This regulatory mechanism is proposed because CA9 expression in tumor
tissues is linked with the hypoxic phenotype mediated by hypoxia-inducible
transcription factor 1 (HIF-1) (Wykoff et al. 2000). However, little is known of
other possible regulators of CA IX. In addition to the basic CA function, CA IX has
been implicated in several other processes. It is the only member of the CA family
that contains both a CA domain and a proteoglycan (PG) domain, which has been
suggested to participate in cell adhesion (Svastova et al. 2003). The study describing
Car9?/? mice demonstrated that CA IX deficiency leads to gastric pit cell
hyperplasia and a depletion of chief cells (Ortova Gut et al. 2002). Based on this
observation, it was concluded that CA IX probably regulates cell proliferation and
differentiation. Thus, it appears that the functions of CA IX extend far beyond that
of pH regulation.
Similar to CA IX, CA XII is a membrane-associated isozyme. However, CA XII
is expressed in a variety of normal tissues, and its expression generally becomes
stronger or more widespread in tumors compared to normal tissues. Accordingly,
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CA XII does not appear to be as tightly regulated by the hypoxia pathway or as
strongly linked to cancer as CA IX (Wykoff et al. 2000, Ivanov et al. 2001).
Therefore, it is likely that the regulators of CA XII are mainly undiscovered at
present.
This study aims to uncover other factors that regulate CA IX and CA XII in
addition to hypoxia. Moreover, the expression patterns of these isozymes during
mouse embryonic development is investigated, given that mammalian embryonic
and early fetal development occur in a hypoxic environment. Additionally, the
specific molecular mechanisms underlying the observed phenotype of CA IX-
deficient mice are examined in greater detail. The final aim is to examine further the
properties of NCCRP1 protein whose mRNA levels were observed to be
significantly upregulated in response to CA IX deficiency in the mouse gastric
mucosa.
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2. REVIEW OF THE LITERATURE
2.1 The importance of acid-base balance
Almost every biological process is pH-dependent, meaning that a small change in
pH can have large effects on the rate of a given process. This property is due to the
fact that many biological molecules, such as proteins, amino acids and phosphates,
contain chemical groups that can function as weak acids or weak bases that can
release or bind H+ ions, respectively. Thus, a change in pH may affect the
protonation state of these groups and, therefore, impact the biological activity and
conformation of the molecule. For example, enzymes typically demonstrate
maximal catalytic activity at a characteristic pH, which is referred to as the pH
optimum. On either side of the optimum pH, catalytic activity often declines
sharply. Therefore, biological control of cellular and extracellular fluid pH is highly
important for all aspects of metabolism and cellular activities. The organism's first
line of defense against changes in internal pH is provided by buffer systems. Three
important systems include the bicarbonate, phosphate, and ammonia buffer systems.
(Nelson and Cox 2000)
The bicarbonate buffer system is based on the following reactions: CO2 + H2O ?
H2CO3 ? H+ + HCO3?. In animals with lungs, the bicarbonate buffer system is an
effective physiological buffer at approximately pH 7.4. This property is observed
because the H2CO3 of blood plasma is in equilibrium with a large reserve capacity
of gaseous CO2 in the air space of the lungs. The dissociation of carbonic acid to
form bicarbonate and a proton is a rapid reaction that does not require enzymatic
catalysis. Alternatively, the hydration of carbon dioxide occurs too slowly without
catalysis. Thus, the carbonic anhydrase enzyme family evolved to catalyze a
reaction in which carbon dioxide is hydrated to form a proton and bicarbonate:
CO2 + H2O ? H+ + HCO3? (Nelson and Cox 2000, Supuran 2008).
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2.2 The carbonic anhydrase isozyme family
2.2.1 Historical and general aspects
In the beginning of the 20th century, it was not clear how bicarbonate was
transported in the blood and released in the lung capillaries; however, it was known
that the transit time of blood through the capillaries was only about 1 s. In the late
1920s, it was realized that blood probably contains a catalyst for this reaction
(Henriques 1928, Van Slyke and Hawkins 1930). Some years later, it became
evident that the catalyst in blood is, indeed, an enzyme (Meldrum and Roughton
1932, Meldrum and Roughton 1933). The name of this enzyme was reportedly
suggested by Philip Eggleton to be "carbonic anhydrase" (Davenport 1984).
Nevertheless, it was not until 1960 that the CA enzyme was purified for the first
time from bovine erythrocytes (Lindskog 1960).
To date, four evolutionarily unrelated CA gene families have been identified: ?,
?, ?, and ? (Chegwidden and Carter 2000). The ?-CAs are present in animals, plants,
algae, and certain eubacteria and viruses (Hewett-Emmett 2000). The ?-CAs have
been reported in many photosynthetic organisms, including plants and algae, but
they are also widespread among invertebrates (Hewett-Emmett 2000, Syrjanen et al.
2010). The ?-CAs are expressed primarily in archaea and some eubacteria, whereas
?-CAs are present in marine diatoms (Hewett-Emmett 2000, Xu et al. 2008). In the
active site of ?-, ?- and ?-CAs, the zinc atom is coordinated by three histidine
residues, whereas in ?-CAs it is coordinated by one histidine and two cysteine
residues (Cox et al. 2000).
In mammals, 13 enzymatically active ?-CAs have been identified. Of these CAs,
CA I, II, III, VII, and XIII are cytoplasmic (Lehtonen et al. 2004); CA IV, IX, XII,
XIV, and XV are membrane-associated (Pastorekova et al. 1997, Tureci et al. 1998,
Parkkila et al. 2001, Hilvo et al. 2005); CA VA and VB are mitochondrial
(Fujikawa-Adachi et al. 1999b); and CA VI is the only secreted isozyme (Kivela et
al. 1999, Karhumaa et al. 2001b). These enzymes catalyze a simple reaction,
specifically, the interconversion between carbon dioxide and the bicarbonate ion,
and are, therefore, involved in crucial physiological processes related to pH
homeostasis. These processes include CO2 and ion transport, respiration, bone
resorption, biosynthetic reactions (e.g., gluconeogenesis, lipogenesis, and
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ureagenesis), the production of body fluids, fertilization, tumorigenesis, and many
other physiological or pathological processes (Sly and Hu 1995, Parkkila 2000,
Supuran 2008). Each ?-CA isozyme has a characteristic distribution in mammalian
tissues; certain isozymes are expressed in certain cell types of nearly all tissues,
whereas others are expressed only in a small number of tissues. Furthermore, each
of these isozymes has a unique enzymatic activity and affinity for inhibitors. The
features of these isozymes are summarized in Table 1.
Table 1. Catalytic activities, inhibition constants of acetazolamide (AZA) and
subcellular localizations of all human CAs (hCAs) and mouse CA XV
(mCA XV). The table is modified from (Hilvo et al. 2008b).
Isozyme kcat (s-1) kcat/kM (M-1s-1) KI AZA (nM)
Subcellular
localization
hCA I 2.0 x 105 5.0 x 107 250 cytosol
hCA II 1.4 x 106 1.5 x 108 12 cytosol
hCA III 1.3 x 104 2.5 x 105 240000 cytosol
hCA IV 1.1 x 106 5.1 x 107 74 GPI-anchored
hCA VA 2.9 x 105 2.9 x 107 63 mitochondria
hCA VB 9.5 x 105 9.8 x 107 54 mitochondria
hCA VI 3.4 x 105 4.9 x 107 11 secreted
hCA VII 9.5 x 105 8.3 x 107 2.5 cytosol
hCA IX 1.1 x 106 1.5 x 108 16 transmembrane
hCA XII 4.2 x 105 3.5 x 107 5.7 transmembrane
hCA XIII 1.5 x 105 1.1 x 107 16 cytosol
hCA XIV 3.1 x 105 3.9 x 107 41 transmembrane
mCA XV 4.7 x 105 3.3 x 107 72 GPI-anchored
2.2.2 Catalytic mechanism
The ?-CAs are globular proteins that exhibit a considerable degree of three-
dimensional similarity and a typical folding structure characterized by a central
antiparallel ?-sheet (Di Fiore et al. 2009). The active site is located in a large, cone-
shaped cavity that reaches the center of the protein molecule. The metal ion, which
is Zn2+ in all ?-CAs examined to date, is essential for its catalytic mechanism
(Lindskog and Silverman 2000, Supuran 2004). The Zn2+ ion is coordinated by three
histidine residues (His94, His96 and His119 in CA II) and a water molecule or
hydroxide ion (Stams and Christianson 2000). The active form of the enzyme is
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basic with a hydroxide ion bound to Zn2+ (Lindskog and Silverman 2000). This
strong nucleophile attacks the CO2 molecule that binds in a nearby hydrophobic
pocket, leading to the formation of bicarbonate coordinated to Zn2+. The bicarbonate
ion is subsequently displaced by a water molecule and liberated into solution. This
results in the enzyme being in the acidic, catalytically inactive form with a water
molecule coordinated to Zn2+. This reaction is shown in Equation 1 (Lindskog and
Silverman 2000, Supuran 2004). To regenerate the basic form, a proton transfer
reaction from the active site to the environment takes place, which may be assisted
either by active-site residues or by buffers present in the medium. This reaction is
represented in Equation 2 (Lindskog and Silverman 2000, Supuran 2004).
(1) EZn2+?? OH? + CO2              EZn2+ ? HCO3?               EZn2+ ? OH2 + HCO3?
(2) EZn2+?? OH2              EZn2+ ? HO? + H+
The rate-limiting step in the catalysis is the proton transfer reaction (Equation 2).
In isozymes with high catalytic activity, this step is assisted by a histidine residue
(His64), which is termed a proton-shuttle residue and is located at the opening of the
active site (Tu et al. 1989). In addition to His64, a unique cluster of histidines is
thought to be important for the high catalytic activity of the CA II isozyme, ensuring
an efficient proton transfer process (Di Fiore et al. 2009). This property also
explains the fact that CA II is one of the most active enzymes known, approaching
the limit of diffusion control. Interestingly, in addition to its catalytic function, the
intramolecular proton shuttle supports a non-catalytic function of CA II by
enhancing the activity of acid- or base-transporting proteins in a direct, non-catalytic
manner (Becker et al. 2011).
In addition to the reversible hydration of carbon dioxide, ?-CAs can catalyze a
variety of other reactions, such as the hydration of cyanate to carbamic acid, the
hydration of cyanamide to urea, and other less-investigated processes. It is still
unclear whether CA-catalyzed reactions other than CO2 hydration have
physiological significance. (Supuran 2004)
Because CAs are involved in numerous physiological and pathological processes,
their inhibition has long been considered an important area of research. There are
two primary classes of CA inhibitors: the unsubstituted sulfonamides, including
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their bioisosteres (e.g., sulfamates and sulfamides) and metal-complexing anions.
Sulfonamide inhibitors bind to the Zn2+ ion via a substitution mechanism where the
sulfonamide is exchanged for the water molecule (Equation 3), whereas the anionic
inhibitors become a portion of the metal coordination sphere (Equation 4). (Supuran
2004)
(3) EZn2+ ? OH2 + I                 EZn2+ ? I + H2O   (substitution)
(4) EZn2+ ? OH2 + I                  EZn2+ ? OH2(I)   (addition)
Coumarins are a recently discovered class of CA inhibitors (Vu et al. 2008,
Maresca et al. 2009). They do not directly interact with the metal ion in the enzyme
active site, which is an interaction that is critical for the inhibition of CAs by other
classes of compounds, including sulfonamides and metal-complexing anions. In
fact, as shown by kinetic and X-ray crystallographic studies, coumarins are
mechanism-based inhibitors; they undergo hydrolysis under the influence of the
zinc-hydroxide in the nucleophilically active species of the enzyme, thereby
generating substituted-2-hydroxycinnamic acids. These acids bind at the entrance of
the active site cavity and block the entire entrance to it, thereby inhibiting the
catalytic activity of the enzyme (Maresca et al. 2010). Sulfonamides incorporating
coumarin rings have also been examined and were shown to possess a distinct
inhibition mechanism compared to the coumarins (Wagner et al. 2010). Thus, the
discovery of these compounds may further broaden the repertoire of CA inhibitors
against various enzymes of mammalian or parasitic origin.
CA inhibitors have been primarily used as diuretics and to treat glaucoma,
epilepsy and acute mountain sickness. A crucial problem in CA inhibitor design is
related to the high number of isoenzymes and their scattered localization in several
tissues and organs. Moreover, the use of presently available inhibitors is hampered
by their lack of isozyme selectivity. However, progress has recently been made in
the generation of CA-selective and isozyme-specific inhibitors; it is now possible to
design membrane-impermeant CA inhibitors, which may specifically inhibit
membrane-associated CAs without interacting with the cytosolic mitochondrial
isoforms. A further approach for selectively inhibiting the tumor-associated
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isoforms (CAs IX and XII) that are present in hypoxic tumor tissues makes use of
bioreductive prodrugs that are activated by hypoxia. (Supuran 2008)
Although CA inhibitors have been extensively examined, the subject of CA
activators has remained largely unexplored. However, over the past decade,
activators have been demonstrated to bind within the CA active cavity at a site
distinct from the inhibitor or substrate-binding sites. These activators facilitate the
proton-transfer step. Several physiologically relevant compounds, such as biogenic
amines (histamine, serotonin and catecholamines), amino acids, oligopeptides or
small proteins, act as efficient CA activators. It has been suggested that CA
activators may be used for treating Alzheimer’s disease and other conditions in
which the improvement of spatial learning and memory is necessary. (Supuran
2008)
2.2.3 Carbonic anhydrase-related proteins
Members of the ?-CA family encode not only proteins that possess the catalytic
activity of CA but also carbonic anhydrase-related proteins (CA-RPs). Members of
this latter group are devoid of CA catalytic activity, due to the absence of one or
more of the zinc-binding histidine residues. The CA-RPs that are found in mammals
include CA-RP VIII, X, and XI (Kato 1990, Hewett-Emmett and Tashian 1996,
Lovejoy et al. 1998). In addition, the receptor-type protein tyrosine phosphatases ?
and ? (RPTP? and RPTP?) contain 'CA-like' domains in their N-termini (Tashian et
al. 2000).
Studies on the distribution of CA-RPs have demonstrated wide expression
profiles in all parts of the human and mouse brain (Fujikawa-Adachi et al. 1999c,
Okamoto et al. 2001, Taniuchi et al. 2002). CA-RP VIII is predominantly expressed
in the human and mouse cerebellum, especially in Purkinje cells. However, weaker
expression has been detected in several other mouse tissues, including the liver,
submandibular gland, stomach, and lung (Aspatwar et al. 2010). In the same study,
CA-RP XI was shown to exhibit a similar expression pattern as CA-RP VIII,
although the staining intensity was clearly less intense. Moreover, CA-RP X
expression was only observed in a small number of tissues, including the brain. The
presence of CA-RPs in the human and mouse brain implies important roles for these
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proteins in brain development and/or neural function. Furthermore, CAs VIII and XI
appear to have a role in cancer development in the gastrointestinal tract and the
lungs (Akisawa et al. 2003, Miyaji et al. 2003, Morimoto et al. 2005, Ishihara et al.
2006, Nishikata et al. 2007).
Both RPTP? and RPTP? are expressed in specific areas of the developing and
adult central nervous system (CNS). In addition to their CA domain, their
extracellular portion consists of a fibronectin III (FN III) repeat domain and a Cys-
free domain. The long extracellular region is joined by a transmembrane region to
the intracellular catalytic D1 and D2 phosphatase domains. The exact roles of
RPTP? and RPTP? have not been fully elucidated. (Tashian et al. 2000)
2.3 Expression and function of carbonic anhydrase
isozymes
2.3.1 Cytosolic isozymes (I, II, III, VII, XIII)
CA I is highly expressed in human erythrocytes (Tashian 1989) but appears to
contribute only 50% of the total CA activity in these cells (Dodgson et al. 1988).
However, the presence of CA I may explain why no abnormal phenotype has been
detected in the erythrocytes of individuals with CA II deficiency syndrome (Sly and
Hu 1995). Alternatively, there is no clear abnormal phenotype in CA I-deficient
individuals, suggesting that other CA isozymes may complement the function of CA
I (Tashian 1992). In effect, the functional importance of CA I remains unclear. In
addition to erythrocytes, CA I is expressed in several other tissues, including the
epithelia of the esophagus, small intestine and colon and the ?-cells of the islets of
Langerhans (Lonnerholm et al. 1985, Parkkila et al. 1994, Christie et al. 1997).
Furthermore, CA I is expressed in the placenta and fetal membranes, the corneal
endothelium, the lens of the eye, sweat glands, adipose tissue, neutrophils and the
zona glomerulosa of the adrenal glands (Venta et al. 1987, Parkkila et al. 1993,
Campbell et al. 1994, Muhlhauser et al. 1994, Sly and Hu 1995). The gene encoding
CA I has two tissue type-specific promoters, which are separated by a large 35-36
kb intron (Fraser et al. 1989, Brady et al. 1991). One of these promoters is
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functional in erythrocytes, whereas the other produces a transcript in non-erythroid
tissues.
CA II is a highly active enzyme and has the widest expression pattern of all CA
isozymes. Accordingly, CA II is considered to play an important role in various
physiological reactions. CA II was first discovered in erythrocytes where it
catalyzes the reversible hydration of carbon dioxide (Meldrum and Roughton 1932,
Meldrum and Roughton 1933). In the human alimentary tract, CA II is thought to
participate in many processes. CA II is expressed in serous acinar cells of the
parotid and submandibular glands and is thought to supply the saliva with
bicarbonate (Parkkila et al. 1990). Similarly, CA II may contribute to the
bicarbonate production in the esophagus where it is expressed by the stratified
squamous epithelium (Parkkila et al. 1994). In the stomach, both surface epithelial
cells and parietal cells express high levels of CA II. In parietal cells, CA II produces
protons for gastric acid and further provides bicarbonate in the surface epithelial
cells to protect these cells from acid digestion (Davenport 1939, Parkkila et al.
1994). CA II is also expressed in the duodenum, colon, liver, gallbladder, pancreas
and brain (Maren 1967, Kumpulainen and Korhonen 1982, Parkkila et al. 1994).
Furthermore, CA II is expressed in renal tissues where it participates in the
acidification of urine (Parkkila 2000). In bones, CA II is expressed in osteoclasts
where it provides the protons required for bone resorption, and it has also been
proposed to contribute to osteoclast differentiation (Vaananen 1984, Lehenkari et al.
1998).
In addition to various normal tissues, CA II expression has been detected in
neoplastic tissues, including malignant brain tumors (Parkkila et al. 1995a,
Haapasalo et al. 2007, Korhonen et al. 2009), leukemia (Leppilampi et al. 2002),
lung cancer (Chiang et al. 2002), pancreatic cancer (Parkkila et al. 1995b),
colorectal cancer (Bekku et al. 2000), and gastrointestinal stromal tumors (GISTs)
(Parkkila et al. 2010). In some tumor types, such as astrocytomas, CA II expression
is associated with a poor prognosis (Haapasalo et al. 2007). In contrast, CA II
expression indicates a favorable prognosis in GISTs (Parkkila et al. 2010).
Moreover, CA II expression has been observed in tumor vessel endothelia,
suggesting that CA II may play a role in tumor angiogenesis (Yoshiura et al. 2005).
A deficiency of human CA II produces a syndrome that is characterized by
osteopetrosis, renal tubular acidosis, cerebral calcification, mental retardation, and
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impaired growth (Sly et al. 1983, Sly et al. 1985). Surprisingly, no gastrointestinal
symptoms have been described in CA II-deficient patients, despite the fact that CA
II is highly expressed in various tissues of the gastrointestinal tract. However, a
study of Car2 knockout mice demonstrated an abnormal histological phenotype
with impaired prostaglandin E2-mediated bicarbonate secretion in the duodenum
(Leppilampi et al. 2005b). This finding implies that there may be an abnormal
gastrointestinal phenotype in CA II-deficient patients.
CA III has unique properties among the CA isozymes, including low catalytic
activity, a resistance to sulfonamide inhibitors and an unusual tissue distribution.
The primary reasons for the low activity of CA III are the absence of the proton
shuttle residue His64 and the presence of Phe198 in place of Leu198 (Tu et al. 1989,
Chen et al. 1993, LoGrasso et al. 1993). CA III is primarily concentrated in skeletal
muscle type I fibers but is also present in other fiber types at lower levels (Vaananen
et al. 1985, Laurila et al. 1991). Additionally, CA III is highly expressed in adipose
cells (Stanton et al. 1991). Serum CA III is a potential marker of myocardial
infarction because these patients show a significantly increased serum
myoglobin/CA III ratio (Vaananen et al. 1990, Beuerle et al. 2000). The same ratio
may be useful in evaluating the success of reperfusion following acute myocardial
infarction (Vuotikka et al. 2003).
Given that CA III has a notably low catalytic activity, it is plausible that pH
regulation is not the primary function of this isozyme. In fact, several studies have
suggested that CA III may be an antioxidative agent. In NIH/3T3 cells, the
expression of CA III was demonstrated to protect the cells from hydrogen peroxide-
induced apoptosis (Raisanen et al. 1999). CA III expression is also increased in
experimentally-induced alcoholic liver disease (Parkkila et al. 1999). Furthermore, it
has been shown that CA III has two sulfhydryl groups that can conjugate to
glutathione (GSH) in a process termed S-glutathiolation (Mallis et al. 2000). This
process is important for protecting cells from reactive oxygen and nitrogen species
(Klatt and Lamas 2000). It is, therefore, somewhat surprising that CA III knockout
mice exhibit no apparent abnormal phenotype (Kim et al. 2004). However, it was
later found that CA III deficiency may impair mitochondrial ATP synthesis (Liu et
al. 2007).
CA VII is one of the least-examined and understood cytosolic CA isoforms, even
though it was identified and characterized 20 years ago (Montgomery et al. 1991).
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With respect to its amino acid sequence, CA VII appears to be the most highly
conserved CA isozyme in mammals (Earnhardt et al. 1998). CA VII is expressed in
the human salivary gland and in the mouse cerebrum and cerebellum (Montgomery
et al. 1991, Lakkis et al. 1997). In the brain, CA VII contributes to gamma-
aminobutyric acid (GABA)-mediated signaling by enabling the synchronous firing
of CA1 pyramidal neurons (Ruusuvuori et al. 2004). It was recently demonstrated
that there are two isoforms of CA VII of which the full-length form appears to be
the primary isoform expressed in vivo (Bootorabi et al. 2010). The same study also
demonstrated that in addition to the brain, CA VII is also expressed in several other
organs, including the stomach, duodenum, colon, liver, and skeletal muscle,
suggesting that this isozyme may play multiple roles in different organs.
CA XIII was first characterized in 2004 and was shown to be phylogenetically
most closely related to the cytosolic isozymes I, II, and III (Lehtonen et al. 2004).
CA XIII expression has been examined in human and mouse tissues by
immunohistochemistry. CA XIII is widely expressed in the gastrointestinal tract of
both species; however, the expression pattern is somewhat different between the two
species (Lehtonen et al. 2004, Pan et al. 2007). Moreover, both human and mouse
kidneys express CA XIII in the renal cortex and medulla with the strongest
expression detected in the collecting ducts (Lehtonen et al. 2004). In mice, CA XIII
is also expressed in the brain and lungs. Interestingly, CA XIII appears to be
abundant in reproductive tissues. In humans, different stages of developing sperm
cells express CA XIII, but the enzyme is not present in mouse testis. In the human
female reproductive tract, CA XIII is expressed in the uterine cervix, and certain
endometrial glands are also positive. In addition, CA XIII is expressed in the mouse
uterine epithelial cells. CA XIII expression in the reproductive tract indicates that
CA XIII may contribute to the fertilization process. Accordingly, it has been
observed that the inhibition constant of bicarbonate for mouse CA XIII is
exceptionally high (Innocenti et al. 2004). Therefore, it is plausible that this isozyme
is active in physiological environments characterized by high bicarbonate
concentration, such as reproductive tissues.
In neoplastic tissues, CA XIII has been investigated only in colorectal tumors
(Kummola et al. 2005). The results indicated that the expression pattern of CA XIII
is a similar to CAs I and II, i.e., expression becomes weaker with increasing
dysplasia and malignancy grades. It was suggested that this downregulation may
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result from reduced levels of a common transcription factor or the loss of the closely
linked CA1, CA2 and CA13 alleles on chromosome 8.
2.3.2 Mitochondrial isozymes (VA and VB)
Mitochondrial CA activity was originally observed several decades ago (Dodgson et
al. 1980), yet this enzyme was only later named CA V (Dodgson and Forster 1986).
It was not until 1999 that two nuclear-encoded mitochondrial CAs were described in
mammals (Fujikawa-Adachi et al. 1999b). Consequently, CA V was designated CA
VA, and the newly discovered enzyme was named CA VB. CA VA is abundantly
expressed in the liver and, to a lesser degree, in the skeletal muscle and kidney. CA
VB is ubiquitously expressed in several tissues, excluding the liver in humans; it is,
however, expressed in the mouse liver (Fujikawa-Adachi et al. 1999b, Shah et al.
2000). Mitochondrial CAs have been suggested to contribute to several metabolic
processes, such as gluconeogenesis, lipogenesis and ureagenesis, by providing
bicarbonate for the early carboxylation reaction (Chegwidden et al. 2000).
2.3.3 Secretory isozyme (VI)
CA VI is the only secreted member of the CA family (Fernley et al. 1979). CA VI is
secreted into the saliva by the serous acinar cells of the parotid, submandibular
(Parkkila et al. 1990), and lingual von Ebner's glands (Leinonen et al. 2001). It has
been shown that salivary CA VI concentrations follow a circadian periodicity with
low levels observed during the sleeping period (Parkkila et al. 1995c). CA VI is also
secreted into milk by the mammary glands (Karhumaa et al. 2001b). Furthermore,
CA VI has been detected in the lacrimal (Ogawa et al. 2002), nasal, septal, and
lateral glands (Kimoto et al. 2004), the esophagus (Kasuya et al. 2007), the
tracheobronchial glands, epithelial serous cells (Leinonen et al. 2004), and the
alimentary canal (Kaseda et al. 2006). Low concentrations of CA VI have also been
observed in human serum because small amounts leak from the salivary glands or
are absorbed from the alimentary canal (Kivela et al. 1997).
Even though CA VI has been studied for 30 years, its physiological role is still
uncertain. It has been suggested that salivary CA VI may protect teeth from caries
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(Kivela et al. 1999, Kimoto et al. 2006). It is also thought that CA VI may protect
the esophageal and gastric epithelium from acid injury, given that low CA VI
concentrations are linked to the appearance of acid-peptic diseases in many patients
suffering from gastrointestinal (GI) disorders (Parkkila et al. 1997). CA VI has also
been proposed to be an essential factor in normal growth and development of the
infant alimentary tract, given that it is found in both human and rat milk with
particularly high concentrations in the colostrum (Karhumaa et al. 2001b).
Furthermore, it has been suggested that CA VI contributes to the growth and
development of taste buds (Henkin et al. 1999). A stress-inducible form of CA VI
has also been described (Sok et al. 1999). This form is expressed from an internal
promoter and encodes an intracellular form of the protein. However, the
physiological significance of the stress-inducible form is unknown.
A recent study reported the generation and phenotype of CA VI-deficient mice,
which were viable and fertile and had a normal life span (Pan et al. 2011a). No
morphological differences were observed between knockout and wild-type mice in
the salivary, lacrimal, or mammary glands, all of which are known to secrete CA VI.
The only histological difference between the knockout and control mice was that the
number of lymphoid follicles in small intestinal Peyer’s patches was substantially
higher in adult knockout mice than in wild-type mice. Analysis of the transcriptomic
differences between Car6?/? and wild-type mice revealed that genes important in
catabolic processes were downregulated in both the submandibular gland and
stomach, although they were upregulated in the duodenum. This finding may
suggest a functional role for CA VI in catabolic processes.
2.3.4 Membrane-bound isozymes (IV, XIV, XV)
CA IV is attached to the cell membrane with a glycosylphosphatidylinositol (GPI)-
anchor and was originally observed in the lung and kidney (Whitney and Briggle
1982, Wistrand and Knuuttila 1989). CA IV is expressed in multiple tissues and has
been shown to perform important functions. The presumed function of CA IV in the
lung is to catalyze the dehydration of plasma HCO3? to  CO2, which can readily
diffuse across the capillary endothelial surface and pass out of the lungs through
expiration (Zhu and Sly 1990). CA IV has been found in the thick ascending limb
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and S2 segments of the proximal tubules in the rat kidney (Brown et al. 1990) and in
the intercalated cells of the rabbit collecting duct (Schwartz et al. 2000), suggesting
that this isozyme contributes to HCO3? reabsorption. CA IV has been principally
observed in the luminal membranes of the kidney, and some expression has been
reported in the basolateral membranes (Brown et al. 1990, Purkerson et al. 2007). In
the gastrointestinal tract, CA IV was detected in the submucosal capillary
endothelium of all gastrointestinal regions and in the apical plasma membranes of
the epithelial cells in the small and large intestine, where it is proposed to participate
in ion and water transport (Fleming et al. 1995). CA IV is also expressed in the
apical plasma membrane of gallbladder epithelial cells and in the endothelium of the
subepithelial capillaries, suggesting that it may participate with CA II and ion
transporters in the acidification of bile via bicarbonate reabsorption (Parkkila et al.
1996). Furthermore, CA IV is expressed in several other tissues, including skeletal
and heart muscle (Sender et al. 1994, Sender et al. 1998), the brain (Ghandour et al.
1992) and the eye (Hageman et al. 1991).
It has been suggested that CA IV may form a metabolon with CA II and several
other anion exchange proteins because CA II and CA IV have been experimentally
shown to interact with several anion exchange proteins, including Cl?/HCO3?
exchangers, Na+/HCO3? cotransporters and Na+/H+ exchangers. Therefore, it has
been proposed that CA II and CA IV may facilitate the rate of anion exchange
across the plasma membrane in physiologically relevant tissues, such as renal
tubules (Purkerson and Schwartz 2007).
CA XIV was originally characterized by two independent research groups from
the mouse kidney (Mori et al. 1999) and human spinal cord (Fujikawa-Adachi et al.
1999a). In terms of amino acid similarity, CA XIV is most closely related to CA
XII. CA XIV is expressed in various human and mouse tissues, including the
kidney, heart, brain, skeletal muscle, and liver (Fujikawa-Adachi et al. 1999a, Mori
et al. 1999). In the mouse kidney, CA XIV is abundantly expressed in the apical
plasma membranes of the S1 and S2 segments of the proximal tubules and, more
weakly, in the basolateral membranes (Kaunisto et al. 2002). It is also present in the
initial portion of the thin descending limbs of Henle. These results indicate that CA
XIV is likely to contribute to the acidification of urine in cooperation with CA IV.
In the mouse liver, CA XIV is also expressed on both the apical and basolateral
plasma membranes of hepatocytes (Parkkila et al. 2002). Moreover, CA XIV has
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been observed on neuronal membranes and axons in the human and mouse brain
(Parkkila et al. 2001). The highest degree of expression is observed on the large
neuronal bodies and axons in the anterolateral portion of pons and medulla
oblongata. Furthermore, it has been demonstrated that both CA XIV and CA IV
contribute to extracellular buffering in the central nervous system (CNS) (Shah et al.
2005). Interestingly, CA XIV has been shown to interact with the AE3 Cl?/HCO3?
exchanger in the CNS, indicating that the AE3/CA XIV metabolon constitutes a
system to dispose of high CO2 and H+ production and to regulate pH in the brain and
retina (Casey et al. 2009).
CA XV is the most recently identified member of the mammalian CA family and
was characterized in 2005. CA XV appears to be a unique member of the CA family
because the gene encoding this isozyme is a non-processed pseudogene in humans
and chimpanzees. In contrast, several other species appear to possess an active gene
coding for CA XV. According to sequence analysis, this isozyme is evolutionarily
conserved from fish to mammals but has become an inactive gene recently in the
evolutionary timescale. Phylogenetic analyses have indicated that CA XV is most
closely related to CA IV. In fact, the biochemical properties of CA XV are similar to
those of CA IV; both isozymes are attached to the cell membrane by a GPI anchor
and are N-glycosylated. The activity of mouse CA XV has been shown to be
comparable to that of human CA XII and XIV, placing CA XV within the group of
CAs with moderate levels of catalytic activity. (Hilvo et al. 2005)
The distribution of Car15 in different mouse tissues is quite limited with
expression being observed predominantly in the kidney. Within this organ, the
highest signal is observed in the renal cortex and lower expression is seen in the
medulla (Hilvo et al. 2005). In a recent study, the localization of CA XV in the
kidney was confirmed at the protein level (Saari et al. 2010). Moreover, a systematic
study of CA mRNA expression in the mouse digestive system showed that Car15
expression is extremely low in the gastrointestinal tract (Pan et al. 2007). The
absence of CA XV in some species raises the questions of why it was lost during
evolution and why it is not required in humans. It is possible that CA IV and CA
XV are functionally redundant and that a highly active human CA IV may
compensate for the loss of CA XV.
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2.3.5 Membrane-bound isozyme IX
2.3.5.1 General aspects
CA IX was originally named MN protein and was identified as a cell density-
regulated plasma membrane antigen in the HeLa human cervical carcinoma cell line
using the monoclonal antibody M75 (Pastorekova et al. 1992). The MN antigen was
detected in several tumor cell lines and surgical tumor specimens but not in
corresponding normal tissues (Zavada et al. 1993). These two pioneering studies
revealed the connection between the MN protein and cancer. Later, the full-length
cDNA for the MN protein was cloned and was found to contain a large CA domain
in the extracellular portion of the encoded protein (Pastorek et al. 1994, Opavsky et
al. 1996). Sequence analysis revealed that the MN gene encodes a 459-amino acid
protein. The protein consists of a 414-amino acid N-terminal extracellular portion
followed by 20-amino acid hydrophobic transmembrane region and a 25-amino acid
C-terminal intracellular tail. The extracellular portion of the protein is composed of
a 37-amino acid signal peptide, a 59-amino acid proteoglycan (PG) domain with
similarity to the keratan sulfate-binding domain of the large proteoglycan aggrecan,
and a 257-amino acid CA domain. Because the CA domain was found to be well-
conserved, exhibiting significant identity with CA VI, II, and other CA isozymes,
the MN protein was renamed carbonic anhydrase IX as the ninth mammalian CA
identified (Hewett-Emmett and Tashian 1996). Moreover, CA IX is the only
member of the CA isozyme family with both PG and CA domains.
In an independent line of research, the monoclonal antibody G250 was reported
to recognize a specific antigen in renal cell carcinomas (RCCs) (Oosterwijk et al.
1986). Much later, this antigen was shown to be identical to CA IX (Oosterwijk
2008).
CA IX is a dimeric enzyme, and the dimerization is suggested to be mediated by
the formation of an intermolecular disulfide bond between the same Cys residue on
the CA catalytic domain of the two monomers (Hilvo et al. 2008a, Alterio et al.
2009). According to crystallographic data, both active sites of the dimer are exposed
to the extracellular medium for efficient CO2 hydration (Alterio et al. 2009). The
catalytic activity of the entire extracellular portion of CA IX (composed of the PG
and CA domains) that is expressed in the baculovirus system is high and is in the
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same range as CA II (Hilvo et al. 2008a). Furthermore, the addition of ZnCl2
increased the catalytic activity of the insect-cell derived human enzyme by
approximately 10-fold. Thus, CA IX appears to possess the highest catalytic activity
that has ever been measured for a human CA enzyme. The three-dimensional
structure of the dimeric CA IX catalytic domain is presented in Figure 1.
Figure 1. The X-ray structure of the dimeric CA IX catalytic domain. This figure was
generated from X-ray coordinates as reported previously (Alterio et al. 2009).
The PDB ID for the structure is 3IAI, and the figure was generated using the
PyMOL Molecular Graphics System, Version 1.3 (Schrödinger, LLC). The Zn2+
ion and intramolecular disulfide bond are shown in purple and yellow,
respectively.
2.3.5.2 Expression in normal tissues
CA IX has an exceptional expression pattern, as it is only expressed in a small
number of normal tissues; however, its ectopic expression is induced in a wide
spectrum of human tumors. CA IX expression has been reported in human, rat, and
mouse tissues.
In humans, CA IX expression has been examined thoroughly in the alimentary
tract (Pastorekova et al. 1997). The strongest expression is detected in the gastric
mucosa from the gastric pits to the deep gastric glands and is confined to the
basolateral surface of the epithelial cells. Staining is observed in all of the major cell
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types of the gastric epithelium, including the surface epithelial cells, parietal cells
and glandular chief cells. In the human intestine, the most intense CA IX expression
is observed in the crypt enterocytes of the duodenum and jejunum (Saarnio et al.
1998b). Moderate staining is detected in the crypts of the ileum, cecum, and
ascending colon. Expression becomes weaker toward the rectum. In addition to the
gastric and intestinal epithelium, the gallbladder epithelium also shows abundant
expression of CA IX (Pastorekova et al. 1997). Furthermore, CA IX is expressed
moderately in the basolateral membrane of epithelial cells in the bile ducts and
faintly in the pancreatic ducts (Pastorekova et al. 1997). Varying expression
intensities of CA IX in humans have been observed in the coelomic epithelium of
the body cavities, the rete ovarii, the rete testis and efferent ducts, the ventricular
linings of the CNS and the choroid plexus (Ivanov et al. 2001, Karhumaa et al.
2001a).
In rats, staining for CA IX is strong in the stomach with the same expression
pattern as in humans. In the rat intestine, epithelial staining is present in the
duodenum and colon but is absent from sections of the jejunum and ileum. Again,
the positive reaction is confined to the basolateral surface of the epithelium. In the
rat colon, the distribution of CA IX through the mucosal layer is different from that
of humans, as the positive signal is strongest in the surface epithelium. In human
colon, however, expression is highest at the base of the crypts. CA IX is also present
at the basolateral plasma membrane of rat bile ducts but is absent from the
pancreatic ducts. (Pastorekova et al. 1997)
In mice, the highest expression of CA IX has been observed in the stomach,
where it is confined to the basolateral plasma membrane of the surface epithelial
cells, chief cells and parietal cells, similar to humans and rats. Moderate expression
has been observed in the colon with the strongest reaction in the surface epithelial
cuff region. In the mouse small intestine, CA IX expression is generally weak. A
moderate level of expression has been detected in the pancreas, brain, and
cerebellum. Lower levels of CA IX are expressed in the mouse liver, spleen,
thymus, epididymis, testis, and kidney. (Hilvo et al. 2004)
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2.3.5.3 Expression in neoplastic tissues
CA IX is ectopically expressed at relatively high levels and with a high prevalence
in different tumor tissues with normal counterparts that show low levels of this
protein or none at all. These include carcinomas of the brain, lung, esophagus,
colon, pancreas, liver, breast, endometrium, ovary, skin, and kidney (Liao et al.
1997, McKiernan et al. 1997, Turner et al. 1997, Saarnio et al. 1998a, Vermylen et
al. 1999, Kivela et al. 2000b, Ivanov et al. 2001, Saarnio et al. 2001, Bartosova et al.
2002). In contrast, tissues with high natural CA IX expression, such as the stomach
and gallbladder, have been shown to lose a portion of or all CA IX expression upon
conversion to carcinoma (Saarnio et al. 2001, Leppilampi et al. 2003). In the colonic
epithelium, CA IX is normally expressed in the deep crypts and abnormally in
superficial adenomas and carcinomas; the most intense staining is detected in
tumors with a mucinous component (Saarnio et al. 1998a). For unknown reasons,
CA IX is generally absent from normal prostate tissues and from prostate
carcinomas. CA IX overexpression has correlated with poor prognosis in a broad
spectrum of tumor types (Chia et al. 2001, Giatromanolaki et al. 2001, Loncaster et
al. 2001, Haapasalo et al. 2006).
Cancers that contain a high proportion of CA IX-positive specimens include
carcinomas of the cervix, lung, and kidney. CA IX is expressed in virtually all
cervical carcinomas and the majority of cervical intraepithelial neoplasias (Liao et
al. 1994). In lung cancer, CA IX is not found in preneoplastic lesions but is present
in malignant tumors with expression being associated with tumor aggressiveness,
hypoxia, and necrosis (Vermylen et al. 1999, Giatromanolaki et al. 2001, Swinson et
al. 2003). In renal cell carcinomas (RCCs), CA IX is most strongly expressed in
clear cell RCCs (ccRCC), the most common form of RCC, and is expressed in
virtually all cases (Uemura et al. 1999). High levels of CA IX protein and/or mRNA
are detected in primary, cystic, and metastatic ccRCCs but not in benign lesions
(Liao et al. 1997, McKiernan et al. 1997). However, in contrast to several other
cancers, it appears that decreased CA IX expression levels predict a poor prognosis
for RCC patients (Bui et al. 2003, Sandlund et al. 2007).
Because there is a clear division between tissues with normal and ectopic
expression, CA IX has been proposed to be a promising tumor biomarker and a
potential therapeutic target. In fact, the anti-CA IX antibody Rencarex® is currently
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being investigated in a phase III clinical trial (www.wilex.de) as a treatment for non-
metastatic ccRCC. In phase I and II studies, Rencarex® was demonstrated to be safe
and well-tolerated and exhibited a promising efficacy profile.
2.3.5.4 Knockout mouse model
The generation of Car9 knockout mice revealed that CA IX is required for normal
gastric morphogenesis, as these mice exhibit gastric hyperplasia of the glandular
epithelium and numerous cysts (Ortova Gut et al. 2002). The most pronounced
hyperplasia was in the stomach corpus region. No changes were visible in CA IX-
deficient mice during embryonic development, but an increase in mucosal thickness
was detected in newborn animals. The hyperplasia became prominent at the end of
gastric morphogenesis in four-week-old mice but did not progress with age. The loss
of CA IX led to an overproduction of mucus-secreting pit cells and a depletion of
pepsinogen-positive chief cells. The absolute number of parietal cells was increased
in the Car9 knockout mice, but the proportion of these cells was significantly
reduced when compared to the gastric epithelium of wild-type mice. These
alterations suggest that CA IX may contribute to the balance between differentiation
and proliferation in the gastric mucosa.
Based on the available evidence, CA IX-deficiency does not appear to have
serious physiological consequences; Car9?/? mice showed normal gastric pH, gastric
acid secretion, and gastrin serum levels. In addition, systemic acid-base balance and
plasma electrolyte values were normal in CA IX-deficient mice. These mice showed
no deviations from their wild-type controls in terms of growth, behavior,
reproductive potential, health, or life span. Moreover, CA-deficiency had no effect
on the morphology or histology of other tissues, including the lung, spleen, liver,
kidney, jejunum, ileum, and colon.
Given that hyperplasia can lead to dysplasia or malignancy in the presence of
carcinogenic factors, it has been studied whether the effects of CA IX deficiency
may be modified by a high-salt diet, which is a known co-factor of carcinogenesis
(Leppilampi et al. 2005a). Two strains of CA IX-deficient mice, C57BL/6 and
BALB/c, were fed either a standard or high-salt diet for 20 weeks. Excess dietary
salt did not significantly affect the severity of pit cell hyperplasia, and dysplasia was
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not observed in any of the groups. In C57BL/6 mice, however, CA IX-deficiency
was associated with gastric submucosal inflammation. Thus, these results indicate
that CA IX deficiency alone may not be a significant carcinogenic factor but may
initiate a carcinogenic process by affecting cell proliferation and/or differentiation in
the gastric mucosa.
The brain phenotype of CA IX-deficient mice was published recently (Pan et al.
2011b). In a one-year study, the brain histology and behavior of Car9?/? and wild-
type mice were monitored. Morphological analyses revealed vacuolar degenerative
changes in the brains of Car9?/? mice. These changes became visible at the age of
eight to ten months. Behavioral tests indicated that Car9?/? mice exhibited abnormal
locomotor activity and poor performance in a memory test. Furthermore, the
transcriptomic responses to CA IX deficiency in the brain were examined using
genome-wide cDNA microarray analyses. Thirty-one and 37 genes were
significantly up- or downregulated, respectively, in the brains of CA IX-deficient
mice compared to wild-type animals. Functional annotation showed that the genes
with increased expression were involved in several processes, such as RNA
metabolism, whereas the genes with reduced expression were implicated in other
important processes, such as the regulation of cellular ion homeostasis. Consistent
with the behavioral phenotype, the biological processes ‘‘behavior’’ and
‘‘locomotory behavior’’ were the two prominent terms overrepresented among the
down-regulated genes. Based on these observations, the authors concluded that CA
IX may directly or indirectly have novel functions in the brain.
2.3.5.5 Functional role
There is emerging evidence that the roles of CA IX extend far beyond the basic pH
regulation function of CAs. For example, CA IX is the only member of the CA
isozyme family with both the CA catalytic domain and the PG domain.
Accordingly, CA IX was suggested to participate in cell adhesion processes
(Pastorekova and Zavada 2004).
In normal tissues, the distribution pattern of CA IX is relatively limited. It has
been proposed to participate in the regulation of the acid-base balance on the
basolateral surfaces of the gastrointestinal tract epithelia. In addition to the other
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major cell types of gastric mucosa, CA IX is highly expressed in the parietal cells,
suggesting a role in acid secretion. In fact, CA IX has been shown to interact
functionally and physically with the SLC4 family of Cl?/HCO3? anion exchange
proteins, including AE1, AE2, and AE3. Moreover, CA IX colocalizes with AE2 at
the basolateral plasma membrane of parietal cells. Therefore, it is conceivable that
these proteins form a bicarbonate transport metabolon. Upon stimulation, the
parietal cells of the gastric mucosa actively secrete H+ into the gastric lumen, and
Cl? concomitantly moves through Cl? channels. To sustain acid secretion, parietal
cells must replace the HCl lost at the apical surface using two coupled processes. At
the parietal cell's basolateral surface, CO2 diffuses into the cell from adjacent
capillaries. CA II catalyzes CO2 conversion, producing HCO3? and  H+ and thus
supplying the parietal cells with protons. In the basolateral membrane, Cl?/HCO3?
exchangers extrude excess HCO3? while importing Cl?, thereby regulating the
intracellular pH. The basolateral localization of CA IX enables it to catalyze the
conversion of extruded HCO3?, thereby plausibly contributing to gastric acid
secretion as part of the AE2-CA II-CA IX bicarbonate transport metabolon.
(Morgan et al. 2007)
In tumor tissues, CA IX expression is strongly linked with a hypoxic phenotype,
implicating a role for this enzyme in the pH regulation of malignancies. Hypoxia
occurs frequently in tumors as a result of aberrant vasculature. Hypoxia triggers the
development of acidosis, due to the induction of metabolic shift from oxidative
phosphorylation to aerobic glycolysis. While glycolytic metabolism helps tumor
cells meet their energy demands in low-oxygen conditions, it also generates an
excess of acidic products, such as lactic acid, H+ and CO2. These products must
subsequently be extruded from the cell.
A proposed involvement of CA IX in the pH regulation of tumors is based on a
model that includes a bicarbonate transport metabolon (Pastorekova and Zavada
2004). As an extracellular component of the metabolon, CA IX probably hydrates
carbon dioxide, thereby providing bicarbonate for the anion exchanger (AE). Next,
the AE transports bicarbonate molecules to the cytoplasm in exchange for chloride.
In the cytosol, CA II may convert bicarbonate to carbon dioxide, which would
subsequently diffuse out through the plasma membrane, leading to neutralization of
the internal pH. At the same time, the protons generated by the activity of CA IX
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would contribute to the acidification of the extracellular space. The transport
metabolon is illustrated in Figure 2.
Figure 2. A proposed model of the role of CA IX in the pH regulation of hypoxic tumors.
The transport metabolon is composed of an anion exchanger (AE) and CAs II
and IX (refer to text for details). The figure is adapted from a prior study
(Pastorekova and Zavada 2004).
In fact, there is experimental evidence regarding the functional involvement of
CA IX in pH regulation. For example, CA IX was shown to contribute to the
acidification of the extracellular microenvironment in hypoxic tumor cells (Svastova
et al. 2004). CA IX also minimizes the intracellular pH gradient and increases the
extracellular pH gradient in the core of three-dimensional tumor spheroids but not in
isolated cells (Swietach et al. 2008). Furthermore, CA IX contributes to extracellular
acidification and more alkaline resting intracellular pH in response to CO2 load,
thereby supporting cell survival during acidosis (Chiche et al. 2009). The regulation
of CA IX by hypoxia may have a strong effect on cancer progression because an
acidic extracellular microenvironment has been shown to contribute to the
aggressiveness of tumors by promoting invasion and metastasis (Harris 2002).
Accordingly, the silencing of CA9 mRNA has been demonstrated to lead to a 40%
reduction in tumor growth in vivo, whereas the silencing of both CA IX and CA XII
results in an impressive 85% reduction in tumor growth (Chiche et al. 2009).
Another important function of CA IX is related to cell adhesion and intercellular
communication. CA IX was first shown to mediate cell attachment to solid support,
and this phenomenon was blocked by an M75 antibody that binds to the CA IX PG
domain (Zavada et al. 2000). In addition, experiments with Madin-Darby canine
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kidney (MDCK) epithelial cells have shown that CA IX can reduce E-cadherin-
mediated cell-cell adhesion by interacting with ?-catenin (Svastova et al. 2003).
This function of CA IX is in agreement with the proposal that hypoxia can initiate
tumor invasion via decreased E-cadherin-mediated cell-cell adhesion and suggests
that CA IX may participate in this process.
The third role of CA IX is its contribution to cell proliferation and differentiation,
which was revealed by the generation of CA IX knockout mice and is reviewed in
detail in a previous section.
Finally, CA IX has been implicated in cell signaling (Dorai et al. 2005). In renal
carcinoma cells, the tyrosine residue in the intracellular tail of CA IX can be
phosphorylated in an EGF-dependent manner, thereby leading to interaction with
the regulatory subunit of phosphatidylinositol 3-kinase (PI3K). This kinase can
subsequently contribute to the activation of the serine/threonine protein kinase Akt
and, thereby, to cancer progression.
2.3.6 Membrane-bound isozyme XII
2.3.6.1 General aspects
CA XII was identified a few years after CA IX in two independent studies. CA XII
was first identified in a human RCC by serological expression screening with
autologous antibodies (Tureci et al. 1998). In this study, CA12 mRNA was shown to
be overexpressed in approximately 10% of RCC patients. Nearly simultaneously,
CA XII was cloned as a novel target of von Hippel Lindau protein (pVHL) using
RNA differential display (Ivanov et al. 1998). It was also demonstrated that CA12
expression is strongly inhibited by wild-type pVHL in RCC cell lines, suggesting
that it is regulated in a similar manner as CA9.
CA XII is expressed as a 354-amino acid protein consisting of a 29-amino acid
signal peptide, a 261-amino acid CA domain, a 9-amino acid juxtamembrane
segment, a 26-amino acid transmembrane domain, and a 29-amino acid cytoplasmic
tail. The molecular weight of human CA XII expressed in COS-7 cells is 43-44 kDa
and is reduced to 39 kDa following PNGase treatment, indicating that CA XII has
two N-linked glycosylations. (Tureci et al. 1998)
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The catalytic activity of recombinant human CA XII in Chinese hamster ovary
(CHO) cells was shown to be similar to that of the high-activity human membrane-
associated CA IV (Ulmasov et al. 2000). The crystal structure of the extracellular
domain of CA XII produced in E. coli revealed that the active site cavity is similar
to those of CA II and IV (Whittington et al. 2001). It was also demonstrated that CA
XII contains one intramolecular disulfide bond and forms dimers. Moreover, the
transmembrane domain of CA XII was shown to contain GXXXG and GXXXS
motifs that are considered to contribute to this dimerization.
2.3.6.2 Expression in normal tissues
In contrast to CA IX, CA XII has been detected in several normal tissues (Ivanov et
al. 2001). Initially, CA9 mRNA was observed to be expressed in the normal adult
kidney, pancreas, colon, prostate, ovary, testis, lung, and brain (Ivanov et al. 1998,
Tureci et al. 1998). In addition to the human expression pattern, CA XII protein
expression has also been examined in rodents.
In humans, CA XII expression is observed on the epithelial cells of the
endometrium where it is present on the basolateral membrane (Karhumaa et al.
2000). It is possible that CA XII participates in the reproductive functions of the
uterus by contributing to bicarbonate production. Additionally, CA XII may affect
the morphological changes in the uterus that occur during the menstrual cycle. CA
XII is also expressed on the basolateral membrane of the epithelial cells in the male
efferent ducts (Karhumaa et al. 2001a).
In the human gut, CA XII is expressed in all segments of the large intestine but is
absent from the small intestine (Kivela et al. 2000a). Staining is detected on the
basolateral plasma membrane of the enterocytes with the reaction being most
intense in the surface epithelial cuff region. Thus, CA XII may play a role in the net
acidification and concentration of the extracellular fluid.
In human renal tissues, CA XII is highly expressed in the basolateral plasma
membrane of the epithelial cells in the thick ascending limb of Henle, the distal
convoluted tubules, and in the principal cells of the collecting ducts (Parkkila et al.
2000). A weak basolateral signal was also observed in the epithelium of the
proximal convoluted tubules. Additionally, CA XII expression has been
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demonstrated in the pancreatic epithelium where it is present on the basolateral
plasma membrane of acinar and ductal cells (Kivela et al. 2000b). CA XII is also
weakly expressed in the gastric mucosa (Leppilampi et al. 2003) and in the eye
where the expression has been shown to increase in the non-pigmented ciliary
epithelial cells of patients with glaucoma (Liao et al. 2003).
In mice and rats, CA XII is expressed in the kidney (Kyllonen et al. 2003). In the
mouse kidney, CA XII is present in the proximal tubules and in the intercalated cells
of the collecting ducts. Positive staining for CA XII is restricted to the basolateral
plasma membrane, while the luminal brush border membrane remains negative.
This staining pattern is echoed in the rat kidney; however, the expression intensity is
weaker in the proximal tubules.
CA XII expression has also been demonstrated in other mouse tissues (Halmi et
al. 2004). While CA XII is not expressed in the stomach, duodenum or jejunum,
there is a faint staining signal in ileal enterocytes. The staining reaction is much
more intense in the colon and rectum. Similar to expression in the human large
intestine, the strongest expression in mice is observed in the surface epithelial cuff
region. In the same study, weak staining was also detected in developing sperm
cells. Furthermore, CA XII expression has been observed in the epithelial cells of
the mouse endometrium with the deeper endometrial glands stained most intensely
(Hynninen et al. 2004). In rats, CA XII was detected in the epididymis (Hermo et al.
2005). The expression is most intense in the corpus and proximal cauda regions
where CA XII is observed on the basolateral plasma membranes of the principal
cells.
2.3.6.3 Expression in neoplastic tissues
CA XII expression has been observed in various cancers (Ivanov et al. 2001). A
characteristic feature of CA XII expression is that it generally becomes stronger or
more widespread in tumors compared to the corresponding normal tissue. Moreover,
CA XII expression may indicate a poor or favorable prognosis depending on the
type of cancer.
In addition to the normal human kidney, CA XII expression has been reported in
most clear-cell carcinomas and oncocytomas (Parkkila et al. 2000). In clear-cell
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carcinomas, CA XII expression shows a correlational trend with histological grade,
being slightly weaker in well-differentiated carcinomas. However, the difference
does not reach statistical significance. In colorectal tumors, CA XII expression
clearly differs from that of normal tissue (Kivela et al. 2000a). The most obvious
change is observed in the deep parts of the adenomatous mucosa where positive
staining clearly increases with the grade of dysplasia. Additionally, the staining
pattern of CA XII was observed to associate with the malignant behavior of the
colorectal tumors. In brain tumors, the overexpression of CA XII has been detected
in gliomas, hemangioblastomas and meningiomas (Proescholdt et al. 2005) and in
diffuse astrocytomas where its expression is linked to a poorer prognosis (Haapasalo
et al. 2008). CA XII is also expressed in pancreatic tumors, but no correlation has
been detected between the staining extent or intensity and the differentiation grade
(Kivela et al. 2000b). Similarly, CA XII expression is slightly increased in all
pathological lesions when compared to staining in non-neoplastic gastric mucosa,
but it does not exhibit any prominent changes in different tumor categories
(Leppilampi et al. 2003).
CA XII expression has been detected in 75% of invasive breast carcinomas
where it is associated with positive estrogen receptor (ER) status, negative
epidermal growth factor receptor (EGFR) status, lower grade disease, lower relapse
rate, and superior overall patient survival (Watson et al. 2003). Likewise, CA XII
expression has been shown to correlate with favorable prognosis in non-small cell
lung cancer (Ilie et al. 2011) and cervical cancer (Yoo et al. 2010).
It has been proposed that CA XII has a similar role in tumors as CA IX, i.e., to
maintain a neutral intracellular pH and to acidify the extracellular environment.
There is also experimental evidence to support this hypothesis because it has been
shown that CA XII and CA IX contribute to cell survival in acidosis (Chiche et al.
2009).
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2.4 Carbonic anhydrases in embryonic development
2.4.1 Carbonic anhydrases I, II, III and VI
In erythrocytes, human CA I is expressed in a developmental stage-specific manner.
No CA I protein is detectable in fetal erythrocytes prior to birth; however, at
approximately the time of normal delivery (40 weeks gestation), CA I begins to be
expressed. (Brady et al. 1990)
CA II expression at both mRNA and protein levels has been examined in
cultured mouse brain cells (De Vitry et al. 1989). Hypothalamic cells of embryonic
day (ED) 12-14 were cultured for various periods. It was observed that Car2
transcripts are detectable as early as ED 12-13, although CA II protein is not
detectable until ED 17-18. At postnatal stages, the majority of glial cells express
both Car2 mRNA and protein. Additionally, CA II is present in the epithelial cells
of the choroid plexus during human development (Catala 1997). It was observed
that both CA activity and the isozyme CA II are present as early as the 9th week of
gestation. Therefore, it appears that CA II may already contribute to the secretion of
cerebrospinal fluid during fetal life. CA II has also been detected in the developing
chicken retina at ED 5 when it is expressed in all retinal cells (Linser and Moscona
1981). As differentiation progresses, neurons cease expressing CA II; by ED 13, the
isozyme is found only in Müller glia cells. During retinal maturation, CA II
accumulates to a new high level that persists in the adult. Moreover, CA II
expression has been demonstrated in the developing chicken lens where it appears to
peak at ED 4.5 (Buono et al. 1992).
In the mouse embryonic and fetal heart, CA II expression has been observed
from ED 13 to ED 16 (Vuillemin and Pexieder 1997). CA II is present in a unique
region of the ventricular myocardium: the anterior and left lateral wall of the left
ventricle. In addition, CA II expression has been observed in the developing mouse
pancreas, kidney, and lung (Inada et al. 2006). In the pancreas, CA II is expressed in
glucagon-positive cells at ED 15.5. At ED 18.5, CA II is faintly evident in the larger
ducts and more strongly in some of the intercalated ducts. In both the mouse kidney
and lung at ED 15.5, CA II is abundantly expressed in tubular or duct-like
structures.
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CA III has been detected in human fetal muscles at low levels at the 10th week
of gestation but is not expressed in significant amounts until the 15th week of
gestation (Jeffery et al. 1980). CA III levels gradually rise until the 25th week of
gestation. At this point, there is a more dramatic increase in expression levels, which
reach approximately half of the adult level by the time of birth. CA III is also
expressed in the embryonic mouse skeletal muscle and notochord (Lyons et al.
1991). Car3 mRNA is first detected in somite myotomes between 9.5 and 10.5 days
post coitum (p.c.). At 15.5 days p.c., Car3 begins to be restricted to developing slow
muscle fibers. By two weeks postpartum (p.p.), Car3 transcripts are detected
primarily in slow muscle fibers. In the developing notochord, Car3 is observed at an
earlier stage (7.25 days p.c.). Car3 is also expressed at a much higher level in the
notochord than in the developing skeletal muscle. Furthermore, CA III expression
has been observed in the extraocular muscles of human embryos (Carnegie stages
13-23) (Oguni et al. 1992). At Carnegie stage 20, CA III immunoreactivity appears
in some fibers of the extraocular muscles. From stage 21 to stage 23, more CA III-
immunoreactive fibers are observed.
CA II and III expression has been demonstrated in the rat liver during fetal and
postnatal development (Laurila et al. 1989). It was shown that in the 12-day fetus,
the early strong expression of CA I in hepatocytes is partially replaced by CA II and
CA III during late prenatal development. In the 20-day fetus, CA III staining
intensity is equal to that of a mature female rat. In males, the staining intensity in
hepatocytes clearly increases during sexual maturation.
The expression of CA II and III has also been detected in bovine parotid glands
during fetal development (Asari et al. 1994). In a 3-month-old fetus with a crown-
rump length (CRL) of 17 cm, CA II expression in undifferentiated epithelial cells is
observed, whereas immunostaining for CA III remains negative. At 26 cm CRL (4-5
months old), weak CA III expression is observed in large ductal epithelial cells. The
accumulation of secreted granules in primary acinar cells is initially observed at this
stage. In newborn calves, anti-CA II reactivity nearly disappears from most duct
segments. It has been suggested that the time-dependent expression and distribution
of the isozymes in parotid glands reflects the different biological functions of these
closely structurally related isozymes.
CA VI expression has been observed in the ovine parotid and submandibular
glands during fetal and postnatal development (Penschow et al. 1997). CA VI is
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detectable by immunohistochemistry in parotid excretory ducts from 106 days of
gestation (full-term gestation is 145 days), in striated ducts from 138 days and in
acinar cells from 1 postnatal day. The duct cell content of CA VI declines as the
acinar cell population increases. The production of CA VI by submandibular duct
cells is initially detectable at 125 days gestation, and the acinar production is not
observed until 29 postnatal days. With the development of the acinar tissues in the
postnatal lamb, there is a dramatic increase (approximately 600-fold) in the level of
CA VI expression in the parotid gland between days 7 and 59. The distribution of
CA VI has also been examined in bovine parotid glands (Asari et al. 2000). In the
26 cm CRL fetus, which is estimated to be 4-5 months of fetal age, a few immature
epithelial cells weakly express CA VI. These cells eventually differentiate into
ductal and acinous epithelial cells of the ductal and terminal regions. In the 52 cm
CRL fetus, which is estimated to be 7 months of fetal age, most acini (matured
terminal tubules) and ductal epithelial cells intensely express CA VI. Both acini and
ductal cells exhibit CA VI expression throughout prenatal development. Following
birth, CA VI expression gradually begins to disappear from all small (intercalated)
and large (interlobular) duct segments. Eventually, staining nearly completely
disappears from the entire ductal cell region. Instead, there is strong
immunoreactivity observed in acinar cells from 1 to 5 months of age, and the
expression pattern is nearly indistinguishable from that of the adult.
2.5 Regulation of carbonic anhydrases
2.5.1 Carbonic anhydrase II
An interesting feature of the CA II gene in mammals is that it is expressed in nearly
all tissues but only in a limited subset of cells. Thus, it is conceivable that a variety
of mechanisms participate in the regulation of CA II expression. Nevertheless, the
regulation of CA2 gene has not been thoroughly described.
One example of where the regulation of CA II expression has been examined is
the rodent reproductive system. In the rat prostate, CA II is regulated in a tissue-
specific manner by androgens and estrogens (Harkonen and Vaananen 1988,
Harkonen et al. 1991). Moreover, CA II is expressed in all regions of the rat
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epididymis where it is also under androgen regulation (Kaunisto et al. 1999). In the
rat uterus and liver, CA2 is downregulated by estrogen in a time-dependent manner
with the most pronounced effect detectable 72 h following treatment (Caldarelli et
al. 2005).
CA II is one of the proteins expressed by hematopoietic precursors upon their
differentiation towards an osteoclast phenotype. In fact, 1,25-dihydroxyvitamin D3
(1,25(OH)2D3) has been shown to stimulate CA II expression in cell culture and in
avian marrow cultures (Billecocq et al. 1990, Biskobing et al. 1994). Accordingly, a
vitamin D response element (VDRE) consensus sequence has been identified in the
chicken CA II promoter (Quelo et al. 1994). However, 1,25(OH)2D3 is also known
to promote osteoclast formation. Thus, the question remains whether stimulation of
CA II expression in marrow culture is due to direct upregulation of the CA II gene
by 1,25(OH)2D3 or whether it arises during the 1,25(OH)2D3-induced program of
osteoclastogenesis, which requires the presence of accessory stromal cells. Some
studies support the first hypothesis (Billecocq et al. 1990, Biskobing et al. 1994),
while others suggest that the ability of 1,25(OH)2D3 to stimulate early CA II
expression depends on the presence of stromal cells (Biskobing et al. 1997).
Furthermore, it has been shown in avian macrophage HD11 cells that the CA2
promoter contains a retinoic acid response element (RARE) (Quelo and Jurdic
2000). This study also demonstrated that CA II expression is stimulated by all-trans
retinoic acid when retinoic acid receptor ? (RAR?) is overexpressed. In this context,
CA II expression is dependent on a RARE that is located in the distal portion of the
promoter and is bound by the RAR? homodimer.
Interestingly, CA II was found to be regulated by hypoxia in an in vitro
angiogenesis model (Yoshiura et al. 2005). In this investigation, CA II expression in
normal human vein endothelial cells was significantly upregulated when cells were
cultured in acidic and hypoxic conditions, suggesting that CA II may play a role in
tumor angiogenesis.
2.5.2 Carbonic anhydrase IX
The CA9 promoter has been localized to a genomic sequence spanning 173
nucleotides upstream of the transcription initiation site. The promoter possesses five
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regulatory regions designated protected regions 1-5 (PR1-5) where cis-acting
regulatory proteins can bind (Kaluz et al. 1999). PR1 and PR2 were shown to be
important elements for transcriptional activation, whereas PR4 functions as a
silencer. PR5 has a high sequence identity to PR1 and also contributes to the
transcriptional activity of CA9; however, its activation effect is not as strong (Kaluz
et al. 2003). The SP1/SP3 (specificity protein 1/3) complex binds to the PR1 and
PR5 elements, while the AP1 (activator protein 1) transcription factor binds to the
PR2 region. The synergy achieved by the binding of the SP1 and AP1 transcription
factors to the PR1 and PR2, respectively, is required for the basic transcriptional
activation of CA9 gene (Kaluzova et al. 2001, Kaluz et al. 2003). However, the most
important regulatory element of the CA9 promoter is between the SP1 binding site
and the transcription start site at nucleotide position -10/-3. The nucleotide sequence
of this element is 5’-TACGTGCA-3’, which corresponds to a hypoxia response
element (HRE) (Wykoff et al. 2000).
The HRE is recognized by hypoxia-inducible factor-1 (HIF-1), which is a
transcription factor consisting of two subunits. The oxygen-sensitive ?-subunit is
cytosolic and is stable only in hypoxic conditions, whereas the ?-subunit is
constitutively expressed and is localized in the nucleus. Under normal oxygenation
conditions, HIF prolyl-4-hydroxylases (PHDs) hydroxylate one or two conserved
proline residues on HIF-1?. von Hippel-Lindau protein (pVHL) binds hydroxylated
HIF-1? and targets it for degradation by the ubiquitin-proteasome system (Ivan et al.
2001, Jaakkola et al. 2001). In contrast, HIF-1? is not hydroxylated under hypoxic
conditions because PHDs are inactive in the absence of dioxygen. Non-hydroxylated
HIF-1? is not recognized by pVHL; instead, it is stabilized and accumulates in the
cell. HIF-1? then translocates to the nucleus and dimerizes with the HIF-1? subunit
to form the active transcription factor HIF. This factor subsequently activates the
transcription of hypoxia-regulated genes, including those related to angiogenesis,
glycolysis, cell proliferation and survival, metabolism and pH regulation (Maxwell
et al. 2001, Semenza 2001). The VHL/HIF-pathway is shown in Figure 3.
 The fact that CA IX is highly expressed in ccRCCs can be explained by its
regulation by the VHL/HIF pathway. Germline mutations of the VHL gene  in
humans cause a hereditary cancer syndrome, termed von Hippel-Lindau disease, and
one typical cancer among these patients is ccRCC (Kondo and Kaelin 2001).
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Inactivating mutations in the VHL gene result in activation of the VHL/HIF
pathway, leading to constitutive upregulation of HIF targets, including CA IX.
Figure 3. Illustration of the VHL/HIF-pathway. The mechanism is described in detail in the
text. The figure is adapted from a prior study (Pastorekova and Pastorek 2004).
Interestingly, CA IX has also been shown to be regulated by a HIF-independent
mechanism under hypoxia (van den Beucken et al. 2009). This regulation probably
occurs via a PERK/eIF2?/ATF4-dependent pathway, which mediates the unfolded
protein response (UPR). In response to stress, such as hypoxia, the UPR is activated
in the following way: protein kinase RNA-like endoplasmic reticulum kinase
(PERK) phosphorylates eukaryotic translation initiation factor eIF2?, which
stimulates the translation of activating transcription factor 4 (ATF4) (Feldman et al.
2005, Koumenis and Wouters 2006). Furthermore, it appears that ATF4 directly
binds to the CA9 promoter and is required for transcriptional induction of CA9 under
hypoxia (van den Beucken et al. 2009). These data, therefore, indicate that the
regulation of CA IX is achieved through independent activation of both the HIF and
UPR hypoxia response.
In addition, CA IX expression can be modulated by methylation of CpG
dinucleotides within the promoter region. Hypomethylation of the promoter has
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been shown to induce CA9 expression in RCC cell lines and in tumors (Cho et al.
2000, Cho et al. 2001). Moreover, it has been demonstrated that in RCCs with VHL
mutations, hypomethylation of the promoter at CpG sites -74 and -6 relative to the
transcriptional start site is required for CA9 expression (Ashida et al. 2002).
Methylation at nucleotide position -74 can also affect CA9 expression in carcinoma
cell lines other than RCCs. In these other cell lines, methylation appears to down-
regulate the expression of CA9 at high cell densities but not under hypoxic
conditions or sparse cell densities (Jakubickova et al. 2005). According to a recent
study, CA IX expression in gastric cancer is predominantly regulated by
methylation of a CpG site at the -74 bp position rather than by hypoxia. Moreover,
epigenetic alterations of CA9 differ with tumor histologic type with the gene being
significantly unmethylated in intestinal-type cancers and methylated in diffuse-type
cancers (Nakamura et al. 2011).
CA IX expression in tumors is not confined to hypoxic regions, indicating that
there may be other pathways that regulate its expression. In fact, it has been shown
that CA IX expression is induced under mild hypoxia by high cell density. This
regulation is mediated by PI3K signaling; however, minimal HIF-1 activity is also
required (Kaluz et al. 2002). Furthermore, the mitogen-activated protein kinase
(MAPK) pathway is involved in the regulation of CA IX expression via the control
of the CA9 promoter by both HIF-1-dependent and -independent signals (Kopacek
et al. 2005). This pathway is also interconnected with the PI3K pathway and the
action of the SP1 transcription factor.
CA IX has also been demonstrated to exist in two splice forms. The short splice
variant of CA9 does not contain exons 8-9 and codes for a truncated protein lacking
the C-terminal portion of the catalytic domain (Barathova et al. 2008). This splice
variant exhibits diminished catalytic activity and is intracellular or secreted. Its
expression level is principally independent of hypoxia and tumor phenotype and
can, therefore, give false-positive results in studies designed to assess the prognostic
value of hypoxia- and tumor-related CA9 gene expression. Furthermore, this splice
variant can functionally interfere with full-length CA IX, especially under moderate
hypoxia.
Finally, CA IX expression has also been examined at the post-translational level.
The protein is notably stable with a half-life of approximately 38 h and persists in
reoxygenated cells (Rafajova et al. 2004). However, the protein’s abundance on the
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cell surface is modulated by both constitutive and inducible shedding into the
extracellular space, the latter effect being mediated by the metalloproteinase
TACE/ADAM17 (Zatovicova et al. 2005). The clinical usefulness of serum CA IX
levels in RCCs has also been investigated (Li et al. 2008). Mean serum CA IX levels
were observed to be significantly higher in patients with metastatic disease
compared to those with localized disease. Levels were also higher in patients with
localized disease compared to those of healthy controls. Moreover, higher CA IX
levels were significantly associated with postoperative recurrence.
2.5.3 Carbonic anhydrase XII
There is no thorough data concerning the transcriptional regulation of CA12. The
position and architecture of the promoter and the identity of the critical regulatory
factors remain to be elucidated. However, similar to CA IX, CA XII expression is
induced by hypoxia (Wykoff et al. 2000, Ivanov et al. 2001). It is not known,
however, whether the CA12 gene  is  a  direct  target  of  HIF  or,  if  so,  where  the
relevant hypoxia-responsive element is located. The induction of CA XII by
hypoxia is weaker compared to CA IX, and the region proximal to the
transcriptional start site of CA12 gene does not contain a HRE consensus site. It is,
therefore, plausible that hypoxia regulates CA12 expression via putative HRE
elements located in the distant 5' upstream region. Similar to CA IX, CA XII
expression is inhibited by wild-type VHL in RCC cell lines (Ivanov et al. 1998).
However, the suppression of CA12 requires both the central VHL domain involved
in HIF-1? binding and the C-terminal elongin-binding domain, whereas only the
latter is required for the negative regulation of CA9.
Furthermore, it has been shown that CA XII expression in breast tumors is
associated with positive estrogen receptor ? (ER?) status (Wykoff et al. 2001,
Watson et al. 2003). It was also demonstrated that the CA12 gene  is  regulated  by
estrogen via ER? binding to a distal, estrogen-responsive enhancer region in breast
cancer cells (Barnett et al. 2008). Upon the addition of estradiol, ER? binds directly
to the distal enhancer in vivo, resulting in the recruitment of RNA polymerase II and
the steroid receptor coactivators SRC-2 and SRC-3 and inducing changes in histone
acetylation.
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A recent paper indicated that gene knockdown of CA XII in the human breast
cancer cell line MDA-MB-231 results in decreased invasion and migration by
interfering with the p38 MAPK pathway (Hsieh et al. 2010). CA XII knockdown
was also shown to decrease the expression of matrix metalloproteinase (MMP)-2,
MMP-9 and urokinase-type plasminogen activator (u-PA). CA XII knockdown,
however, increased the expression of tissue inhibitor of metalloproteinases (TIMP)-
2 and plasminogen activator inhibitor (PAI)-1. However, c-Jun N-terminal kinase
(JNK), extracellular signal- regulated kinase (ERK) and the Akt pathways were not
affected by CA XII knockdown. Moreover, the invasive and migratory abilities of
CA XII-knockdown cells were restored by CA XII overexpression.
Similar to CA IX, CA XII exists in two splice forms. One splice variant of CA12
mRNA lacks only a short segment coding for 11 amino acids and has been reported
to be common in diffuse astrocytomas with poor prognosis (Haapasalo et al. 2008).
However, the reasons for the association of this CA12 splice variant with aggressive
brain tumors and the biological role of the variant remain to be elucidated.
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3. AIMS OF THE STUDY
The specific aims of this study were to
1) investigate the effects of certain hormones and growth factors on CA9 and
CA12 transcript levels in human cancer-derived and normal cell lines.
2) examine CA IX and CA XII expression levels during mouse embryonic
development.
3) elucidate the whole-genome gene expression changes that occur in response
to CA IX deficiency in the murine gastric mucosa.
4) further investigate specific protein(s) that are either up- or downregulated in
the stomachs of CA IX-deficient mice.
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4. MATERIALS AND METHODS
4.1 Cell lines (II, IV)
A total of 16 pancreatic cancer cell lines were used in the study (IV). Thirteen of
these lines (AsPC-1, BxPC-3, Capan-1, Capan-2, CFPAC-1, HPAC, HPAF-II, Hs
700T, Hs 766T, MIA PaCa-2, PANC-1, Su.86.86, and SW1990) were purchased
from the American Type Culture Collection (ATCC, Manassas, VA, USA) and
three (DanG, Hup-T3, and Hup-T4) were purchased from the German Collection of
Microorganisms and Cell Cultures (Braunschweig, Germany). A panel of 21 breast
cancer cell lines (BT-474, CAMA-1, DU4475, HCC38, HCC1419, HCC1954,
MCF7, MDA-MB-134-VI, MDA-MB-231, MDA-MB-361, MDA-MB-415, MDA-
MB-436, MDA-MB-453, SK-BR-3, T-47D, UACC-732, UACC-812, UACC-893,
UACC-3133, ZR-75-1, and ZR-75-30) were obtained from the ATCC (IV). The
Caki-1 and A-498 human RCC lines and HepG2 human hepatocellular carcinoma
cell line were also obtained from the ATCC (II). The U373 human glioblastoma
astrocytoma cell line (II, IV) and normal human umbilical vein endothelial cell
(HUVEC) line (II) were purchased from the European Collection of Cell Cultures.
The HeLa human cervical carcinoma cell line (II, IV) and MCF-7 (II) human breast
adenocarcinoma cell line were from the laboratory of Professor Jorma Isola
(Institute of Biomedical Technology, University of Tampere, Tampere, Finland). All
of the cell lines were grown under recommended culture conditions.
4.2 Protein expression analyses
4.2.1 Antibodies (I, IV)
The production of polyclonal rabbit antibodies against mouse CA IX and CA XII
was previously described by Ortova Gut et al. (Ortova Gut et al. 2002) and Kyllonen
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et al. (Kyllonen et al. 2003), respectively (I). The M75 monoclonal antibody
specific for the PG region of human CA IX has also been previously described
(Pastorekova et al. 1992) (IV). Rabbit anti-human NCCRP1 serum against the
purified full-length NCCRP1 was obtained from Innovagen AB (Lund, Sweden)
(IV).
4.2.2 Immunohistochemistry (I)
CA IX and CA XII expression during mouse embryonic development was examined
by immunohistochemical staining. Mouse embryos were obtained by mating male
and female NMRI mice. The procedures were approved by the animal care
committees of Helsinki University and Tampere University. To determine a time
point, noon of the day on which the copulation plug was found was considered to be
0.5 days p.c. Embryos of the following days p.c. were obtained: 7.5 (n=2), 11.5
(n=3), 12.5 (n=4) and 13.5 (n=2). Embryos with or without extraembryonic tissues
were briefly washed with PBS, fixed with 4% paraformaldehyde and embedded in
paraffin. Sections were cut at 5-8 µm and placed on SuperFrost® Plus microscope
slides (Menzel; Braunschweig, Germany). Tissue samples from the stomach, heart,
brain, liver, kidney, and pancreas of an adult Balb/c mouse were obtained for
control purposes. Immunoperoxidase staining was performed using an automated
Lab Vision Autostainer 480 (ImmunoVision Technologies Co., Brisbane, CA,
USA). As this automated immunostaining method produced some nonspecific
labeling of the nuclei in the embryonic tissues, immunostaining was repeated using
a less sensitive but more specific peroxidase-antiperoxidase staining protocol
(manual PAP) to confirm the validity of the results.
The automated immunostaining was performed using Power Vision+™ Poly-
HRP IHC Kit (ImmunoVision Technologies, Co.) reagents and included the
following steps:
1) rinsing in wash buffer
2) treatment in 3% H2O2 in ddH2O for 5 min and rinsing in wash buffer
3) blocking with Universal IHC Blocking/Diluent for 30 min and rinsing in
wash buffer
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4) incubation with the primary antibody (rabbit anti-mouse CA IX or XII) or
normal rabbit serum diluted 1:2000 in Universal IHC Blocking/Diluent for
30 min
5) rinsing in wash buffer for 3 x 5 min
6) incubation in poly-HRP-conjugated anti-rabbit IgG for 30 min and rinsing in
wash buffer for 3 x 5 min
7) incubation in DAB (3,3’-diaminobenzidine tetrahydrochloride) solution (one
drop of DAB solution A and one drop of DAB solution B in 1 ml) ddH2O for
6 min
8) rinsing with ddH2O
9) CuSO4 treatment for 5 min for signal enhancement
10)  rinsing with ddH2O
All the procedures were performed at room temperature. The sections were
mounted in Entellan Neu (Merck; Darmstadt, Germany) and examined and
photographed with a Zeiss Axioskop 40 microscope (Carl Zeiss; Göttingen,
Germany).
Immunostaining using the PAP method included the following steps:
1) treatment with 3% H2O2 in methanol for 5 min and washing in PBS for 5
min
2) treatment with undiluted cow colostral whey (Biotop) for 30 min and
rinsing in PBS
3) incubation with the primary antibody (rabbit anti-mouse CA IX or XII)
diluted 1:100 in 1% bovine serum albumin (BSA) in PBS for 1 h and
washing in PBS for 3 x 10 min
4) treatment with undiluted cow colostral whey for 30 min and rinsing in
PBS
5) incubation with the secondary antibody (swine anti-rabbit IgG; DAKO,
Glostrup, Denmark) diluted 1:100 in 1% BSA in PBS for 1 h and washing
in PBS for 3 x 10 min
6) incubation with peroxidase-antiperoxidase complex (PAP-rabbit; DAKO)
diluted 1:100 in PBS for 30 min and washing in PBS for 4 x 5 min
7) incubation for 2½ min in DAB solution (6 mg 3,3’-diaminobenzidine
tetrahydrochloride; Sigma, St Louis, MO) in 10 ml PBS and 3.3 µl 30%
H2O2
56
All incubations and washes were performed at room temperature. The sections
were mounted in Entellan Neu (Merck; Darmstadt, Germany) and were examined
and photographed using a Zeiss Axioskop 40 microscope.
4.2.3 Immunocytochemistry (IV)
Immunocytochemical analysis was used to investigate the subcellular localization of
human NCCRP1 in HeLa cells. The HeLa cells were fixed with 4% (vol/vol)
neutral-buffered formaldehyde for 30 min. The cells were subsequently rinsed with
PBS and were subjected to immunofluorescence staining through the following
steps:
1) pretreatment of the cells with 0.1% BSA in PBS (BSA-PBS) for 30 min
2) incubation for 1 h with rabbit NCCRP1 antiserum or normal rabbit serum
diluted 1:100 in 0.1% BSA-PBS or mouse CA IX antiserum diluted 1:10 in
0.1% BSA-PBS
3) rinsing for 3 x 5 min with BSA-PBS
4) incubation for 1 h with 1:100 diluted Alexa Fluor 488 goat anti-rabbit IgG
antibodies or Alexa Fluor 568 goat anti-mouse IgG antibodies (both of
which were obtained from Molecular Probes, Eugene, Oregon, USA) in
0.1% BSA-PBS
5) rinsing twice for 5 min with BSA-PBS and once with PBS
All incubations and washes were performed in the presence of 0.05% saponin.
Immunostained cells were analyzed and photographed using a Zeiss LSM 700
confocal laser scanning microscope.
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4.3 mRNA expression analyses
4.3.1 Quantitative real-time PCR (QRT-PCR) (II-IV)
4.3.1.1 Human cancer-derived and normal cell lines (II)
The Caki-1, A-498 and HepG2, MCF-7, HeLa, U373, and HUVEC cell lines were
used to study whether treatment with certain hormones and growth factors can affect
CA9 and CA12 mRNA levels. When the cultured cells reached 80-90% confluence,
they were trypsinized and plated in 6-well plates (except for the HUVEC cells,
which were plated in 59 cm2 dishes) at appropriate densities. After 24 h, the cells
were changed to fresh serum-free medium with the tested hormones and growth
factors. Serum-free medium was added to two control wells/dishes. The cells were
incubated for 24 h in the presence of different hormones or growth factors. The
treatments were performed using recombinant human growth hormone (400 ng/ml),
hydrocortisone (10 ?M), insulin (30 nM), tri-iodothyronine (T3; 10 nM), estradiol
(E2; 2.5 µM), recombinant human insulin-like growth factor 1 (IGF-1; 50 ng/ml),
recombinant human transforming growth factor-alpha (TGF-?; 10 ng/ml),
recombinant human transforming growth factor-beta 1 (TGF-?1; 10 ng/ml),
recombinant human epidermal growth factor (EGF; 10 ng/ml), and deferoxamine
mesylate (200 ?M), which is an iron chelator commonly used to activate the
hypoxia regulatory pathway. Each cell line was treated with the same hormones or
growth factors with the exception of the MCF-7 line, which was not treated with
insulin because these cells require a high insulin concentration in their culture
medium. The growth hormones IGF-1, TGF-?1, and EGF were purchased from
ProSpec-Tany TechnoGene Ltd. (Rehovot, Israel). TGF-? was purchased from
PromoCell GmbH (Heidelberg, Germany). The other chemicals were obtained from
Sigma-Aldrich Finland Oy (Helsinki, Finland) and were diluted when necessary
according to the manufacturers’ instructions.
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4.3.1.2 Car9?/? mice tissue samples (III)
QRT-PCR was performed to confirm the results of the microarray analysis
performed in article III. The knockout mouse model for CA9 used in this work was
developed and characterized elsewhere (Ortova Gut et al. 2002). These Car9-
deficient C57BL/6 mice were produced and maintained in the animal facility of the
University of Oulu and then delivered to the animal facility of the University of
Tampere. Permission for the use of the experimental mice was obtained from the
Animal Care Committees of the Universities of Oulu and Tampere. Six Car9?/? mice
(3 males and 3 females) and six wild-type control mice (3 males and 3 females)
were kept under tightly controlled specific pathogen-free conditions and were fed
identical diets. The mice were sacrificed at approximately 11 (SD = ±1.35) months
of age. Tissue specimens from the body of the stomach were immediately collected,
immersed in RNAlater solution (Ambion, Austin, TX, USA), and frozen at –80 oC.
4.3.1.3 Murine tissue samples (IV)
To study Nccrp1 mRNA expression in mouse tissues, 2-month-old C57BL/6 mice
(3 males and 3 females) were used. These mice were maintained in the animal
facility of the University of Oulu. Tissue specimens were taken from the following
areas: parotid gland, submandibular gland, stomach, duodenum, jejunum, ileum,
colon, lung, kidney, prostate, and testis. The tissue samples were immediately
immersed in RNAlater solution (Ambion, Austin, TX, USA) and were frozen at –80
oC.
4.3.1.4 HeLa cell line samples (IV)
The effects of different treatments on NCCRP1 transcript levels were examined in
HeLa cells. When the cultured cells reached 80-90% confluency, they were
trypsinized and plated in 58 cm2 dishes at a density of 1 million cells per dish. After
24 h, the medium was replaced with fresh medium containing one of the following
chemicals: recombinant human transforming growth factor-alpha (TGF-?; 10
ng/ml), recombinant human transforming growth factor-beta 1 (TGF-?1; 10 ng/ml),
recombinant human epidermal growth factor (EGF; 10 ng/ml), or deferoxamine
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mesylate (200 ?M). Untreated medium was added to a control dish. The chemicals
were diluted when necessary according to the manufacturers’ instructions. The cells
were incubated for 72 h after which they were harvested.
4.3.1.5 Human pancreatic and breast cancer cell line samples (IV)
Human CA9 and NCCRP1 mRNA levels were screened in 16 pancreatic cancer cell
lines and 21 breast cancer cell lines (see section 4.1).
4.3.1.6 U373, HeLa and Su.86.86 cell line samples (IV)
The CA9 and NCCRP1 genes were silenced using siRNAs in the human U373,
HeLa and Su.86.86 cell lines. The efficacy of silencing was verified each time using
QRT-PCR.
4.3.1.7 RNA extraction and cDNA synthesis (II-IV)
Total RNA from the cultured cells (excluding the human pancreatic and breast
cancer cell lines) and murine tissue samples was extracted using the RNeasy RNA
isolation kit (Qiagen, Valencia, USA) following the manufacturer's instructions.
Residual  DNA  was  removed  from  the  samples  using  RNase-free  DNase  (Qiagen)
(II-IV). For the human pancreatic and breast cancer cells, total RNA was isolated
using the TRIzol reagent (Invitrogen, Carlsbad, CA) (IV). Total RNA was
converted into first strand cDNA using a First Strand cDNA synthesis kit
(Fermentas, Burlington, Canada) or a SuperScript III First-Strand Synthesis kit
(Invitrogen) according to the manufacturer’s recommended protocol.
4.3.1.8 Quantitative real-time PCR (II-IV)
QRT-PCR was performed using the LightCycler detection system (Roche, Rotkreuz,
Switzerland). The majority of the primer sets employed in these analyses were
designed using Primer3 (http://frodo.wi.mit.edu/primer3/), and primer specificity
was verified using NCBI Blast (http://blast.ncbi.nlm.nih.gov/Blast.cgi). To avoid the
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amplification of genomic DNA, the primers from each primer pair were targeted to
different exons when possible. The human and mouse primer sequences used in
these studies are given in Tables 2 and 3, respectively.
Each PCR reaction was performed in a total volume of 20 µl containing 1.0 µl
(II, IV) or 0.5 µl (III) first strand cDNA, QuantiTect SYBR Green PCR Master Mix
(Qiagen, Hilden, Germany) and 0.5 µM of each primer. The amplification and
detection were performed as follows: following an initial 15 min activation step at
95 oC, amplification was performed using 45 repeats of a three-step cycling
procedure of denaturation at 95 oC for 15 s, annealing at a temperature determined
according to the Tm for each primer pair for 20 s, and elongation at 72 oC for 15 s
(the ramp rate was 20 oC/s for all the steps). A final cooling step was added
following the amplification cycles. A melting curve analysis was always performed
following the amplification to confirm the specificity of the PCR reaction.
To quantify the target transcript levels, a standard curve was established for each
gene using fivefold serial dilutions of known concentrations of purified PCR
products generated with the same primer pairs. In most cases, the cDNA sample was
tested in triplicate. Using the standard curve method, the crossing point (Cp) values
were transformed by the LightCycler software into copy numbers. In the case of
triplicate samples, the expression value for each sample was the mean of the copy
numbers of the sample’s replicates. Expression values were normalized against one
(IV), two (II) or three (III) housekeeping genes. When several housekeeping genes
were employed, the geometric mean of these genes was used as an accurate
normalization factor for gene expression levels.
61
Table 2. Human primer sequences used for QRT-PCR analyses in original papers
II and IV.
Gene Direction Sequence (5’-3’)
GenBank
number
Original
paper
B2M
F
R
GTATGCCTGCCGTGTGAA
CTCCATGATGCTGCTTAC
NM_004048 II
CA9a
F
R
GGAAGGCTCAGAGACTCA
CTTAGCACTCAGCATCAC
NM_001216 II
CA9b
F
R
ATGAGAAGGCAGCACAGAAG
TAATGAGCAGGACAGGACAG
NM_001216 IV
CA12
F
R
CTGCCAGCAACAAGTCAG
ATATTCAGCGGTCCTCTC
NM_001218 II
GAPDH
F
R
TGCACCACCAACTGCTTAGC
GGCATGGACTGTGGTCATGAG
NM_002046 IV
HIF-1?
F
R
TCACCTGAGCCTAATAGTCC
GCTAACATCTCCAAGTCTAA
NM_001530 II
NCCRP1
F
R
TTCCGTGGCTGGTACATTAG
ATGGCTGGTTGTTCGTCATC
NM_001001414 IV
UBC
F
R
ATTTGGGTCGCGGTTCTTG
TGCCTTGACATTCTCGATGGT
NM_021009 II, IV
aThe primers recognize only the full-length splice variant of CA9.
bThe primers recognize both splice variants of CA9.
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Table 3. Mouse primer sequences used for QRT-PCR analyses in original papers
III and IV.
Gene Direction Sequence (5’-3’)
GenBank
number
Original
paper
Actb
F
R
AGAGGGAAATCGTGCGTGAC
CAATAGTGATGACCTGGCCGT
NM_007393 III, IV
Adipoq
F
R
TCCTGCTTTGGTCCCTCCAC
TCCTTTCTCTCCCTTCTCTCC
NM_009605 III
Car3
F
R
GCTCTGCTAAGACCATCC
ATTGGCGAAGTCGGTAGG
NM_007606 III
Cela2a
F
R
TGATGTGAGCAGGGTAGTTGG
CACTCGGTAGGTCTGATAGTTG
NM_007919 III
Cela3b
F
R
TGCCTGTGGTGGACTATGAA
CAGCCCAAGGAGGACACAA
NM_026419 III
Cfd
F
R
AACCGGACAACCTGCAATC
CCCACGTAACCACACCTTC
NM_013459 III
Cpb1
F
R
GGTTTCCACGCAAGAGAG
GTTGACCACAGGCAGAACA
NM_029706 III
Cym
F
R
ATGAGCAGGAATGAGCAG
TGACAAGCCACCACTTCACC
NM_001111143 III
Dmbt1
F
R
GCACAAGTCCTCCATCATTC
AGACAGAGCAGAGCCACAAC
NM_007769 III
Egf
F
R
GCTCGGTGTTTGTGTCGTG
CTGTCCCATCATCGTCTGG
NM_010113 III
Hprt
F
R
AGCTACTGTAATGATCAGTCAACG
AGAGGTCCTTTTCACCAGCA
NM_013556 III
Il1rl1
F
R
ATTCTCTCCAGCCCTTCATC
AAGCCCAAAGTCCCATTCTC
NM_010743 III
Nccrp1
F
R
GCTGCATGTCTGGCTGTTAG
ATGCGGTTCTTAGCCTTGTG
NM_001081115 IV
Pkp4
F
R
GAACATAACCAAAGGCAGAGG
GGTGGACAGAGAAGGGTGTG
NM_026361 III
Pnlip
F
R
CCCGCTTTCTCCTCTACACC
TCACACTCTCCACTCGGAAC
NM_026925 III
Sdha
F
R
GCTTGCGAGCTGCATTTGG
CATCTCCAGTTGTCCTCTTCCA
NM_023281 III
Sftpd
F
R
CCAACAAGGAAGCAATCTGAC
TCTCCCATCCCGTCCATCAC
NM_009160 III
Slc9a3
F
R
TGACTGGCGTGGATTGTGTG
ACCAAGGACAGCAGGAAGG
NM_001081060 III
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4.3.2 MediSapiens data (IV)
Human NCCRP1 gene mRNA expression levels across a large number of tissues
were retrieved from the IST database system developed by MediSapiens Ltd. The
current version of the IST database (4.3) contains 20,218 human tissue or cell line
samples analyzed using Affymetrix gene expression microarrays. The database was
constructed and validated using methods similar to those described previously
(Kilpinen et al. 2008, Autio et al. 2009) for the construction of GeneSapiens
database. As the database contains fully integrated expression data both in terms of
the annotation and numerical compatibility, it allows for analysis of the expression
levels of 19,123 genes across 228 distinct tissues.
4.3.3 cDNA microarray (III)
4.3.3.1 Experimental procedure
Microarray analysis was performed to study the effect of CA IX deficiency on
whole-genome gene expression in the mouse gastric mucosa. Microarray
experiments were performed in the Finnish DNA Microarray Centre at the Turku
Centre for Biotechnology. Total RNA was extracted from the stomachs of six
C57BL/6 Car9?/? mice (3 males and 3 females) and six wild-type mice (3 males and
3 females), which were used as controls. All 12 samples were analyzed individually.
Four hundred nanograms of total RNA from each sample was amplified using the
Illumina® TotalPrep RNA Amplification kit (Ambion) as recommended by the
manufacturer. The in vitro transcription reaction, which was conducted for 14.5 h,
included labeling of the cRNA by biotinylation.
Labeled and amplified cRNAs (1.5 ?g/array) were hybridized to Illumina’s
Sentrix? Mouse-6 Expression Bead Chips (Illumina, Inc., San Diego, CA) at 58 oC
for 18 h according to the manual for the Illumina? Whole-Genome Gene
Expression with IntelliHyb Seal System. The arrays were washed and subsequently
stained with 1 ?g/ml cyanine3-streptavidin (Amersham Biosciences,
Buckinghamshire, UK). The Illumina BeadArray™ Reader was used to scan the
arrays according to the manufacturer’s instructions. The numerical results were
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extracted with Illumina’s BeadStudio software without any normalization or
background subtraction.
4.3.3.2 Data analysis
The array data were normalized with Chipster (v1.3.0) using the quantile
normalization method. The data were filtered according to the SD of the probes. The
percentage of data that did not pass through the filter was adjusted to 99.4%,
indicating a SD value of nearly 3. Statistical analyses were subsequently performed
using the empirical Bayes t-test for the comparison of the two groups. Finally, the
probes were further filtered according to fold change with ±1.4 as the cut-off for up-
and downregulated expression, respectively. This cut-off value has been proposed as
an adequate level above which there is a high correlation between microarray and
QRT-PCR data regardless of other factors, such as spot intensity and cycle threshold
(Morey et al. 2006).
The functional annotation tool DAVID (Database for Annotation, Visualization
and Integrated Discovery, http://david.abcc.ncifcrf.gov/) (Dennis et al. 2003) was
used to identify enriched biological categories among the regulated genes when
compared to all the genes present on Illumina's Sentrix Mouse-6 Expression Bead
Chip. The annotation groupings analyzed were the following: Gene Ontology
biological process and molecular functions; SwissProt comments; SwissProt Protein
Information Resources Keywords; the Kyoto Encyclopedia of Genes and Genomes
pathway; and the Biocarta pathway. Results were filtered to remove categories with
EASE (Expression Analysis Systematic Explorer) scores greater than 0.05.
Overlapping categories with the same gene members were removed to yield a single
representative category.
4.4 siRNA-mediated gene silencing (IV)
Gene silencing using gene-specific siRNAs in cancer-derived cell lines was
performed to study whether human CA9 and NCCRP1 directly regulate each other
and to investigate the effect of NCCRP1 silencing on cell growth. The NCCRP1 and
CA9 genes were silenced using specific ON-TARGETplus SMARTpool small
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interfering RNAs (siRNAs) (Thermo Fisher Scientific, Lafayette, CO). The
catalogue numbers for the NCCRP1 and CA9 SMARTpools are L-032307-01-0005
and L-005244-00-0005, respectively. The U373 cells, HeLa and Su.86.86 cells were
transfected with the siRNAs using INTERFERin™ reagent (PolyPlus-transfection,
Illkirch, France) according to the manufacturer's instructions. The transfections were
performed on 24-well plates with a desired cell density (25,000 cells per well for
U373 and HeLa cells and 50,000 cells per well for Su.86.86 cells). A final siRNA
concentration of 10 nM was used for CA9 siRNA and 30 nM for NCCRP1 siRNA.
Parallel control experiments using a siRNA targeting the firefly luciferase
(PPYLUC) gene were performed in an identical manner. The sequence of the
PPYLUC siRNA  was 5’-GAUUUCGAGUCGUCUUAAUTT-3’. All siRNA
experiments were performed with three replicates and were repeated twice. The
efficacy of the gene silencing was consistently verified using the QRT-PCR protocol
that was described earlier (see section 4.3.1).
4.5 Cell growth analyses (IV)
For cell growth analyses, HeLa cells were transfected with NCCRP1 SMARTpool
siRNAs or luciferase control siRNA as described in the previous section with the
exception that the cell density was 15,000 cells per well. The influence of NCCRP1
silencing on cell growth was analyzed 48, 96, and 144 h following transfection.
From each well, 4x4 fields were photographed using an Olympus IX71
microscope with 100 x magnification. Quantitative analysis of the captured images
was performed using a public domain image processing software, ImageJ
(http://rsbweb.nih.gov/ij/), with a custom-made algorithm developed by Dr. Vilppu
Tuominen. This algorithm first identifies the cellular area of the sample image at
each time point and subsequently measures the relative change of the cellular area as
a percentage of the well surface over the sample-specific time course.
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4.6 Production of recombinant human NCCRP1 using a
bacterial expression system (IV)
4.6.1 Construction of recombinant human NCCRP1
The full-length protein coding cDNA sequence for human NCCRP1 was obtained
from the Mammalian Gene Collection, and the cDNA clone (IMAGE ID:
30348184) was purchased from Source BioScience LifeSciences (Cambridge,
United Kingdom). The plasmid DNA was isolated from an overnight culture using
the QIAprep Spin Miniprep Kit (Qiagen, Hilden, Germany). To generate the GST-
NCCRP1 construct, the following primers were used: the forward primer sequence
was 5´-CCG CGG ATC CAT GGA GGA GGT GCG TGA GGG A-3', and the
reverse primer sequence was 5´-CGC CGT CGA CTC ACT CCC GGA GCT GCA
CAG-3' with the restriction sites for BamHI and SalI underlined, respectively. The
primers were ordered from Biomers (Ulm, Germany). The NCCRP1 cDNA
amplification was performed using Phusion™ Hot Start High Fidelity DNA
Polymerase (Finnzymes, Espoo, Finland). PCR was performed in a XP Thermal
Cycler (Bioer Technology, Hangzhou, China). The program consisted of a single 98
oC denaturation step for 30 s followed by 35 cycles of denaturation at 98 oC for 10 s,
annealing at 64 oC for 30 s and extension at 72 oC for 30 s. A final extension was
performed at 72 oC for 5 min. The PCR product band was separated from the gel and
dissolved using Illustra™ GFX PCR DNA and GEL Band Purification Kit (GE
Healthcare Life Sciences, Buckinghamshire, UK). The purified PCR product and
pGEX-4T-1 vector (Invitrogen, Carlsbad, CA) were digested at 37 oC for 2 h with
BamHI and SalI restriction enzymes (New England Biolabs). The digested plasmid
and NCCRP1 construct were purified and ligated overnight at 4 oC using T4 DNA
ligase (New England Biolabs). Next, the pGEX-4T-1/GST-NCCRP1 construct was
transformed into E. coli BL21(DE3)pLysS bacteria (Promega, Madison, WI, USA).
Overnight cultures (5 ml) were grown from these colonies, and the plasmids were
purified using a QIAprep Spin Miniprep Kit™ (Qiagen). Sequencing was performed
to verify the validity of the NCCRP1 construct. The expression of pGEX-4T-
1/GST-NCCRP1 constructs in E. coli yielded fusion proteins containing a thrombin
protease site between the GST tag and NCCRP1. In addition, this vector construct
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codes for additional Gly and Ser residues at the N-terminus of the recombinant
protein.
4.6.2 Production and purification of recombinant human
NCCRP1
A single colony of BL21(DE3)pLysS transformants was amplified through
overnight cultivation in 5 ml LB medium containing 50 µg/ml ampicillin. The
colonies were grown at room temperature and were shaken (200 rpm). Next, 500 ml
of LB/amp medium was inoculated with the resultant growth. This culture was
grown until the optical density (OD) at 600 nm reached 0.6. NCCRP1 protein
expression was induced using isopropyl ?-D-1-thiogalactopyranoside (IPTG)
(Fermentas, Ontario, Canada) overnight at room temperature with a final
concentration of 0.25 mM.
The cells were harvested by centrifugation (Sorvall RC 28S) at 5000 rpm for 5
min at room temperature. The cell pellet was suspended in 10 ml Tris-buffer
containing 0.1M Tris-Cl, pH 8, 0.05% Triton X-100, 200 mg lysozyme, 200 U
DNase (Roche, Penzberg, Germany), and the protease inhibitors
phenylmethanesulfonylfluoride (0.2 mg; Sigma-Aldrich, Helsinki, Finland) and
leupeptin (0.1 mg) (Santa Cruz, Heidelberg, Germany). After 30 min of incubation
at room temperature, the cell suspension was kept on ice and was sonicated for 1
min. The suspension was clarified by centrifugation at 10,000 rpm for 30 min at 4
oC, and the clear supernatant was subsequently subjected to affinity purification
using Glutathione Sepharose 4B medium (GE Healthcare, Buckinghamshire, UK).
NCCRP1 recombinant protein was isolated under native conditions as described by
the manufacturer. A site-specific thrombin (GE Healthcare) was used for specific
cleavage of the GST. Cleavage was achieved by shaking the sample at room
temperature overnight. Finally, the protein was eluted using the glutathione elution
method (GE Healthcare) as recommended by the manufacturer. The size of the
expressed NCCRP1 protein was determined under reducing conditions by SDS-
PAGE analysis.
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4.7 Mass spectrometry (IV)
Mass spectrometry analysis of recombinant human NCCRP1 was conducted in Prof.
Janne Jänis’ laboratory (Department of Chemistry, University of Eastern Finland)
using a 4.7-T Fourier transform ion cyclotron resonance (FT-ICR) mass
spectrometer (APEX-Qe; Bruker Daltonics, Billerica, MA, USA) equipped with an
Apollo-II ion source and a mass-selective quadrupole front-end. This instrument has
been described in detail elsewhere (Bootorabi et al. 2008). The protein samples were
buffer-exchanged into a 10 mM ammonium acetate pH 6.9 buffer using PD-10
columns (Amersham Biosciences, Billingham, UK) and were directly
electrosprayed at a flow rate of 1.5 ?L/min. ESI-generated ions were externally
accumulated for 1 s in a hexapole ion trap and transmitted to the ICR for trapping,
excitation and detection. For each spectrum, one thousand co-added 512-kWord
time-domain transients were recorded, zero-filled twice, Gaussian multiplied, and
fast Fourier transformed. Magnitude calculations and external mass calibrations
with respect to the ions of an ES Tuning Mix (Agilent Technologies, Santa Clara,
CA, USA) were then performed. All the data were acquired and processed using
Bruker XMASS 6.0.2 software. Mass spectra were further charge-deconvoluted
using a standard deconvolution macro implemented in the XMASS software. A
tryptic digest was obtained by dissolving a small amount of the protein precipitate in
100 ?l of a 10 mM ammonium bicarbonate pH 8.5 buffer to which was added 15 ?g
of sequencing grade trypsin (Promega GmbH, Mannheim, Germany) in 15 ?l of
water. The digest sample was incubated at 37 oC for 1.5 h after which no precipitate
was observed, and the sample was directly analyzed without chromatographic
separation. The obtained protein or peptide masses were matched against the protein
sequence with the use of GPMAW 8.11 software, and tryptic peptide masses were
further subjected to a database search using the Mascot search engine
(www.matrixscience.com).
4.8 Bioinformatic analyses (IV)
Bioinformatic analyses were performed by Dr. Martti Tolvanen. Sequences were
retrieved from Ensembl release 62 (www.ensembl.org) (Flicek et al. 2010), UniProt
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(www.uniprot.org) (Jain et al. 2009), GenBank (www.ncbi.nlm.nih.gov/genbank/)
(Benson et al. 2011) and RefSeq (www.ncbi.nlm.nih.gov/RefSeq/) (Pruitt et al.
2009). BLAST searches were performed via NCBI
(blast.ncbi.nlm.nih.gov/Blast.cgi) (Altschul et al. 1997). Multiple sequence
alignments were prepared using ClustalW (www.ebi.ac.uk/Tools/msa/clustalw2/)
(Thompson et al. 1994) and Mafft (www.ebi.ac.uk/Tools/msa/mafft/) (Katoh et al.
2005) and were visualized with GeneDoc (www.nrbsc.org/gfx/genedoc/). Protein
motifs were searched using InterProScan (www.ebi.ac.uk/Tools/pfa/iprscan/)
(Hunter et al. 2009), and transmembrane domains were predicted with TMHMM (v.
2.0) (www.cbs.dtu.dk/services/TMHMM/) (Emanuelsson et al. 2007). Signal
peptides and other target peptides were predicted using SignalP 3.0 with eukaryotic
parameters (www.cbs.dtu.dk/services/SignalP/) (Emanuelsson et al. 2007) and
TargetP 1.1. with non-plant parameters (www.cbs.dtu.dk/services/TargetP/)
(Emanuelsson et al. 2007), respectively. Intrinsic protein disorder was predicted
with DISpro (retire-me.ics.uci.edu/tools/proteomics/psss.html) (Cheng et al. 2005).
Phylogenetic trees were prepared using MEGA4 software (www.megasoftware.net/)
(Tamura et al. 2007) with maximum parsimony and the complete deletion option for
gapped sites with 1000 bootstrap replicates. Molecular images were prepared with
PyMol 0.99 (DeLano Scientific, South San Francisco, CA).
4.9 Statistical analyses (III, IV)
In article III, statistical analyses of the microarray data were performed using the
empirical Bayes t-test for comparison of the group values for Car9?/? vs. wild-type
mice. The p-values are shown in Appendix 1. For the QRT-PCR results in the same
study, the Mann-Whitney test was used to evaluate differences between these two
groups. For the cell growth analyses in article IV, the Mann-Whitney test was used
to evaluate differences in growth between the NCCRP1 SMARTpool siRNA-treated
HeLa cells and the luciferase control siRNA-treated HeLa cells.
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5. RESULTS
5.1 Influence of different treatments on CA9, CA12 and
NCCRP1 mRNA levels in human cell lines (II, IV)
It has long been known that CA IX and CA XII are regulated by the HIF pathway.
However, there is a lack of information concerning the other mechanisms through
which these isozymes are regulated. Our aim was, therefore, to study other possible
regulators of these enzymes in human cancer-derived and normal cell lines. CA9
expression was detected in only two out of seven cell lines (Table 2 in II). The basal
level of CA9 expression was relatively high in the U373 human glioblastoma cell
line (Figure 1A in II). Compared to the control sample, CA9 expression increased
4.2-fold following deferoxamine mesylate treatment, which was used as a positive
control to induce the hypoxia regulatory pathway (Table 2 and Figure 1A in II).
Moreover, the IGF-1, TGF-? and EGF treatments markedly elevated CA9
expression compared to the control sample (fold changes of 2.4, 2.6 and 2.2,
respectively). TGF-?1 treatment caused a moderate increase in CA9 levels (1.7-
fold).
In HeLa cells, CA9 expression was observed only when stimulated with
deferoxamine mesylate (Table 2 in II). The change in expression was prominent. In
the remaining lines, including MCF-7, Caki-1, A-498, HUVEC, and HepG2 cells,
the basal CA9 expression was below the detection limit (copy number <100) of the
QRT-PCR analysis (Table 2 in II). In addition, none of the treatments induced CA9
expression in these cell lines.
CA12 had a wider expression pattern compared to CA9; it was observed in the
U373, MCF-7, Caki-1, A-498, and HUVEC cell lines (Table 3 in II). CA12 was
expressed in a similar manner to CA9 in U373 cells (Table 3 and Figure 1B in II).
Deferoxamine mesylate treatment notably increased CA12 expression compared to
the control sample (3.8-fold). Additionally, stimulation with TGF-? and EGF both
caused a considerable increase in CA12 expression (fold changes of 3.1 and 2.9,
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respectively). Likewise, IGF-1 and TGF-?1 treatments elevated CA12 levels twofold
and 1.6-fold, respectively. Following growth hormone treatment, the levels of CA12
slightly decreased (fold change of -1.6).
CA12 showed an exceptional expression profile in the human breast
adenocarcinoma cell line MCF-7 (Table 3 in II). CA12 transcription was markedly
increased following TGF-?1 and EGF treatments (changes of 2.8- and 2.4-fold,
respectively). Stimulation with estradiol also elevated CA12 mRNA levels (1.9-
fold). Interestingly, the hypoxia pathway was clearly not induced in this cell line by
deferoxamine mesylate treatment. In contrast, deferoxamine mesylate treatment
decreased CA12 levels somewhat.
The Caki-1 and A-498 human renal carcinoma cell lines were selected for this
study because the former produces wild-type VHL protein, and the latter represents
a VHL-null mutant cell line. In Caki-1 cells, CA12 expression was highest following
deferoxamine mesylate treatment (10.2-fold) as expected (Table 3 in II).
Additionally, the growth factors IGF-1, TGF-?1, and EGF elevated CA12 levels
moderately (changes of 1.5-, 1.7- and 1.8-fold, respectively). Moreover, estradiol
increased CA12 expression 1.5-fold. Similar to U373 cells, growth hormone
treatment caused a decrease in CA12 levels (change of -1.5-fold). In A-498 cells,
CA12 transcripts were present at high levels, and, as anticipated, deferoxamine
mesylate treatment did not affect CA12 expression (Table 3 in II). Again, CA12
mRNA levels were elevated following growth factor treatments. The highest levels
of induction were observed following stimulation with TGF-?1 and EGF (fold
changes of 2.5 and 2.6, respectively), whereas TGF-? had a slightly weaker effect
(2.2-fold). Furthermore, IGF-1 treatment caused a 1.7-fold increase in CA12 mRNA
levels. The addition of hydrocortisone moderately decreased CA12 expression
(change of -1.6-fold).
In the normal HUVEC cell line, the basal expression level of CA12 was low.
None of the treatments markedly increased CA12 expression, whereas several
treatments reduced its expression (Table 3 in II). Hydrocortisone and IGF-1 caused
an approximately twofold decrease in CA12 levels, while TGF-? and TGF-?1
treatments resulted in minor decreases (changes of -1.8- and -1.6-fold, respectively).
In HeLa and HepG2 cells, CA12 expression levels were below the detection limit of
the QRT-PCR.
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The effects of growth factors and deferoxamine mesylate on NCCRP1 mRNA
levels were examined in HeLa cells where the gene’s basal level of expression was
relatively high. None of the tested treatments had a notable influence on NCCRP1
expression (Figure 11 in IV). Following deferoxamine mesylate treatment, the
expression of NCCRP1 decreased moderately (-1.4-fold). Likewise, stimulation with
EGF modestly decreased NCCRP1 transcript levels (-1.2-fold).
5.2 Roles of CA IX and CA XII during mouse
organogenesis (I, III)
5.2.1 Expression of CA IX and CA XII during mouse embryonic
development (I)
Immunochemical staining was used to investigate whether CA IX and CA XII are
expressed in mouse embryos of different ages. A relatively wide distribution pattern
was observed for both isozymes; however, the signal intensity was quite low or
moderate at best.
E7.5 embryos, representing a gastrulation stage, were completely negative for
both  CA  IX  and  CA  XII  (Figure  1  in I). The expression of both isozymes in the
tested tissues during organogenesis is summarized in Tables 1 and 2, respectively,
of original publication I. Both isozymes were present in the developing brain at all
ages examined (Figure 2 in I). Moderate CA IX staining was observed in the nerve
ganglia and choroid plexus. CA XII staining was most prominent in the choroid
plexus at E12.5 and E13.5 when the developing choroid plexus generally becomes
visible. CA IX was not detected in the urogenital system at E11.5, whereas a weak
positive signal appeared at E12.5 (Figure 3 in I). It is notable that although CA XII
is highly expressed in the adult mouse kidney, the embryonic kidney showed only a
weak signal (Figure 3 in I). With respect to CA IX, the developing pancreas showed
a moderate positive reaction at E12.5 (Figure 4 in I). CA XII showed weak
immunostaining in the pancreas where only a few of the developing ducts were
positive (Figure 4 in I). Weak staining for CA IX was observed in the stomach at all
ages examined (Figure 5 in I). Additionally, the liver showed positive
immunoreactions in scattered cells (Figure 5 in I). No CA XII staining was detected
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in the stomach or liver at E11.5, while a weakly positive signal appeared at E12.5
(Figure 5 in I). The control stainings using normal rabbit serum in place of the anti-
CA IX or anti-CA XII serum presented no positive signals.
5.2.2 Genome-wide mRNA expression profiling in the gastric
mucosa of Car9?/? mice (III)
The generation of CA IX-deficient mice has revealed that CA IX contributes to cell
proliferation in the gastric mucosa (Ortova Gut et al. 2002); however, the exact
molecular mechanisms underlying the hyperplastic phenotype in these mice have
not been previously examined. Our aim was, therefore, to investigate the global
gene expression changes in the stomach of Car9?/? mice.  Stomach  RNA  from  6
Car9?/? mice and 6 wild-type mice was subjected to microarray analysis. The results
revealed 86 upregulated genes and 46 downregulated genes using a fold change cut-
off of ±1.4 for up- and downregulated expression, respectively (Appendix 1). The
fold changes ranged from 10.46 to –12.14. When using a cut-off value of ±2.5-fold,
all the genes with significantly (p<0.05) altered expression are displayed, that is, 14
genes with induced expression and 21 genes with repressed expression (Tables 1
and 2 in III). The list of all of the differentially regulated genes was functionally
annotated (Appendix 2), showing enrichment for genes related to hydrolase activity,
developmental processes, cell differentiation, proteolysis, peptidase activity,
structural molecule activity, and immune system process, among others. The
functional annotation categories and the number of genes in each category are
shown in Table 3 of original publication III.
Fourteen genes with notable fold change values were selected from the
microarray results for validation. The selected genes contained representatives from
different functional categories. The expression levels of these genes were analyzed
by QRT-PCR using the same RNA samples as those used for the microarray.
Thirteen (92.9%) of the 14 genes showed concordant results between microarray
analysis and QRT-PCR, and 9 of these genes displayed statistically significant
differences between the knockout and wild-type groups (Tables 1 and 2, Figure 1 in
III). The sole discrepant result was Pkp4, which was upregulated according to the
microarray and did not change according to the QRT-PCR (1.09-fold).
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5.3 Characterization of recombinant human NCCRP1
(IV)
5.3.1 Bioinformatic analyses
One of the upregulated genes in the gastric mucosa of the CA IX-deficient mice was
Nccrp1, which was selected for further bioinformatic analyses. An ortholog of
NCCRP1 was identified in 35 vertebrate genomes in Ensembl ortholog tables. Two
orthologs were identified in fugu (Takifugu rubripes). We identified 21 protein
sequences from 20 species to be at least 90% complete. Table 1 in IV shows the
Ensembl gene identifiers for all identified orthologs with boldface font for the 20
species used for additional bioinformatic analyses.
The multiple sequence alignment of the 21 NCCRP1 protein sequences (Figure 1
in IV) revealed that the mouse and rat sequences in Ensembl are either 25 residues
longer in the N-terminus, or the true start codon actually corresponds to M26.
Mammalian sequences are characterized by a proline-rich N-terminal domain of
approximately 60 residues, whereas fish sequences show shorter insertions
approximately at columns 150 and 190 in the alignment. NCCRP1 from the frog X.
tropicalis has short insertions similar to fish sequences, but the N-terminus is
incomplete such that the presence of the N-terminal domain remains inconclusive.
The major portion of the N-terminal domain in mammals is predicted to be
disordered. We ran human, mouse, and wallaby sequences through a prediction
server, which predicted disordered domains of 70, 57, and 49 residues in length,
respectively. These regions are shown underlined in Figure 1 of original publication
IV, which displays the endpoint of the disordered regions to be close to the end of
the additional sequence observed in mammals. There is an analogous Glu-and-Ala-
rich N-terminal domain in the PEST domain of FBXO2 that also appears to be
disordered. The N-terminal 47 residues show no electron density in the crystal
structures of mouse FBXO2 (2E31, 2E32, 2E33) (Mizushima et al. 2007), and the
disorder prediction is consistent with the 41 N-terminal residues predicted to be
disordered.
The human paralogs of NCCRP1, as shown by the Ensembl comparative
genomics tools and Blast searches, include the genes FBXO2, FBXO6, FBXO17,
FBXO27, and FBXO44. The protein products of these five genes are components of
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the E3 ubiquitin ligase complex and define a lectin subfamily within the ubiquitin
ligases (Glenn et al. 2008). In humans, the genes FBXO2, FBXO6, and FBXO44 are
contiguous genes on chromosome 1 (at 11.70 to 11.74 Mb), whereas FBXO17,
FBXO27 and NCCRP1 are on chromosome 19 (at 39.4 to 39.7 Mb). The protein
sequence identity of NCCRP1 with the other five lectin-type FBXO proteins ranges
from 31% to 36% in the last 180 residues, and the Blast E values range from 10-27 to
10-18, clearly indicating that these proteins share homology and common ancestry.
In the available fish genomes, we can find orthologs only to FBXO2, FBXO44,
and NCCRP1. Interestingly, the zebrafish genome carries a cluster of ten copies of
FBXO44 orthologs on chromosome 23.
By Interpro scan, all 21 protein sequences had domain matches to “Fbox-
associated” (FBA, IPR007397) and “galactose-binding domain-like” (IPR008979)
patterns in the ~200 C-terminal residues in fish and frog species and ~180 residues
in mammalian species. Only the protein products of NCCRP1 and the above five
FBXO gene loci are annotated to contain an FBA domain (InterPro entry
IPR007397), and no other human proteins were found in Blast searches when
NCCRP1 or the FBA domain of FBXO2 were used as queries. The products of these
five human FBXO genes also contain a cyclin-like F-box domain pattern (InterPro
entry IPR001810) in the N-terminal region that spans 50 residues or less, but none
of the NCCRP1 proteins matches this pattern.
Figure 2 in IV shows the alignment of human NCCRP1 with these five FBXO
proteins and their phylogenetic tree. Although there was no match to the cyclin-like
F-box domain pattern in the NCCRP1 sequence, 12 residues are conserved between
human NCCRP1 and at least three other FBXO proteins within the F-box domain
region (lines on top of the alignment in Figure 2 in IV). The primary differences in
this region are found in three indels in which NCCRP1 has the shorter sequences
and lacks many conserved residues, most notably the signature pattern CRxVC.
TMHMM predicts no transmembrane helices in any of the 21 examined
NCCRP1 ortholog proteins. SignalP predicts no signal peptides in any of the
proteins, and TargetP predicts a non-mitochondrial, non-secreted localization for all
of these proteins. The predictions for mouse and rat sequences were run with
alternative start sites: residue 1 (as for the Ensembl proteins) and residue 26 in
keeping with the translation start site of other mammalian sequences. All of these
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results indicate the absence of transmembrane domains and predict a cytoplasmic
localization of NCCRP1 in all of the examined species.
5.3.2 Biochemical properties
The human NCCRP1 cDNA was cloned into the expression vector pGEX-4T-1 and
expressed as a fusion protein with GST. The recombinant NCCRP1 protein was first
characterized using SDS-PAGE to determine its apparent molecular mass.
Following purification by affinity chromatography and digestion with thrombin,
NCCRP1 had an apparent mass of approximately 30 kDa in an SDS-PAGE gel
(Figure 5, lane 1 in IV).
High-resolution ESI FT-ICR mass spectrometry was used to confirm the amino-
acid sequence and disulfide arrangements in NCCRP1. Upon buffer exchange, the
NCCRP1 protein sample precipitated slightly, and mass analyses, therefore, were
conducted from both the precipitate and supernatant. A small amount of the
precipitate was dissolved in 100 ?l of 10 mM ammonium bicarbonate buffer pH 8.5,
further diluted with a acetonitrile/water/acetic acid (49.5:49.5:1.0, v/v) mixture and
directly analyzed with ESI FT-ICR mass spectrometry. Based on this analysis, the
precipitate was found to contain a 27-kDa protein and a small 3-kDa peptide (Figure
7A in IV). A reasonable match was found between most abundant isotopic mass of
the protein (27743.57 Da) and the NCCRP1 sequence. The fragment contained
residues 31-275 (theoretically 27743.45 Da), indicating the presence of one intra-
molecular disulfide bond (Cys158-Cys192) in the protein structure (see inset in
Figure 7A in IV). The monoisotopic mass of the observed peptide P (3260.51 Da)
was also matched against the NCCRP1 sequence and was found to correspond to the
first 30 residues of NCCRP1 with an additional Gly-Ser in the N-terminus
(theoretically 3260.52 Da). These amino acids are attributable to the pGEX-4T-1
expression vector construct (Figure 7B in IV).
To identify the produced protein further, a database search for the trypsin-
digested protein was performed. An aliquot of 20 ?l of the tryptic digest sample was
further diluted with 150 ?l of an acetonitrile/water/acetic acid (49.5:49.5:1.0, v/v)
mixture and analyzed directly. The digestion resulted in 18 identified tryptic
peptides within an average mass error of 6 ppm, covering 75% of the NCCRP1
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sequence. A search against the SwissProt database gave an unambiguous hit for
human NCCRP1 with a Mowse score of 370 (data not shown).
Mass spectra measured from the supernatant instead revealed the same 3-kDa
peptide that was detected in the precipitate and a small amount of the NCCRP1 [31-
275] fragment. In addition, small amounts of larger, currently unidentified 7-10 kDa
polypeptides were detected (data not shown).
5.3.3 Subcellular localization
Given that NCCRP1 has been predicted to be a type II (Jaso-Friedmann et al. 1997)
or type III (Evans et al. 1998) membrane receptor protein and because our
bioinformatic analyses strongly contradicted this prediction, we wished to study the
subcellular localization of NCCRP1 in HeLa cells using a novel NCCRP1 antibody.
NCCRP1 was detected in the cytoplasm as shown in green in Figure 8A and B of
original publication IV. Predictably, CA IX was expressed on the cell membrane
(Figure 8A and C, red color in IV). Interestingly, these two proteins were only
rarely co-expressed in the same cells (Figure 8A, arrows in IV). The control
immunostaining using 30 ?g of blocking NCCRP1 recombinant protein and anti-
NCCRP1 serum together resulted in only faint staining, confirming the specificity of
the antiserum (Figure 8D in IV). The second control staining using preimmune
serum instead of the anti-NCCRP1 serum showed virtually no staining (Figure 8E in
IV).
5.4 mRNA expression of NCCRP1 (IV)
5.4.1 Expression of Nccrp1 in mouse tissues
Nccrp1 expression in murine tissues was investigated using QRT-PCR. Nccrp1
mRNA levels were highest in the kidney and were moderate in the stomach, colon,
duodenum, and prostate (Figure 10 in IV). Transcripts were also present in other
examined tissues, including the parotid and submandibular glands, lung, jejunum,
ileum, and testis.
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5.4.2 Expression of NCCRP1 in human normal and cancer-
derived tissues
The IST database system developed by MediSapiens Ltd. was used to obtain data
regarding NCCRP1 mRNA expression in human normal and cancer-derived tissues
(Figure 9A and B, respectively in IV). The normal tissues with the strongest signal
included the esophagus, oral cavity, skin, tongue, and male and female reproductive
organs. The cancer-derived tissues with high NCCRP1 expression included
squamous cell carcinoma of the skin and cancers of the female reproductive organs.
5.4.3 Expression of NCCRP1 in human pancreatic and breast
cancer cell lines
Sixteen pancreatic cancer cell lines and 21 breast cancer cell lines were screened for
NCCRP1 expression using QRT-PCR. NCCRP1 expression was highest in the
Su.86.86, Hup-T4, and Hs700T pancreatic cancer cell lines and the MDA-MB-415,
SK-BR-3, and BT-474 breast cancer cell lines (Figure 12 in IV). In other cell lines,
NCCRP1 was expressed at moderate or low levels. In addition, CA9 expression was
examined in the same cell lines and compared to the expression of NCCRP1. CA9
gave the strongest signal in the DU4475 breast cancer cell line and the AsPC-1
pancreatic cancer cell line. Its expression was moderate in a few cell lines and was
low in several cell lines. It should be noted that NCCRP1 and CA9 showed
reciprocal expression patterns in some cell lines; i.e., when NCCRP1 expression was
high CA9 expression was low or absent and vice versa.
5.5  Silencing of NCCRP1 and CA9 (IV)
5.5.1 The functional connection between NCCRP1 and CA9
To examine whether NCCRP1 is directly regulated by CA9, siRNA-mediated gene
silencing was used. For this purpose, the CA9 was silenced in the human
glioblastoma cell line U373, which has a high basal level of CA9 expression.
Efficient downregulation of mRNA levels (up to 93% reduction compared to
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luciferase control siRNA-treated cells) was achieved for the CA9 gene with siRNA
treatment. CA9 silencing was monitored until 144 h after transfection and remained
effective at that time point. NCCRP1 expression was below the detection limit of
QRT-PCR at basal levels in U373 cells and did not change following the silencing
of CA9.
It was also investigated whether NCCRP1 silencing has any effect on the
expression level of CA9. NCCRP1 mRNA silencing was efficient in both HeLa and
Su.86.86 cell lines (up to 91% and 83% reduction when compared to luciferase
control siRNA-treated cells, respectively). In HeLa cells, the silencing of NCCRP1
was monitored until 144 h after transfection and remained effective. CA9 mRNA
levels were not affected by the silencing of NCCRP1 (Figure  13  in IV). CA9
expression increased until 120 h after transfection after which it decreased
dramatically. In Su.86.86 cells, CA9 expression also remained unchanged following
the silencing of NCCRP1 (data not shown).
5.5.2 Influence of NCCRP1 silencing on cell growth
The influence of NCCRP1 silencing on cell growth was examined in HeLa cells at
48, 96, and 144 h after transfection. The data analysis for this experiment was
performed using ImageJ. NCCRP1 silencing resulted in a statistically significant
decrease in HeLa cell proliferation at every time point examined (Figure 14 in IV).
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6. DISCUSSION
6.1 CA9 and CA12 are regulated by growth factors in
human cell lines
The results of previous studies examining CA IX and CA XII regulation have been
primarily confined to these proteins’ association with the HIF-regulated hypoxia
pathway. Thus, the aim of this study was to identify additional factors that regulate
these isozymes. This investigation was performed by stimulating seven human cell
lines with several hormones and growth factors.
In untreated cells, high CA9 expression was detected only in the U373 cell line.
Deferoxamine mesylate, which mimics the effect of hypoxia, notably increased CA9
expression in this line. IGF-1, TGF-?, TGF-?1, and EGF treatments also markedly
elevated CA9 levels. Moreover, CA9 levels were increased in HeLa cells following
deferoxamine mesylate treatment. These results are in accordance with the previous
finding that CA9 is strongly regulated by hypoxia (Wykoff et al. 2000).
Furthermore, it appears that CA9 is under tight regulation of HIF-1? given that
additional regulators are not evident. It is noteworthy that basal CA9 expression was
absent in all cell lines in which the treatment failed to induce CA9 expression, which
suggests that the factors necessary to drive CA9 transcription are missing or non-
functional in those cell lines.
Given that CA XII shows more widespread expression than CA IX in non-
malignant tissues, it can be presumed that the gene expression of CA XII is
regulated differently. In addition, no functional HRE has been reported for the CA12
gene. These data imply that hypoxia may not be the most important regulator of
CA12 expression. Therefore, it is not surprising that several treatments in our study
affected CA12 expression. In fact, growth factor treatment increased CA12 transcript
levels in four cell lines, all of which were of cancerous origin. In contrast,
deferoxamine mesylate treatment elevated CA12 expression in only two cell lines.
Interestingly, in the normal HUVEC cell line, growth factor treatments notably
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decreased CA12 expression levels. Therefore, it may be suggested that the induction
of CA12 expression by growth factors is specific to cancerous cells.
One exceptional line with respect to CA12 regulation was the MCF-7 line, which
is derived from human breast adenocarcinoma. First, deferoxamine mesylate did not
elevate CA12 expression but slightly decreased it. Second, in addition to TGF-?1
and EGF treatments, estradiol increased the levels of CA12 ?2-fold. Upregulation by
estradiol was not observed in any other cell line except Caki-1, where it increased
CA12 expression 1.5-fold. It has been demonstrated elsewhere that CA12 is strongly
upregulated by estradiol via ER? in MCF-7 cells and that a distal estrogen-
responsive enhancer region is involved in this induction (Barnett et al. 2008). In line
with these observations, CA XII-positive invasive breast cancer tumors have been
shown to be associated with a positive ER? status, low tumor grade and the absence
of necrosis (Watson et al. 2003). Because CA XII appears to be a favorable
prognostic marker in breast cancer, it could be expected that its expression is not
regulated by hypoxia, which has been linked to poor prognosis. Similar to CA9,
CA12 expression was not induced in cell lines lacking CA12 expression in control
conditions.
Our data provides no mechanistic explanation regarding how the tested growth
factors regulate CA9 and CA12. However, it can be suggested that at least in the
case of CA IX, the primary inductive effects observed in this study are mediated via
stabilization of HIF-1? protein levels. This effect has been previously demonstrated
following treatment with several growth factors under normoxia (Feldser et al. 1999,
Zhong et al. 2000). The hypothesis that HIF-1? stabilization drives CA9 expression
may also hold for CA12, but it is possible that other unidentified regulatory
pathways exist.
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6.2 CA IX and CA XII expression during mouse
organogenesis
6.2.1 CA IX and CA XII are expressed in several tissues during
mouse embryonic development
CA IX and CA XII expression has been previously examined in human and rodent
tissues, but no data concerning their expression during embryonic development have
been published prior to this study. Therefore, our aim was to investigate whether
these enzymes are present in developing mouse embryos.
It was found that both CA IX and CA XII are expressed in several mouse
embryonic tissues. CA IX showed a relatively wide distribution pattern; moderate
signals were observed in the brain, pancreas, and liver, and weak signals were
detected in the urogenital system, lung, and stomach. The fact that CA IX
expression was detected in the stomach at all mouse ages examined is in agreement
with the discovery that CA IX is required for the normal development of the gastric
mucosa (Ortova Gut et al. 2002). The expression pattern of CA XII was also
relatively broad, although the staining was weak in most tissues. The positive tissues
included the brain (most prominently in the choroid plexus), stomach, pancreas,
liver, kidney, and lung.
Interestingly, both isozymes were present in embryonic tissues with adult
counterparts that are negative for expression. Positive labeling for CA IX was
observed in the heart and lung, which have been shown to be negative in the adult
mouse. A weak CA XII signal was detected in several embryonic tissues, including
the stomach, pancreas, and liver, which have been previously reported to be
negative in adult mice (Halmi et al. 2004), and showed no immunoreaction in the
present control stainings with adult tissues. Similar to CA IX, a positive signal was
observed for CA XII in the embryonic heart. However, it must be taken into
consideration that the adult heart tissue also exhibited a slight positive staining for
both CA IX and CA XII based on an automated immunostaining method, even
though the expression of both was considered negative (Halmi et al. 2004, Hilvo et
al. 2004). Therefore, the signal in the heart is interpreted to be nonspecific.
In a recent study, CA IX and CA XII expression was immunohistochemically
examined during human development (Liao et al. 2009). The examined cases
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included the embryonic period (4 to 8 weeks), the fetal period (9 weeks to birth) and
the postnatal period (one day to 8 years old). The expression pattern of CA IX was
considerably extensive, even more so than that of CA XII. CA IX expression was
also notably more extensive in comparison to its expression in adult tissues. The
expression of these isozymes in mouse and human embryonic tissues is shown in
Table 4.
Table 4. CA IX and CA XII expression in mouse and human tissues during
embryonic development. Mouse data are from original publication I of this
study and human data are derived from (Liao et al. 2009).*
Organ CA IX in
mouse
CA IX in
human
CA XII in
mouse
CA XII in
human
Placenta ND X ND -
Skin ND X ND -
Body cavity ND X ND -
Nervous system X X X X
Nose ND X ND -
Oral cavity ND X ND X
Tongue ND - ND X
Salivary glands ND - ND X
Thymus ND X ND -
Heart X X X -
Lung X X X X
Esophagus ND X ND X
Stomach X X X X
Gastrointestinal canal X X X X
Pancreas X X X X
Liver X X X -
Urogenital system X X X X
Genital organ system ND X ND X
Skeletal system ND X ND -
*Abbreviations: signal is present (X), signal is absent (-), not done (ND).
Transient CA IX expression during human development was limited to immature
tissues of mesodermal origin and the skin and ependymal cells (Liao et al. 2009).
The only tissues that persistently expressed CA IX were the coelomic epithelium
(mesothelium) and its remnants, the epithelium of the stomach and biliary tree, the
glands and crypt cells of the duodenum and the more distal small intestine, and the
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cells located at sites that were previously identified as harboring adult stem cells in
(e.g., in the skin and large intestine). It was noted that during human development,
nearly every CA IX-positive cell was derived from the mesoderm and was related to
the embryonic coelom and mesenchyme. The only exceptions were the skin, the
squamous mucosa, the upper gastrointestinal tract and the efferent ductules. It
should also be noted that all of the CA IX positive tissues in our study also showed
positive signals in corresponding human tissues.
CA XII expression in human embryonic tissues was restricted to cells involved in
secretion and water absorption, such as the parietal cells of the stomach, acinar cells
of the salivary glands and pancreas, the epithelium of the large intestine, and the
renal tubules (Liao et al. 2009). In contrast to CA IX, nearly every tissue that
expressed CA XII during embryonic development retained its expression after birth
and throughout adult life. CA XII expression was also rather consistent between
mouse and human tissues with the only exceptions being the heart and liver, which
were positive for CA XII in our study but lacked this isozyme in human embryonic
tissues. These data strongly suggest that both isozymes are required during mouse
and human organogenesis. These isozymes probably have a role in the regulation of
appropriate pH levels in various embryonic tissues.
It has been demonstrated that the environment of the mammalian embryo and the
early fetus is hypoxic (Chen et al. 1999, Ramirez-Bergeron et al. 2004). As
vascularization proceeds, hypoxic tissues become progressively normoxic. Thus, the
co-localization of CA IX and CA XII with HIF-1? during human development was
investigated by a prior study (Liao et al. 2009). The co-localization of CA IX and
HIF-1? was limited to certain cell types in embryonic and early fetal tissues. These
cells comprised the primitive mesenchyma or were involved in chondrogenesis and
skin development. This finding implies that CA IX expression during development
is partially regulated by hypoxia but that other mechanisms are also present.
Alternatively, co-localization of CA XII with HIF-1? was not observed. Therefore,
it appears that CA XII expression is not regulated by hypoxia during human
embryonic development.
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6.2.2 Transcriptional changes in the mouse gastric mucosa in
response to CA IX deficiency
In the present study, we used cDNA microarray technology to identify genes and
pathways that are either down- or upregulated in the gastric mucosa of CA IX-
deficient mice. This method allows for simultaneous, genome-wide gene expression
profiling. The validation of the microarray data was conducted using QRT-PCR.
Notably good agreement between the two methods was observed; 13 (92.9%) out of
14 genes showed concordant results between microarray analysis and QRT-PCR.
Generally, the fold change values obtained by microarray analysis were smaller than
those detected by QRT-PCR. A similar phenomenon has previously been described
(DeNardo et al. 2005) and probably reflects the fact that measurement by array
analysis is much less quantitative than by QRT-PCR. Therefore, the fold changes
observed using the array are likely an underestimation of the true differences in gene
expression.
Car9 knockout mice have been previously described (Ortova Gut et al. 2002).
These mice were reported to appear healthy and fertile, but closer histopathological
analysis of their stomach specimens revealed hyperplastic changes in the gastric
mucosa in comparison to their wild-type littermates. These phenotypic changes were
accompanied by numerous large cysts. Although it has been observed that CA IX is
probably involved in cell proliferation, no detailed data exists to explain this
phenomenon. To this end, we performed a genome-wide cDNA microarray analysis
to detect the specific transcriptomic responses to CA IX deficiency in the stomach,
which is the tissue with the most abundant CA IX expression in normal mice (Hilvo
et al. 2004).
According to our analysis, upregulation was more prevalent than downregulation
among the differentially expressed genes. The functional categories most
overrepresented among the disregulated genes were hydrolase activity,
developmental processes, cell differentiation, proteolysis, peptidase activity,
structural molecule activity, and immune system process. It should be noted that
there was no overrepresented category containing genes involved in the regulation
of cellular ion homeostasis. This finding is in agreement with the observation from
the original study of Car9 knockout mice that these mice had a normal gastric pH,
systemic acid-base balance, and plasma electrolyte values (Ortova Gut et al. 2002).
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However, CA IX has been suggested to participate in gastric acid secretion by
contributing to the AE2-CA II-CA IX bicarbonate transport metabolon (Morgan et
al. 2007). Based on the accumulated data to date, it appears that CA IX is
dispensable in the gastric acid secretion process and is not critical for pH regulation
in the stomach. Interestingly, one of the most highly upregulated genes observed in
the present study was SLC9A3/NHE3, which contributes to the major proton
extruding system driven by the inward sodium ion chemical gradient (He and Yun
2010). SLC9A3 is involved in pH regulation and acts by eliminating acids generated
by active metabolism or by countering adverse environmental conditions. In the
gastrointestinal tract, SLC9A3 is expressed in the apical membrane and recycling
endosomes of the ileum, jejunum, colon, and stomach (Hoogerwerf et al. 1996). The
strong upregulation of SLC9A3 in response to CA IX deficiency may indicate that
CA IX is involved in the regulation of intracellular pH in the stomach. Thus, the
high induction of SLC9A3 may be a compensatory mechanism for the lack of CA
IX.
As expected, our study revealed that genes associated with developmental
processes and cell differentiation were misregulated in the gastric mucosa of CA IX-
deficient mice. This supports the previous notion that CA IX has a role in normal
gastric morphogenesis and is required for proper cell lineage formation (Ortova Gut
et al. 2002). Furthermore, a recent microarray study examining the transcriptomic
responses to Car9 knockout in the brain demonstrated that CA IX deficiency
reduced the expression of genes belonging to the functional category “regulation of
cell proliferation” (Pan et al. 2011b). These results, therefore, imply that CA IX may
contribute to cell proliferation/differentiation in several tissues.
One of the overrepresented functional categories among the misregulated genes
in CA9-deficient mice was “immune system process.” This result is in accordance
with the observation from an earlier study that reported gastric submucosal
inflammation in the body region in a majority of C57BL/6 Car9?/? mice (Leppilampi
et al. 2005a). The category “immune system process” included both up- and
downregulated genes with several genes being highly induced. Among these were
deleted in malignant brain tumors 1 (Dmbt1), surfactant associated protein D
(Sftpd/SP-D), and interleukin 1 receptor-like 1, transcript variant 2 (Il1rl1/ST2).
Moreover, CA IX deficiency significantly repressed the bloom syndrome homolog
(human) gene (Blm), which has a role in the proliferation and survival of both
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developing and mature T lymphocytes (Babbe et al. 2007). In addition, the
conditional knockout of Blm has been shown to cause compromised B cell
development and maintenance (Babbe et al. 2009). Based on these data, it is
plausible that CA IX contributes to immune responses and may have a role in the
development of the immune system.
An interesting finding was that several small proline-rich proteins (Sprr) were
markedly upregulated in the Car9 knockout mice stomach, including Sprr1a,
Sprr2d, Sprr2e, Sprr2i, and Sprr3. It should be noted, however, that only the
upregulation of Sprr1a was statistically significant. SPRR proteins were originally
identified as markers for terminal squamous cell differentiation where they are
precursors of the cornified envelope (Baden et al. 1987). It was later shown that
SPRR proteins participate in the response to various stresses in many tissues without
a stratified epithelium. Therefore, it appears that CA IX deficiency may create a
stress condition in the gastric mucosa, requiring the induction of protective factors.
Interestingly, this study revealed several digestive enzymes among the most
downregulated genes. Only a portion of these changes were statistically significant.
This result may be a direct consequence of the CA IX deficiency or a secondary
event in response to a disturbance in cell lineage in the hyperplastic stomach.
To summarize, our microarray analysis indicates that CA IX is indeed a
multifunctional enzyme with roles extending far beyond the basic pH regulation
function of CAs. In fact, the microarray study of the brain phenotype of Car9
knockout mice demonstrated that these mice exhibited several abnormal behavioral
features and reduced memory capacity (Pan et al. 2011b). Moreover, histological
brain samples of old Car9?/? mice revealed vacuolar degeneration in all regions of
the brain. According to the results, the functional changes preceded the microscopic
alterations in the brain. Thus, it is likely that CA IX also functions in the brain,
which would represent yet another role for this enzyme.
6.3 NCCRP1 is the sixth member of the lectin-type
FBXO gene family
We took notice of the fact that Nccrp1 was significantly overexpressed in the gastric
mucosa of CA IX-deficient mice. Thus, one of the goals of this study was to
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characterize NCCRP1, as it is a strikingly underexamined gene and is studied by
only a few publications. Moreover, NCCRP1 has only been examined in fish
species, and no information exists regarding its mammalian counterparts. Our
bioinformatic analyses clearly showed that the closest human paralogs of NCCRP1
are the lectin-type F-box-only (FBXO) gene family members FBXO2, FBXO6,
FBXO17, FBXO27, and FBXO44. This result was surprising, given that NCCRP1
has been considered to function as an antigen-binding transmembrane receptor on
fish nonspecific cytotoxic cells. For this reason, NCCRP1 was thought to participate
in innate immune responses (Evans et al. 1998). Moreover, all of our bioinformatic
predictions, which were conducted in several species, showed that NCCRP1 is
localized in the cytoplasm. We also experimentally confirmed that human
recombinant NCCRP1 indeed is localized in the cytoplasm in HeLa cells.
Given that the protein products of FBXO genes are components of the E3
ubiquitin ligase complex, it is reasonable to believe that NCCRP1 also functions as
a protein-binding component in these complexes. The presumed role of FBXO
proteins is to bind misfolded and retrotranslocated glycoproteins in the cytoplasm
for ubiquitin conjugation. These bound proteins are then degraded in proteasomes
(Glenn et al. 2008). Among the dozens of different F-box ubiquitin ligase subunits
found in ubiquitin ligase complexes, the ability of the FBXO family members to
bind glycoproteins is unique. This is due to the conserved "F-box associated" (FBA)
or lectin domain, which is located in the C-terminus of the FBXO proteins and is not
found in any other protein in the human proteome. It has been experimentally
demonstrated that there are major functional differences among the FBXO proteins
(Glenn et al. 2008). It appears that FBXO2 and FBXO6 regulate high mannose
glycoproteins while FBXO6 and FBXO17 regulate sulfated glycoproteins. It is also
thought that FBXO6, FBXO17, and FBXO27 may regulate certain complex
glycoproteins. In a previous study (Glenn et al. 2008), FBXO44 failed to bind
glycans. The authors speculated that this may be an actual phenomenom or that the
effect was merely due to technical limitations, such as the possibility that their array
did not contain the appropriate glycoprotein substrate. Taken together, the glycan-
binding ability of NCCRP1 cannot be deduced based on our current studies but
remains to be tested experimentally.
We also produced human recombinant NCCRP1 in E. coli and analyzed it using
mass spectrometry. Surprisingly, mass spectrometry analysis indicated the presence
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of a truncated protein in the NCCRP1 sample following purification and buffer
exchange. This polypeptide corresponded to residues 31-275 of the full-length
protein. However, the peptide corresponding to the first 30 residues was also
detected, suggesting that the N-terminal portion had been cleaved following protein
production, likely during sample treatment for mass spectrometry. In addition,
protein precipitation was observed upon buffer-exchange, but it is not known
whether this is related to the observed N-terminal cleavage or to alterations in the
buffer conditions. The reason underlying the intrinsic structural weakness of the
NCCRP1 protein is also unknown. However, our sequence analyses predict that the
N-terminal proline-rich region of mammalian NCCRP1 proteins is disordered. This
finding may partially explain the observation of N-terminal truncation. Mass
analysis of the NCCRP1 [31-275] fragment also suggested the presence of an intra-
molecular disulfide bond between Cys158 and Cys192.
The mRNA expression of Nccrp1 has previously been examined in different fish
species (Ishimoto et al. 2004, Cuesta et al. 2005, Sakata et al. 2005). Prior to the
present study, however, there were no data regarding the distribution of Nccrp1 in
human or mouse tissues. In mice, Nccrp1 showed a broad expression pattern and
was detected in each of the eleven tested tissues. The strongest expression was
detected in the kidney, and moderate expression was observed in the stomach,
colon, duodenum, and prostate. In addition, Nccrp1 was expressed at a lower level
in the lung, jejunum, ileum, testis and in the parotid and submandibular glands.
These data would place Nccrp1 in the group of FBXO6, FBXO27, and FBXO44,
which also are expressed relatively ubiquitously (Glenn et al. 2008). In fish, Nccrp1
also exhibits a similar ubiquitous expression pattern; it is expressed equally in
immune and in non-immune tissues, further contradicting the previous consensus
that NCCRP1 is a protein involved in immune responses. Interestingly, the NCCRP1
expression in normal human tissues was primarily detected in tissues consisting of
squamous epithelium. These tissues included the esophagus, oral cavity, skin, and
tongue. In human cancerous tissues, the NCCRP1 expression pattern was strikingly
similar; the highest expression was observed in squamous cell carcinomas of the
skin, cervix, and vagina/vulva. Therefore, it appears that human and mouse
NCCRP1 transcripts are expressed in different sets of tissues, and that the
expression pattern of human NCCRP1 is clearly more restricted. It should be noted,
however, that our repertoire of mouse tissues was not as extensive as the database
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from which human data were obtained. Thus, it is possible that mouse transcripts are
also strongly expressed in tissues with squamous epithelium.
In summary, this study provided a wealth of data suggesting that NCCRP1 is the
sixth member of the lectin-type FBXO gene family. Accordingly, we propose that
the gene name should be changed to FBXO50 (the number may change based on the
decision of the Human Gene Nomenclature Committee).
6.4 NCCRP1 is not directly regulated by CA9
One purpose of this study was to elucidate the possible connections between CA IX
and NCCRP1 at both the protein and gene levels. Immunocytochemistry indicated
that co-expression of NCCRP1 and CA IX in HeLa cells was rare. A similar
phenomenon was observed when the expression levels of these two genes were
compared at the mRNA level in an extensive panel of pancreatic and breast cancer
cell lines; NCCRP1 and CA9 expression exhibited an inverse correlation in certain
cell lines. Moreover, it was also revealed that NCCRP1 transcript levels were
moderately decreased following deferoxamine mesylate treatment, which is
commonly used to induce a hypoxia-like response and strongly increases CA9
levels. Based on these preliminary studies, it, therefore, appears that NCCRP1 and
CA IX do not share common regulatory mechanisms with respect to their
expression.
Interestingly, there are other genes that have been demonstrated to be
downregulated by hypoxia. Low oxygen tension has been shown to decrease the
levels of the angiogenesis inhibitor thrombospondin-1 in glioblastoma cells,
suggesting that hypoxia may promote angiogenesis not only by stimulating the
production of angiogenesis inducers but also by reducing the production of
angiogenesis inhibitors (Tenan et al. 2000). In addition, hypoxia has been
demonstrated to downregulate drug-metabolizing enzymes in human hepatoma cells
(Legendre et al. 2009). Furthermore, hypoxia causes a decrease in levels of the CAD
enzyme, which catalyzes the first three steps of de novo pyrimidine biosynthesis
(Chen et al. 2005). DNA synthesis diminishes when cultured cells are exposed to
hypoxia (Amellem et al. 1998), leading to cell-cycle arrest at the G1/S-phase. This
effect may be due to the decrease in CAD enzyme levels. The exact mechanism by
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which hypoxia downregulates NCCRP1 in HeLa cells remains to be elucidated.
However, this downregulation may cause a cell cycle arrest similar to that imparted
by CAD. We arrive at this hypothesis because we also observed that silencing
NCCRP1 in the same HeLa cells led to a statistically significant decrease in cell
growth. One hypothesis is that NCCRP1 controls the cell cycle by adjusting the
degradation of proteins that control the cell cycle, such as cyclins. Cyclins are
present only at particular times during the cell cycle; after they are no longer
required, they are destroyed through ubiquitination and subsequent digestion by the
proteasome (Nandi et al. 2006).
With respect to the regulation of NCCRP1 and the involvement of CA9,  it  was
shown in this research that NCCRP1 is  not  directly  regulated  by CA9; when CA9
was silenced, NCCRP1 levels remained unaltered. Thus, it appears that the
upregulation of Nccrp1 observed in the stomachs of CA IX-deficient mice is a
secondary event. One could speculate that CA IX deficiency leads to an
accumulation of misfolded glycoproteins in the gastric mucosa and that NCCRP1 is
required to target these proteins for degradation in proteasomes. This hypothesis
appears to be reasonable because it is known that CA IX is essential for the
development of proper cell lineage architecture in the gastric epithelium.
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7. SUMMARY AND CONCLUSIONS
The primary conclusions drawn from this study are the following:
1) Treatment with the growth factors IGF-1, TGF-?, TGF-?1, and EGF
increased CA9 and CA12 mRNA levels in cancer cell lines. In contrast to
CA9, CA12 expression does not appear to be primarily regulated by hypoxia.
2) CA IX and CA XII were present in several tissues of the developing mouse
embryo during organogenesis. Both isozymes were expressed in certain
embryonic tissues with adult counterparts that are negative for these
proteins. Thus, it appears that CA IX and CA XII have important roles in the
development of certain tissues.
3) Car9 gene disruption alters the expression of several genes in the mouse
gastric mucosa. The differentially expressed genes include those involved in
developmental processes, cell differentiation, and immune responses.
Additionally, the downregulation of several digestive enzymes was detected.
These data indicate that CA IX is not essential for the pH regulation in the
stomach but is required for many other physiological processes.
4) NCCRP1 was significantly upregulated in the gastric mucosa of CA IX-
deficient mice but is not directly regulated by CA9. Previously, NCCRP1 has
been primarily examined in fish and was thought to be a transmembrane
protein responsible for the cytolytic function of nonspecific cytotoxic cells.
Our characterization of NCCRP1 demonstrated that it is an intracellular
protein and that its mRNA is present in several tissues in human and mouse.
These data are incompatible with an immune receptor function. Because the
paralogs of NCCRP1 are FBXO proteins with protein products that are
components of the E3 ubiquitin ligase complex, it appears evident that
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NCCRP1 also functions as a protein-binding component in ubiquitin ligase
complexes. Thus, the NCCRP1 gene name should be changed to FBXO50.
Additionally, NCCRP1 silencing led to a statistically significant decrease in
the growth of HeLa cells, which is an effect that may be due to the
ineffective degradation of misfolded glycoproteins.
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SUPPLEMENTARY DATA
Appendix 1. Genes that display altered mRNA expression in the stomach of Car9?/?
mice.
FC P-value Symbol Description GeneBank number
Illumina
probe
QRT-
PCR
10.46
8.07
5.95
5.68
5.38
4.26
4.19
4.11
3.81
3.54
3.46
3.45
3.39
3.31
3.30
3.08
3.02
3.01
2.94
2.94
2.88
2.84
2.78
2.69
2.52
2.44
2.35
2.25
2.20
2.16
2.15
2.15
2.11
2.11
2.06
2.02
1.99
1.97
1.94
1.92
1.90
1.89
1.88
1.84
1.83
3.50E-05
3.10E-05
0.0029
8.58E-04
3.53E-04
0.0010
7.92E-04
0.0040
0.0328
0.0103
0.1915
0.0120
0.2717
0.1199
0.0238
0.0482
0.2987
0.2953
0.3442
0.3850
0.0188
0.4324
0.3322
0.0319
0.3413
0.0739
0.1425
0.1958
0.5002
0.5238
0.1051
0.1197
0.1306
0.3698
0.2388
0.5696
0.3104
0.1978
0.3578
0.3797
0.3427
0.3648
0.6306
0.2173
0.4764
Cym
Slc9a3
U46068
Dmbt1
Il1rl1
Tm4sf5
9130204L05Rik
Sftpd
Nccrp1
Pkp4
Sprr2d
Gm14446
Sprr3
Sprr2i
Sprr1a
Ivl
Serpinb12
Krt10
Gm94
Krt13
Gsdmc2
Lor
Dmkn
Ly6d
Krt1
Isg15
Tprg
Mup1
Asprv1
Rptn
Oas1g
Il33
Trex2
Calm4
Stfa1
Lce3f
LOC625123
Igh-VJ558
Hopx
Hrnr
2300005B03Rik
Klk5
Flg
Muc5ac
Lypd3
chymosin
solute carrier family 9 (sodium/hydrogen exchanger),
member 3
cDNA sequence U46068, transcript variant 2
deleted in malignant brain tumors 1
interleukin 1 receptor-like 1, transcript variant 2
transmembrane 4 superfamily member 5
RIKEN cDNA 9130204L05 gene
surfactant associated protein D
non-specific cytotoxic cell receptor protein 1 homolog
(zebrafish)
plakophilin 4, transcript variant 1
small proline-rich protein 2D
predicted gene 14446, transcript variant 2
small proline-rich protein 3
small proline-rich protein 2I
small proline-rich protein 1A
involucrin
serine (or cysteine) peptidase inhibitor, clade B
(ovalbumin), member 12
keratin 10
predicted gene 94
keratin 13
gasdermin C2, transcript variant 2
loricrin
dermokine, transcript variant 2
lymphocyte antigen 6 complex, locus D
keratin 1
ISG15 ubiquitin-like modifier
transformation related protein 63 regulated
major urinary protein 1
aspartic peptidase, retroviral-like 1
repetin
2'-5' oligoadenylate synthetase 1G
interleukin 33
three prime repair exonuclease 2
calmodulin 4
stefin A1
late cornified envelope 3F
PREDICTED: hypothetical LOC625123
PREDICTED: Mus musculus immunoglobulin heavy
chain (J558 family)
HOP homeobox, transcript variant 1
hornerin
RIKEN cDNA 2300005B03 gene
kallikrein related-peptidase 5
PREDICTED: filaggrin
mucin 5, subtypes A and C, tracheobronchial/gastric
Ly6/Plaur domain containing 3
NM_001111143
NM_001081060
NM_153418
NM_007769
NM_010743
NM_029360
NM_001101461
NM_009160
NM_001081115
NM_026361
NM_011470
NM_001101605
NM_011478
NM_011475
NM_009264
NM_008412
NM_027971
NM_010660
NM_001033280
NM_010662
NM_177912
NM_008508
NM_172899
NM_010742
NM_008473
NM_015783
NM_175165
NM_031188
NM_026414
NM_009100
NM_011852
NM_133775
NM_011907
NM_020036
NM_001082543
NM_001018079
XM_889664
XM_001472091
NM_175606
NM_133698
NM_001081961
NM_026806
XM_001481265
NM_010844
NM_133743
101940433
102760048
2690242
7050270
6020347
3120280
105360685
6510181
107100301
106940451
1340458
103610008
580347
6760369
3870064
105570156
1500671
5340471
102350167
540082
104730059
50538
3290575
4050010
2480050
3170093
6860538
430685
2650079
5290605
2450280
6590687
4920707
60026
3610451
540524
100070280
1690184
103850021
780121
3840047
102900390
104760609
103140592
4120288
19.66
10.72
5.29
8.95
3.69
1.09
122
1.79
1.79
1.78
1.76
1.76
1.74
1.71
1.70
1.68
1.67
1.66
1.63
1.62
1.61
1.61
1.61
1.61
1.60
1.59
1.58
1.56
1.55
1.54
1.53
1.52
1.50
1.49
1.49
1.48
1.48
1.47
1.45
1.45
1.44
1.44
1.43
1.43
1.43
1.41
1.41
1.40
-1.53
-1.54
-1.66
-1.67
-1.76
-1.79
-1.93
-2.08
-2.27
-2.32
-2.57
-2.65
-2.68
-2.73
-2.77
-2.91
-2.96
-3.19
-3.27
-3.32
0.3676
0.5632
0.5372
0.3926
0.5030
0.3182
0.3080
0.5794
0.3971
0.3966
0.6872
0.5522
0.4682
0.3825
0.4577
0.4581
0.6711
0.4044
0.4663
0.3848
0.3694
0.6348
0.6474
0.7142
0.4422
0.5629
0.5392
0.5536
0.5780
0.6786
0.7306
0.5631
0.7460
0.5743
0.6371
0.5255
0.5562
0.6134
0.5788
0.6263
0.5496
0.3923
0.4151
0.3482
0.3355
0.4511
0.3131
0.1899
0.1208
0.1201
0.1337
0.3655
0.1128
0.0501
0.1115
0.0270
0.0448
0.0180
0.1251
0.0452
0.0707
9130409I23Rik
Crct1
Lce3c
Lce3b
Tacstd2
Sprr2e
S100a8
Lce1m
Cdsn
Ephx3
Krt14
Lce1f
LOC620017
Klk10
Defb4
LOC677643
Lce1b
Tmem45a
LOC100047788
Scel
S100a9
Casp14
Mt4
Lgals7
Klk13
2310033E01Rik
Mlze
Klk7
Lce1i
Lce1d
Lce1c
LOC100047162
Kprp
Ighg
Serpina12
Ppl
2310005G13Rik
Stfa2
Pla2g4e
Nmu
Trim29
Ins1
Hp
Cxcl13
Cybrd1
Fbxw5
Ins2
Lep
Dbp
Gcg
Cpa2
Zg16
Cyp2e1
Slc5a8
Cpb1
Bhlha15
Sycn
Gper
Ctrl
Scd1
Spink3
RIKEN cDNA 9130409I23 gene
cysteine-rich C-terminal 1
late cornified envelope 3C
late cornified envelope 3B
tumor-associated calcium signal transducer 2
small proline-rich protein 2E
S100 calcium binding protein A8 (calgranulin A)
late cornified envelope 1M
corneodesmosin
epoxide hydrolase 3
keratin 14
late cornified envelope 1F
PREDICTED: similar to Ig kappa chain V-V region L7
precursor
kallikrein related-peptidase 10
defensin beta 4
PREDICTED: similar to monoclonal antibody BBK-2
heavy chain
late cornified envelope 1B
transmembrane protein 45a
PREDICTED: similar to gamma-2a immunoglobulin
heavy chain
sciellin
S100 calcium binding protein A9 (calgranulin B)
caspase 14
metallothionein 4
lectin, galactose binding, soluble 7
kallikrein related-peptidase 13
RIKEN cDNA 2310033E01 gene
melanoma-derived leucine zipper, extra-nuclear factor
kallikrein related-peptidase 7 (chymotryptic, stratum
corneum)
late cornified envelope 1I
late cornified envelope 1D
late cornified envelope 1C
PREDICTED: similar to immunoglobulin kappa-chain
keratinocyte expressed, proline-rich
PREDICTED: immunoglobulin heavy chain (gamma
polypeptide), transcript variant 1
serine (or cysteine) peptidase inhibitor, clade A (alpha-1
antiproteinase, antitrypsin), member 12
periplakin
RIKEN cDNA 2310005G13 gene
stefin A2
phospholipase A2, group IVE
neuromedin U
tripartite motif protein 29
insulin I
haptoglobin
chemokine (C-X-C motif) ligand 13
cytochrome b reductase 1
F-box and WD-40 domain protein 5
insulin II
leptin
D site albumin promoter binding protein
glucagon
carboxypeptidase A2, pancreatic
zymogen granule protein 16
cytochrome P450, family 2, subfamily e, polypeptide 1
solute carrier family 5 (iodide transporter), member 8
carboxypeptidase B1 (tissue)
basic helix-loop-helix family, member a15
syncollin
G protein-coupled estrogen receptor 1
chymotrypsin-like
stearoyl-Coenzyme A desaturase 1
serine peptidase inhibitor, Kazal type 3
NM_001033819
NM_028798
NM_033175
NM_025501
NM_020047
NM_011471
NM_013650
NM_025420
NM_001008424
NM_001033163
NM_016958
NM_026394
XM_357633
NM_133712
NM_019728
XR_031047
NM_026822
NM_019631
XR_033948
NM_022886
NM_009114
NM_009809
NM_008631
NM_008496
NM_001039042
NM_001037143
NM_031378
NM_011872
NM_029667
NM_027137
NM_028622
XM_001477552
NM_028629
XM_001001076
NM_026535
NM_008909
NM_183281
NM_001082545
NM_177845
NM_019515
NM_023655
NM_008386
NM_017370
NM_018866
NM_028593
NM_013908
NM_008387
NM_008493
NM_016974
NM_008100
NM_001024698
NM_026918
NM_021282
NM_145423
NM_029706
NM_010800
NM_026716
NM_029771
NM_023182
NM_009127
NM_009258
101660086
2320040
6620451
4810400
6660341
6620100
70112
5570435
100510520
5270400
2340402
6400593
510347
4540050
4150600
6860520
3120619
100770242
360113
3190129
7050528
6510156
4780338
100840315
105860372
102630524
106510451
870300
3830348
2350014
1780750
110632
101980465
6040164
1230128
2360072
3130577
104670390
103610088
6400025
4560369
5220072
6350068
6290402
105700114
4810102
610040
4010053
4200270
6220735
100380021
1240338
103290400
6130110
290600
6620020
2570040
7570008
2120301
2680441
1580008
-18.22
123
-3.32
-3.36
-3.37
-3.41
-3.48
-3.52
-3.64
-3.67
-3.68
-3.72
-3.74
-3.80
-3.95
-4.07
-4.17
-4.30
-5.00
-5.35
-6.23
-6.27
-7.04
-7.12
-7.59
-9.85
-10.57
-12.14
0.1116
0.0165
0.0137
0.0049
0.1086
0.0468
0.0046
0.0037
0.0046
0.0519
0.0515
0.0048
0.1154
0.0049
0.0033
0.0084
0.1227
0.0451
0.0192
5.80E-04
0.0011
0.0024
0.0153
1.45E-04
9.60E-05
1.02E-04
Cela3b
Nrn1
EG640530
LOC100043836
LOC638418
Chia
Slc38a5
Abpg
Egf
Car3
Adipoq
Slc27a2
Cpa1
Tmed6
Sostdc1
Mug1
Ctrb1
Cfd
Pnlip
Blm
Gdf9
Gm12888
Cela2a
Amy2a5
Prss1
Try4
chymotrypsin-like elastase family, member 3B
neuritin 1
PREDICTED: predicted gene, EG640530
PREDICTED: similar to lacrimal androgen-binding
protein delta, transcript variant 1
PREDICTED: similar to Ela3 protein
chitinase, acidic
solute carrier family 38, member 5
androgen binding protein gamma
epidermal growth factor
carbonic anhydrase 3
adiponectin, C1Q and collagen domain containing
solute carrier family 27 (fatty acid transporter), member 2
carboxypeptidase A1
transmembrane emp24 protein transport domain
containing 6
sclerostin domain containing 1
murinoglobulin 1
chymotrypsinogen B1
complement factor D (adipsin)
pancreatic lipase
bloom syndrome homolog (human), transcript variant 1
growth differentiation factor 9
predicted gene 12888
chymotrypsin-like elastase family, member 2A
amylase 2a5, pancreatic
protease, serine, 1 (trypsin 1)
trypsin 4
NM_026419
NM_153529
XM_917532
XM_001481113
XM_914439
NM_023186
NM_172479
NM_178308
NM_010113
NM_007606
NM_009605
NM_011978
NM_025350
NM_025458
NM_025312
NM_008645
NM_025583
NM_013459
NM_026925
NM_007550
NM_008110
NM_001033791
NM_007919
NM_001042711
NM_053243
NM_011646
4060731
4230471
70601
2360497
3990711
5390131
540093
1660577
5220154
870687
6590519
104480458
4730022
6510048
6760017
3170497
1050347
2320736
6450341
520619
2350181
102060176
5270129
580138
6370400
5860044
-75.74
-3.71
-15.39
-20.51
-27.45
-23.88
-16.23
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Appendix 2. Functional annotation of genes disregulated in the stomach of Car9
knockout mice.
Functional category Gene symbol Description
GenBank
number
FC P-value
Developmental processes
(Contains the following categories:
Epidermis morphogenesis
Tissue morphogenesis
Epidermis development
Ectoderm development
Tissue development
Organ development
Anatomical structure development
Anatomical structure morphogenesis
Cellular developmental process
Multicellular organismal
development
Epidermal cell differentiation)
Dmbt1
Sftpd
Sprr2d
Sprr3
Sprr2i
Sprr1a
Lor
Hopx
Hrnr
Sprr2e
Krt14
Scel
Lgals7
Cxcl13
Lep
Bhlha15
Nrn1
Egf
Sostdc1
Blm
deleted in malignant brain tumors 1
surfactant associated protein d
small proline-rich protein 2d
small proline-rich protein 3
small proline-rich protein 2i
small proline-rich protein 1a
loricrin
HOP homeobox, transcript variant 1
hornerin
small proline-rich protein 2e
keratin 14
sciellin
lectin, galactose binding, soluble 7
chemokine (c-x-c motif) ligand 13
leptin
basic helix-loop-helix family, member a15
neuritin 1
epidermal growth factor
sclerostin domain containing 1
bloom syndrome homolog (human), transcript variant 1
NM_007769
NM_009160
NM_011470
NM_011478
NM_011475
NM_009264
NM_008508
NM_175606
NM_133698
NM_011471
NM_016958
NM_022886
NM_008496
NM_018866
NM_008493
NM_010800
NM_153529
NM_010113
NM_025312
NM_007550
5.68
4.11
3.46
3.39
3.31
3.30
2.84
1.94
1.92
1.74
1.66
1.58
1.53
-1.66
-1.93
-2.77
-3.36
-3.68
-4.17
-6.27
0.0009
0.0040
0.1915
0.2717
0.1199
0.0238
0.4324
0.3578
0.3797
0.3182
0.6872
0.3848
0.7142
0.3482
0.1899
0.0270
0.0165
0.0046
0.0033
0.0006
Keratinization and keratinocyte
differentiation
Sprr2d
Sprr3
Sprr2i
Sprr1a
Lor
Hrnr
Sprr2e
Scel
small proline-rich protein 2d
small proline-rich protein 3
small proline-rich protein 2i
small proline-rich protein 1a
loricrin
hornerin
small proline-rich protein 2e
sciellin
NM_011470
NM_011478
NM_011475
NM_009264
NM_008508
NM_133698
NM_011471
NM_022886
3.46
3.39
3.31
3.30
2.84
1.92
1.74
1.58
0.1915
0.2717
0.1199
0.0238
0.4324
0.3797
0.3182
0.3848
Structural molecule activity Pkp4
Sprr2d
Sprr3
Sprr2i
Sprr1a
Krt10
Krt13
Lor
Krt1
Hrnr
Rptn
Sprr2e
Krt14
plakophilin 4, transcript variant 1
small proline-rich protein 2d
small proline-rich protein 3
small proline-rich protein 2i
small proline-rich protein 1a
keratin 10
keratin 13
loricrin
keratin 1
hornerin
repetin
small proline-rich protein 2e
keratin 14
NM_026361
NM_011470
NM_011478
NM_011475
NM_009264
NM_010660
NM_010662
NM_008508
NM_008473
NM_133698
NM_009100
NM_011471
NM_016958
3.54
3.46
3.39
3.31
3.30
3.01
2.94
2.84
2.52
1.92
1.79
1.74
1.66
0.0103
0.1915
0.2717
0.1199
0.0238
0.2953
0.3850
0.4324
0.3413
0.3797
0.5020
0.3182
0.6872
Embryo implantation, female
pregnancy, and menstrual cycle
Sprr2d
Sprr2i
Sprr2e
small proline-rich protein 2d
small proline-rich protein 2i
small proline-rich protein 2e
NM_011470
NM_011475
NM_011471
3.46
3.31
1.74
0.1915
0.1199
0.3182
Rhythmic process Sprr2d
Sprr2i
Sprr2e
Dbp
small proline-rich protein 2d
small proline-rich protein 2i
small proline-rich protein 2e
d site albumin promoter binding protein
NM_011470
NM_011475
NM_011471
NM_016974
3.46
3.31
1.74
-2.08
0.1915
0.1199
0.3182
0.1208
Multi-organism process Sprr2d
Sprr2i
Isg15
Sprr2e
Defb4
small proline-rich protein 2d
small proline-rich protein 2i
ISG15 ubiquitin-like modifier
small proline-rich protein 2e
defensin beta 4
NM_011470
NM_011475
NM_015783
NM_011471
NM_019728
3.46
3.31
2.44
1.74
1.61
0.1915
0.1199
0.0739
0.3182
0.4577
Cell differentiation Dmbt1
Sprr2d
deleted in malignant brain tumors 1
small proline-rich protein 2d
NM_007769
NM_011470
5.68
3.46
0.0009
0.1915
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Sprr3
Sprr2i
Sprr1a
Lor
Hopx
Hrnr
Sprr2e
Scel
Casp14
Lgals7
Lep
Bhlha15
Nrn1
Blm
small proline-rich protein 3
small proline-rich protein 2i
small proline-rich protein 1a
loricrin
HOP homeobox, transcript variant 1
hornerin
small proline-rich protein 2e
sciellin
caspase 14
lectin, galactose binding, soluble 7
leptin
basic helix-loop-helix family, member a15
neuritin 1
bloom syndrome homolog (human), transcript variant 1
NM_011478
NM_011475
NM_009264
NM_008508
NM_175606
NM_133698
NM_011471
NM_022886
NM_009809
NM_008496
NM_008493
NM_010800
NM_153529
NM_007550
3.39
3.31
3.30
2.84
1.94
1.92
1.74
1.58
1.55
1.53
-1.93
-2.77
-3.36
-6.27
0.2717
0.1199
0.0238
0.4324
0.3578
0.3797
0.3182
0.3848
0.6348
0.7142
0.1899
0.0270
0.0165
0.0006
Serine-type endopeptidase activity,
serine hydrolase activity, and serine-
type peptidase activity
Klk10
Klk13
Klk7
Ctrl
Cela3b
Ctrb1
Cfd
Cela2a
Try4
kallikrein related-peptidase 10
kallikrein related-peptidase 13
kallikrein related-peptidase 7 (chymotryptic, stratum
corneum)
chymotrypsin-like
chymotrypsin-like elastase family, member 3B
chymotrypsinogen B1
complement factor D (adipsin)
chymotrypsin-like elastase family, member 2A
trypsin 4
NM_133712
NM_001039042
NM_011872
NM_023182
NM_026419
NM_025583
NM_013459
NM_007919
NM_011646
1.61
1.52
1.49
-3.19
-3.32
-5.00
-5.35
-7.59
-12.14
0.3825
0.4422
0.5536
0.1251
0.1116
0.1227
0.0451
0.0153
0.0001
Proteolysis Isg15
9130409I23Rik
Klk10
Casp14
Klk13
Klk7
Cpa2
Cpb1
Ctrl
Cela3b
Cpa1
Ctrb1
Cfd
Cela2a
Try4
ISG15 ubiquitin-like modifier
RIKEN cDNA 9130409I23 gene
kallikrein related-peptidase 10
caspase 14
kallikrein related-peptidase 13
kallikrein related-peptidase 7 (chymotryptic, stratum
corneum)
carboxypeptidase A2, pancreatic
carboxypeptidase B1 (tissue)
chymotrypsin-like
chymotrypsin-like elastase family, member 3B
carboxypeptidase A1
chymotrypsinogen B1
complement factor D (adipsin)
chymotrypsin-like elastase family, member 2A
trypsin 4
NM_015783
NM_001033819
NM_133712
NM_009809
NM_001039042
NM_011872
NM_001024698
NM_029706
NM_023182
NM_026419
NM_025350
NM_025583
NM_013459
NM_007919
NM_011646
2.44
1.79
1.61
1.55
1.52
1.49
-2.32
-2.73
-3.19
-3.32
-3.95
-5.00
-5.35
-7.59
-12.14
0.0739
0.3676
0.3825
0.6348
0.4422
0.5536
0.1337
0.1115
0.1251
0.1116
0.1154
0.1227
0.0451
0.0153
0.0001
Peptidase activity 9130409I23Rik
Klk10
Casp14
Klk13
Klk7
Cpa2
Cpb1
Ctrl
Cela3b
Cpa1
Ctrb1
Cfd
Cela2a
Try4
RIKEN cDNA 9130409I23 gene
kallikrein related-peptidase 10
caspase 14
kallikrein related-peptidase 13
kallikrein related-peptidase 7 (chymotryptic, stratum
corneum)
carboxypeptidase A2, pancreatic
carboxypeptidase B1 (tissue)
chymotrypsin-like
chymotrypsin-like elastase family, member 3B
carboxypeptidase A1
chymotrypsinogen B1
complement factor D (adipsin)
chymotrypsin-like elastase family, member 2A
trypsin 4
NM_001033819
NM_133712
NM_009809
NM_001039042
NM_011872
NM_001024698
NM_029706
NM_023182
NM_026419
NM_025350
NM_025583
NM_013459
NM_007919
NM_011646
1.79
1.61
1.55
1.52
1.49
-2.32
-2.73
-3.19
-3.32
-3.95
-5.00
-5.35
-7.59
-12.14
0.3676
0.3825
0.6348
0.4422
0.5536
0.1337
0.1115
0.1251
0.1116
0.1154
0.1227
0.0451
0.0153
0.0001
Endopeptidase activity Klk10
Casp14
Klk13
Klk7
Ctrl
Cela3b
Ctrb1
kallikrein related-peptidase 10
caspase 14
kallikrein related-peptidase 13
kallikrein related-peptidase 7 (chymotryptic, stratum
corneum)
chymotrypsin-like
chymotrypsin-like elastase family, member 3B
chymotrypsinogen B1
NM_133712
NM_009809
NM_001039042
NM_011872
NM_023182
NM_026419
NM_025583
1.61
1.55
1.52
1.49
-3.19
-3.32
-5.00
0.3825
0.6348
0.4422
0.5536
0.1251
0.1116
0.1227
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Cfd
Cela2a
Try4
complement factor D (adipsin)
chymotrypsin-like elastase family, member 2A
trypsin 4
NM_013459
NM_007919
NM_011646
-5.35
-7.59
-12.14
0.0451
0.0153
0.0001
Trypsin and chymotrypsin activity Klk10
Ctrl
Cela3b
Ctrb1
kallikrein related-peptidase 10
chymotrypsin-like
chymotrypsin-like elastase family, member 3B
chymotrypsinogen B1
NM_133712
NM_023182
NM_026419
NM_025583
1.61
-3.19
-3.32
-5.00
0.3825
0.1251
0.1116
0.1227
Hydrolase activity Trex2
9130409I23Rik
Ephx3
Klk10
Casp14
Klk13
Klk7
Pla2g4e
Cpa2
Cpb1
Ctrl
Cela3b
Chia
Cpa1
Ctrb1
Cfd
Pnlip
Blm
Gm12888
Cela2a
Amy2a5
Try4
three prime repair exonuclease 2
RIKEN cDNA 9130409I23 gene
epoxide hydrolase 3
kallikrein related-peptidase 10
caspase 14
kallikrein related-peptidase 13
kallikrein related-peptidase 7 (chymotryptic, stratum
corneum)
phospholipase A2, group IVE
carboxypeptidase A2, pancreatic
carboxypeptidase B1 (tissue)
chymotrypsin-like
chymotrypsin-like elastase family, member 3B
chitinase, acidic
carboxypeptidase A1
chymotrypsinogen B1
complement factor D (adipsin)
pancreatic lipase
bloom syndrome homolog (human), transcript variant 1
predicted gene 12888
chymotrypsin-like elastase family, member 2A
amylase 2a5, pancreatic
trypsin 4
NM_011907
NM_001033819
NM_001033163
NM_133712
NM_009809
NM_001039042
NM_011872
NM_177845
NM_001024698
NM_029706
NM_023182
NM_026419
NM_023186
NM_025350
NM_025583
NM_013459
NM_026925
NM_007550
NM_001033791
NM_007919
NM_001042711
NM_011646
2.11
1.79
1.67
1.61
1.55
1.52
1.49
1.41
-2.32
-2.73
-3.19
-3.32
-3.52
-3.95
-5.00
-5.35
-6.23
-6.27
-7.12
-7.59
-9.85
-12.14
0.1306
0.3676
0.3966
0.3825
0.6348
0.4422
0.5536
0.5788
0.1337
0.1115
0.1251
0.1116
0.0468
0.1154
0.1227
0.0451
0.0192
0.0006
0.0024
0.0153
0.0001
0.0001
Structural constituent of cytoskeleton Krt10
Krt13
Lor
Krt1
Krt14
keratin 10
keratin 13
loricrin
keratin 1
keratin 14
NM_010660
NM_010662
NM_008508
NM_008473
NM_016958
3.01
2.94
2.84
2.52
1.66
0.2953
0.3850
0.4324
0.3413
0.6872
Cell communication Krt10
Krt13
Krt1
Krt14
keratin 10
keratin 13
keratin 1
keratin 14
NM_010660
NM_010662
NM_008473
NM_016958
3.01
2.94
2.52
1.66
0.2953
0.3850
0.3413
0.6872
Metallocarboxypeptidase activity,
carboxypeptidase activity, and
metalloexopeptidase activity
Cpa2
Cpb1
Cpa1
carboxypeptidase A2, pancreatic
carboxypeptidase B1 (tissue)
carboxypeptidase A1
NM_001024698
NM_029706
NM_025350
-2.32
-2.73
-3.95
0.1337
0.1115
0.1154
Serine-type endopeptidase inhibitor
activity, endopeptidase inhibitor
activity, and protease inhibitor
activity
Serpinb12
Serpina12
Spink3
Mug1
serine (or cysteine) peptidase inhibitor, clade B
(ovalbumin), member 12
serine (or cysteine) peptidase inhibitor, clade A (alpha-1
antiproteinase, antitrypsin), member 12
serine peptidase inhibitor, Kazal type 3
murinoglobulin 1
NM_027971
NM_026535
NM_009258
NM_008645
3.02
1.44
-3.32
-4.30
0.2987
0.6371
0.0707
0.0084
Taxis and chemotaxis Sftpd
S100a8
S100a9
Cxcl13
surfactant associated protein d
S100 calcium binding protein A8 (calgranulin A)
S100 calcium binding protein A9 (calgranulin B)
chemokine (c-x-c motif) ligand 13
NM_009160
NM_013650
NM_009114
NM_018866
4.11
1.71
1.56
-1.66
0.0040
0.3080
0.3694
0.3482
Response to external stimulus Sftpd
Hopx
S100a8
S100a9
Cxcl13
Lep
Cfd
surfactant associated protein d
HOP homeobox, transcript variant 1
S100 calcium binding protein A8 (calgranulin A)
S100 calcium binding protein A9 (calgranulin B)
chemokine (c-x-c motif) ligand 13
leptin
complement factor D (adipsin)
NM_009160
NM_175606
NM_013650
NM_009114
NM_018866
NM_008493
NM_013459
4.11
1.94
1.71
1.56
-1.66
-1.93
-5.35
0.0040
0.3578
0.3080
0.3694
0.3482
0.1899
0.0451
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Immune system process Il1rl1
Sftpd
Isg15
Oas1g
S100a9
Cxcl13
Lep
Cfd
Blm
Cela2a
interleukin 1 receptor-like 1, transcript variant 2
surfactant associated protein d
ISG15 ubiquitin-like modifier
2'-5' oligoadenylate synthetase 1G
S100 calcium binding protein A9 (calgranulin B)
chemokine (c-x-c motif) ligand 13
leptin
complement factor D (adipsin)
bloom syndrome homolog (human), transcript variant 1
chymotrypsin-like elastase family, member 2A
NM_010743
NM_009160
NM_015783
NM_011852
NM_009114
NM_018866
NM_008493
NM_013459
NM_007550
NM_007919
5.38
4.11
2.44
2.15
1.56
-1.66
-1.93
-5.35
-6.27
-7.59
0.0004
0.0040
0.0739
0.1051
0.3694
0.3482
0.1899
0.0451
0.0006
0.0153
Defense response Il1rl1
Sftpd
Ly6d
Tacstd2
Defb4
Cxcl13
Cfd
interleukin 1 receptor-like 1, transcript variant 2
surfactant associated protein d
lymphocyte antigen 6 complex, locus D
tumor-associated calcium signal transducer 2
defensin beta 4
chemokine (c-x-c motif) ligand 13
complement factor D (adipsin)
NM_010743
NM_009160
NM_010742
NM_020047
NM_019728
NM_018866
NM_013459
5.38
4.11
2.69
1.76
1.61
-1.66
-5.35
0.0004
0.0040
0.0319
0.5030
0.4577
0.3482
0.0451
Positive regulation of cell
differentiation
Dmbt1
Hopx
Lep
deleted in malignant brain tumors 1
HOP homeobox, transcript variant 1
leptin
NM_007769
NM_175606
NM_008493
5.68
1.94
-1.93
0.0009
0.3578
0.1899
PPAR signaling pathway Scd1
Adipoq
Slc27a2
stearoyl-Coenzyme A desaturase 1
adiponectin, C1Q and collagen domain containing
solute carrier family 27 (fatty acid transporter), member 2
NM_009127
NM_009605
NM_011978
-3.27
-3.74
-3.80
0.0452
0.0515
0.0048
Leukocyte migration Sftpd
S100a9
Cela2a
surfactant associated protein d
S100 calcium binding protein A9 (calgranulin B)
chymotrypsin-like elastase family, member 2A
NM_009160
NM_009114
NM_007919
4.11
1.56
-7.59
0.0040
0.3694
0.0153
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Abstract
Background: Of the thirteen active carbonic anhydrase (CA) isozymes, CA IX and XII have been
linked to carcinogenesis. It has been suggested that these membrane-bound CAs participate in
cancer cell invasion, which is facilitated by an acidic tumor cell environment. Since active cell
migration is a characteristic feature of embryonic development, we set out to explore whether
these isozymes are expressed in mouse embryos of different ages. The studies were focused on
organogenesis stage.
Results: Immunohistochemistry demonstrated that both CA IX and XII are present in several
tissues of the developing mouse embryo during organogenesis. Staining for CA IX revealed a
relatively wide distribution pattern with moderate signals in the brain, lung, pancreas and liver and
weak signals in the kidney and stomach. The expression pattern of CA XII in the embryonic tissues
was also relatively broad, although the intensity of immunostaining was weak in most tissues. The
CA XII-positive tissues included the brain, where the most prominent staining was seen in the
choroid plexus, and the stomach, pancreas, liver and kidney.
Conclusion: Membrane-bound CA isozymes IX and XII are expressed in various tissues during
mouse organogenesis. These enzymes may regulate ion and pH homeostasis within the developing
embryo.
Background
The carbonic anhydrases (CAs) are a group of zinc-contain-
ing metalloenzymes that catalyse the reversible hydration of
carbon dioxide in a reaction CO2 + H2O ↔ H+ + HCO3 -. They
are produced in a variety of tissues, where they play impor-
tant roles in a number of biological processes such as acid-
base balance, respiration, carbon dioxide and ion transport,
bone resorption, ureagenesis, gluconeogenesis, lipogenesis
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BMC Developmental Biology 2006, 6:22 http://www.biomedcentral.com/1471-213X/6/22and body fluid generation [1-3]. Thirteen enzymatically
active alpha CAs have been reported in mammals so far, of
which CA I, II, III, VII, and XIII are cytoplasmic [4], CA IV, IX,
XII, XIV, and XV are anchored to plasma membranes [5-8],
CA VA and VB are mitochondrial [9], and CA VI is the only
secretory form, present in saliva and milk [10,11].
Of the thirteen active isozymes, CA IX and XII have been
linked to neoplastic invasion [12,13]. Both are transmem-
brane proteins. CA IX is composed of four domains: an N-ter-
minal proteoglycan domain, a CA catalytic domain, a
transmembrane region and a short cytoplasmic tail [14]. It is
a highly active enzyme, and its activity can be efficiently
inhibited by sulfonamides [15-19]. In addition to its enzyme
activity and role in pH control, CA IX is a cell adhesion mol-
ecule and may also contribute to cell proliferation [20-22].
The distribution of CA IX has been studied in adult human,
rat and mouse tissues [5,23]. The most abundant expression
of CA IX was observed in the human alimentary tract, partic-
ularly in the mucosa of the stomach and gallbladder, and it
was also detected in the ileum, colon, liver and pancreas. In
mouse tissues, the highest immunoreactivity for CA IX was
reported in the gastric mucosa, while moderate signals were
also seen in the colon and brain and lower expression in
some other tissues, including the pancreas and various seg-
ments of the small intestine. CA IX is ectopically expressed at
relatively high levels and with a high prevalence in some
tumor tissues whose normal counterparts do not contain this
protein, e.g. carcinomas of the cervix uteri, esophagus, kid-
ney, lung and breast [24-29]. On the other hand, tumors
originating from tissues with high natural CA IX expression,
such as the stomach and gallbladder, often lose some or all
of their CA IX upon conversion to carcinomas [30-32].
CA XII contains an N-terminal extracellular domain, a
putative transmembrane α-helix and a small intracellular
C-terminal segment with potential phosphorylation sites
[6,14,33]. Its expression has been demonstrated by
immunohistochemistry in the adult human kidney,
colon, prostate, pancreas, ovary, testis, lung and brain
[34,35], and the enzyme has been localized to the basola-
teral plasma membranes of the epithelial cells [36-38]. In
the human kidney, CA XII is confined to the proximal and
distal tubules and the principal cells of the collecting duct
[39]. In mouse tissues it is most abundant in the kidney
[40] and the surface epithelial cells of the colon [41]. CA
XII expression also shows a clear association with certain
tumors, being overexpressed in renal cancer cells, for
example [6].
One characteristic feature of embryonic development is
active cell migration from one place to another. Although
this clearly represents a benign process, it has some mech-
anistic similarities to cancer cell invasion [42,43], e.g. the
fact that the moving cells invade through the extracellular
matrix. Since CA IX and XII probably participate in neo-
plastic invasion, we set out to explore how these isozymes
are expressed during embryonic development.
Results and discussion
Immunohistochemical staining of CA IX revealed a rela-
tively wide distribution pattern, although the signal inten-
sity most often remained low or moderate. The E7.5
embryos, representing a gastrulation stage, were com-
pletely negative (Figure 1). CA IX expression in the various
tissues during organogenesis is summarized in Table 1.
The protein was present in the developing brain at all ages
Immunostaining of CA IX and CA XII in the embryos at E7.5Figure 1
Immunostaining of CA IX and CA XII in the embryos at E7.5. No immunoreaction is detected for either CA IX (A) or CA XII 
(B). Original magnifications: × 400.Page 2 of 9
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BMC Developmental Biology 2006, 6:22 http://www.biomedcentral.com/1471-213X/6/22studied (Figure 2). The brain tissue was stained moder-
ately, and some positivity was occasionally observed in
cells present in the mesenchyme beneath the developing
brain (data not shown). Moderate staining was also seen
in the nerve ganglia and choroid plexus (Figure 2). No
immunoreaction for CA IX was detected in the kidney at
E11.5, whereas a weak positive signal appeared at E12.5
(Figure 3). The developing pancreas showed a moderate
positive reaction at E12.5, which was primarily seen in the
basolateral plasma membrane and intracellular compart-
ment of the epithelial cells (Figure 4). Weak staining for
CA IX was present in the stomach at all ages studied (Fig-
ure 5). This is in accordance with the finding that CA IX is
functionally important for a normal gastric histological
structure [44]. The liver also showed positive immunos-
taining in scattered cells (Figure 5). Positive labeling was
seen in the lung and heart, tissues not expressing the pro-
tein in the adult mouse (data not shown). It is notable,
however, that the adult heart tissue also gave a slight pos-
itive signal with the automated immunostaining method,
even though it has been previously considered negative
for CA IX [23].
The expression pattern of CA XII in embryonic tissues was
also relatively broad, although the staining intensity was
weak in most tissues. The E7.5 embryos showed no
immunoreaction (Figure 1). Results at later stages are
summarized in Table 2. CA XII protein was expressed in
the brain and nerve ganglia at every subsequent age dur-
ing organogenesis (Figure 2), most prominently in the
choroid plexus at E12.5 and E13.5 (Figure 2), i.e. at the
time when the developing choroid plexus usually
becomes visible. Interestingly, a weak signal for CA XII
was detected in several embryonic tissues, including the
stomach (Figure 5), pancreas (Figure 4) and liver (Figure
5), which are all negative in adult mice [41]. No staining
was detected in the stomach at E11.5, while a weak posi-
tive signal appeared there at E12.5. The liver showed weak
or moderate staining for CA XII during organogenesis. It
is notable that even though CA XII is highly expressed in
the adult mouse kidney, the embryonic kidney showed
only a weak signal (Figure 3). Weak immunostaining was
also seen in the pancreas, where just a few of the develop-
ing ducts were positive (Figure 4). In the heart, the stain-
ing became stronger during mouse development (data not
shown), but as with CA IX, the specificity of CA XII immu-
nostaining is questionable in this particular organ. How-
ever, the control stainings using normal rabbit serum
instead of the anti-CA IX or anti-CA XII serum gave no
positive signals.
CA IX and XII are distinct CA isozymes in that they are
overexpressed in certain tumors and subjected to regula-
tion by the von Hippel Lindau tumor suppressor protein/
hypoxia pathway [35,45]. In developing embryo, the
expression patterns of CA IX and CA XII may also be
related to the presence of hypoxia, which is considered
essential for proper morphogenesis of various tissues [46].
Hypoxia appears important particularly for development
of the brain, myocardial vascularization, lung branching
morphogenesis, formation of mesoderm and establish-
ment of various progenitor cells [47-49].
The high catalytic activities of CA IX and XII support their
role in acidification of the tumor microenvironment,
which in turn facilitates the migration of tumor cells
through the extracellular matrix [12,13]. The question is
whether CA IX and XII also participate in cell migration
during embryonic development. Although the present
results provide no functional evidence that CA IX or XII is
involved in cell migration during embryogenesis, they do
indicate that several cell types in the mouse embryo
express these isozymes. Interestingly, both isozymes were
present though at quite low level in some embryonic tis-
sues whose adult counterparts do not express these partic-
ular proteins or the expression is very low. These findings
contrast with prior studies on the developmental regula-
tion of CA IV. This isozyme, like many of the cytosolic iso-
zymes, is expressed at much lower levels in most tissues of
the embryo than are found in the adult [50,51].
Conclusion
Membrane-bound CA isozymes IX and XII are expressed
in several tissues of developing mouse embryo. As mem-
brane-bound CAs with an extracellular active site, CA IX
and XII represent key enzymes in the maintenance of an
appropriate pH in the extracellular milieu. Future studies
should therefore be focused on exploring how strictly pH
homeostasis is regulated in a developing embryo and
what are the possible structural or functional conse-
quences if this homeostasis is disrupted.
Table 1: Distribution of CA IX in mouse embryonic tissues of 
different age.*
Organ E11.5 E12.5 E13.5
Brain ++ ++ ++
Heart (ventricle/atrium) +/++ ++/++ +/++
Lung ND ++ +
Kidney - + +
Pancreas ND ++ ND
Liver + ++ ++
Stomach + + +
Intestine + ++ +
* Scores in immunohistochemistry: strong reaction (+++), moderate 
reaction (++), weak reaction (+), no reaction (-), not done (ND).Page 3 of 9
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Immunostaining of CA IX and CA XII in embryonic and adult mouse nervous tissuesFigure 2
Immunostaining of CA IX and CA XII in embryonic and adult mouse nervous tissues. All embryos are aged E12.5 except the 
choroid plexus for CA XII, which is aged E13.5. CA IX shows moderate staining in the embryonic brain (A), with the signal 
mainly located in the neurons. CA IX is also present in the trigeminal ganglion (B) and the choroid plexus (C). Panel G shows 
strong positive staining for CA IX in the adult brain. CA XII gives weak staining in the embryonic brain (D), but panel E shows 
moderate staining in the trigeminal ganglion. The strongest immunoreaction is located in the chroid plexus (F). No specific sig-
nal for CA XII is detectable in the adult brain (H) except for the choroid plexus (data not shown). Control immunostaining of 
the embryonic brain with normal rabbit serum is negative (I). Manual PAP staining in panels A-E and I, automated immunostain-
ing in panels F-H. Original magnifications: A-E, I × 400, F × 630, G-H × 200.
BMC Developmental Biology 2006, 6:22 http://www.biomedcentral.com/1471-213X/6/22Methods
Antibodies
Polyclonal rabbit antibodies to mouse CA IX and CA XII
have been described earlier [40,44]. Non-immune normal
rabbit serum (NRS) was used in the control stainings
instead of the specific antisera.
Immunohistochemistry
Mouse embryos were obtained by mating male and
female NMRI mice. The procedures were approved by the
animal care committees of Helsinki University and Tam-
pere University. Noon on the day on which the copula-
tion plug was found was considered to represent 0.5 days
Immunostaining of CA IX and CA XII in the kidney of E12.5 mouse embryos and in the adult mouse kidneyFigure 3
Immunostaining of CA IX and CA XII in the kidney of E12.5 mouse embryos and in the adult mouse kidney. Both CA IX (A) 
and CA XII (B) show weak staining in the ductal epithelium of the embryonic tissue, and a positive immunoreaction is seen for 
both isozymes in the adult mouse renal tubules (C, D), with CA XII also located in the collecting ducts. Control immunostain-
ing of an adult mouse kidney with NRS gave no positive signal (E). Manual PAP staining in panels A-B and E, automated immu-
nostaining in panels C-D. Original magnifications: A-B × 400, C-E × 100.Page 5 of 9
(page number not for citation purposes)
BMC Developmental Biology 2006, 6:22 http://www.biomedcentral.com/1471-213X/6/22p.c. 7.5 (n = 2), 11.5 (n = 3), 12.5 (n = 4) and 13.5 (n = 2)
p.c. embryos with or without extraembryonic tissues were
briefly washed with PBS, fixed with 4% paraformaldehyde
and embedded in paraffin. Sections were cut at 5–8 μm
and placed on SuperFrost® Plus microscope slides (Men-
zel; Braunschweig, Germany). Tissue samples from the
stomach, heart, brain, liver, kidney and pancreas of an
adult NMRI mouse were obtained for control purposes.
Immunoperoxidase staining was performed using an
automated Lab Vision Autostainer 480 (ImmunoVision
Technologies Co., Brisbane, CA, USA). As this automated
immunostaining method produced some nonspecific
Immunostaining of CA IX and CA XII in the embryonic (E12.5) and adult mouse pancreasFigure 4
Immunostaining of CA IX and CA XII in the embryonic (E12.5) and adult mouse pancreas. The reaction for CA IX is moderate 
in the embryonic tissue, with the most intense staining in the epithelial cells (A). CA XII gives weak staining in the epithelium 
(B). A quite strong but focal signal is seen for CA IX in the acinar cells of the adult pancreas (C), while no immunoreaction is 
detected for CA XII (D). The control immunostaining of the mouse embryonic pancreas is negative (E). Manual PAP staining in 
panels A-B and E, automated immunostaining in panels C-D. Original magnifications: A-B, E × 400, C-D × 100.Page 6 of 9
(page number not for citation purposes)
BMC Developmental Biology 2006, 6:22 http://www.biomedcentral.com/1471-213X/6/22labeling of the nuclei in the embryonal tissues, immunos-
taining was repeated using a less sensitive but more spe-
cific peroxidase-antiperoxidase complex method (manual
PAP) to confirm the validity of the results.
The automated immunostaining, performed using Power
Vision+™ Poly-HRP IHC Kit (ImmunoVision Technolo-
gies, Co.) reagents, included the following steps: (a) rins-
ing in wash buffer; (b) treatment in 3% H2O2 in ddH2O
for 5 min and rinsing in wash buffer; (c) blocking with
Universal IHC Blocking/Diluent for 30 min and rinsing in
wash buffer; (d) incubation with the primary antibody
(rabbit anti-mouse CA IX or XII) or NRS diluted 1:2000 in
Universal IHC Blocking/Diluent for 30 min; (e) rinsing in
wash buffer for 3 × 5 min; (f) incubation in poly-HRP-
conjugated anti-rabbit IgG for 30 min and rinsing in wash
buffer for 3 × 5 min; (g) incubation in DAB (3,3' -diami-
nobenzidine tetrahydrochloride) solution (one drop of
DAB solution A and one drop of DAB solution B in 1 ml)
ddH2O for 6 min; (h) rinsing with ddH2O ; (i) CuSO4
treatment for 5 min to enhance the signal; and (j) rinsing
with ddH2O. All procedures were carried out at room tem-
perature. The sections were mounted in Entellan Neu
(Merck; Darmstadt, Germany) and finally examined and
photographed with a Zeiss Axioskop 40 microscope (Carl
Zeiss; Göttingen, Germany).
Immunostaining of CA IX and CA XII in the embryonic (E12.5) mouse stomach and liverFigure 5
Immunostaining of CA IX and CA XII in the embryonic (E12.5) mouse stomach and liver. Both CA IX (A) and CA XII (B) show 
weak immunoreaction in the stomach (CA XII barely detectable). CA IX gives moderate staining in the liver, the signal being 
seen in scattered cells (C). Panel D shows a weak positive signal of CA XII in the liver (D). Manual PAP staining in panels A-D. 
Original magnifications: × 400.Page 7 of 9
(page number not for citation purposes)
BMC Developmental Biology 2006, 6:22 http://www.biomedcentral.com/1471-213X/6/22The immunostaining by the PAP method included the fol-
lowing steps: (a) 3% H2O2 in methanol for 5 min and
washing in PBS for 5 min; (b) treatment with undiluted
cow colostral whey (Biotop) for 30 min and rinsing in
PBS; (c) incubation with the primary antibody (rabbit
anti-mouse CA IX or XII) diluted 1:100 in 1% bovine
serum albumin (BSA) in PBS for 1 hr and washing in PBS
3 times for 10 min; (d) treatment with undiluted cow
colostral whey for 30 min and rinsing in PBS; (e) incuba-
tion with the secondary antibody (swine anti-rabbit IgG;
DAKO, Glostrup, Denmark) diluted 1:100 in 1% BSA in
PBS for 1 hr and washing in PBS 3 times for 10 min; (f)
incubation with peroxidase-antiperoxidase complex
(PAP-rabbit; DAKO) diluted 1:100 in PBS for 30 min and
washing in PBS 4 times for 5 min; and (g) incubation for
2 1/2 min in DAB solution (6 mg 3,3' -diaminobenzidine
tetrahydrochloride; Sigma, St Louis, MO) in 10 ml PBS
plus 3,3 μl 30% H2O2. All incubations and washings were
carried out at room temperature. The sections were
mounted in Entellan Neu (Merck; Darmstadt, Germany)
and finally examined and photographed with a Zeiss Axi-
oskop 40 microscope.
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Cancer-Associated Carbonic Anhydrases IX and XII:  
Effect of Growth Factors on Gene Expression in Human 
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AIM: Carbonic anhydrase IX (CA9) and carbonic anhydrase XII (CA12) are cancer-
associated enzymes that are strongly up-regulated by hypoxia via hypoxia-inducible 
factor HIF-1, but whether these isozymes are regulated by other mechanisms is not 
well understood.  In the present study, we investigated the effects of certain hor-
mones and growth factors on the levels of CA9 and CA12 mRNA expression in 
human cancer cell lines.  
METHODS: Seven human cell lines were selected for the study.  The cells were 
treated with several hormones and growth factors for 24 h.  Changes in the levels of 
human CA9 and CA12 transcripts were detected using quantitative real-time PCR. 
RESULTS: Different growth factors or hormones had different effects on CA9 and 
CA12 mRNA expression in different cancer cells.  The strongest up-regulation of CA9 
and CA12 expression was observed after deferoxamine mesylate treatment, which 
was used to induce a hypoxia-like response.  Additionally, CA12 expression could be 
stimulated by growth factors like IGF-1, TGF-β1 and EGF in U373, MCF-7, Caki-1, and 
A-498 cells.  Induction of CA9 expression was obvious only in U373 cells.  Con-
versely, CA12 expression was reduced in human endothelial cells after growth factor 
treatments. 
CONCLUSION: The results suggest that the increase in CA9 and CA12 stimulated 
by IGF-1, TGF-α , TGF-β1 and EGF is mediated through HIF-1α  protein expression, 
which has been shown to be up-regulated by several growth factors under normal 
oxygenation conditions in human cell lines.  This could represent a novel regulatory 
mechanism for CA9 and CA12 expression. 
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Introduction 
 
Carbonic anhydrases IX (CA92) and XII (CA12) are cancer-
associated zinc metalloenzymes belonging to a large 
enzyme family of mammalian α-carbonic anhydrases that 
contains 13 active isoforms (i.e., I, II, III, IV, VA, VB, VI, VII, IX, 
XII, XIII, XIV, and XV).  These enzymatically active CAs 
catalyze the reversible hydration of carbon dioxide in the 
reaction CO2 + H2O ↔  H+ + HCO3-.  This reaction affects 
various biological processes, such as regulation of pH 
homeostasis, CO2 and ion transport, respiration, bone 
resorption, ureagenesis, gluconeogenesis, lipogenesis, 
production of body fluids, and fertilization [1,2].  Each 
isozyme has a characteristic subcellular localization, distri-
bution within the body, enzyme activity, and affinity for 
inhibitors.  
Both CA9 and CA12 are transmembrane proteins.  CA9 is 
an unusual isoform because it is present in few normal 
human tissues, but is ectopically expressed in some tumor 
cells  whose normal counterparts contain none or low levels  
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of this protein.  CA9-positive tumors include colon, cervical, 
breast and renal carcinomas and brain tumors [3].  In 
addition, the few normal tissues with high natural CA9 
expression, such as the stomach and gallbladder, have been 
demonstrated to lose some, or all, of their CA9 upon con-
version to carcinomas [4,5].  The presence of CA9 in various 
tumor types has been found to correlate with poor progno-
sis [6-9].  CA9 has also been implicated in the regulation of 
pH balance during carcinogenesis and tumor progression, 
but this hypothesis still requires further proof. 
In contrast to CA9, CA12 is expressed in a variety of nor-
mal human tissues including kidney, colon, prostate, 
pancreas, ovary, testis, lung, and brain [10,11].  Expression 
of CA12 usually becomes stronger or more widespread in 
tumors compared to the corresponding normal tissues [12-
15].   
Tissue oxygen content has been considered to be the 
main regulatory mechanism for CA9 and CA12 expression, 
as both CA9 and CA12 transcript levels are strongly up-
regulated via hypoxia-inducible transcription factor 1 (HIF-1).  
HIF-1 is a heterodimer that consists of an oxygen-sensitive 
α  subunit and a constitutively expressed β  subunit.  Under 
normal oxygenation conditions, prolyl-4-hydroxylases 
(PHDs) hydroxylate two conserved proline residues of HIF-
1α .  The von Hippel-Lindau protein (pVHL) binds hydroxy-
lated HIF-1α  and targets it for degradation by the ubiquitin-
proteasome system, and thus abrogates its function in the 
Kallio et al. J Cancer Mol 5(3): 73-78, 2010	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transcriptional activation of downstream genes [16,17].  In 
hypoxia, which occurs frequently in tumors as a result of 
aberrant vasculature, HIF-1α  is not hydroxylated, because 
PHDs are inactive in the absence of oxygen.  Non-
hydroxylated HIF-1α  is not recognized by pVHL; instead, it is 
stabilized and accumulates in the cell.  HIF-1α  then translo-
cates to the nucleus and dimerizes with the HIF-1β  subunit 
to form the active transcription factor.  The HIF-1 then binds 
to hypoxia-responsive elements (HREs) within the promoter 
regions of hypoxia-inducible genes, leading to gene expres-
sion.  In addition to CA9 and CA12, target genes include 
glucose transporters (GLUT-1 and GLUT-3), vascular endo-
thelial growth factor (VEGF), erythropoietin (EPO-1), and a 
number of other genes with functions in cell survival, 
proliferation, metabolism, and other cellular processes 
[18,19].  Thus, activation of the HIF-1 pathway substantially 
alters the expression profile of pre-malignant lesions by 
generating tumor cells which either die via apoptosis or 
adapt to hypoxia.  As a result, hypoxia selects more aggres-
sive tumor cells with an increased capability to metastasize, 
and is therefore often associated with poor prognosis and 
resistance to anti-cancer therapy [20]. 
In addition to hypoxia, increased activity of the HIF-1 
pathway can result from genetic events such as inactivating 
mutations in the VHL gene or activation of oncogenic 
pathways, e.g. mitogen-activated protein kinase (MAPK) 
and/or phosphatidylinositol 3-kinase (PI3K)[20-22].  Notably, 
suppression of CA12 expression requires both a central VHL 
domain involved in the HIF-1α  binding and a C-terminal 
elongin-binding domain, whereas only the latter is needed 
for the negative regulation of CA9.  Therefore, CA12 is 
regulated by hypoxia, in a similar manner to CA9, but using 
different biochemical pathways [23,24].  Furthermore, CA9 is 
directly induced by binding of HIF-1 to the HRE within the 
basal promoter, whereas the CA12 gene does not contain 
any HRE that corresponds to the HRE of CA9.  In fact, the 
upstream region of the CA12 gene possesses several 
putative HREs with a core HIF-binding sequence, but their 
functionality has not been examined to date.  According to 
tissue distribution analyses and in vitro experiments, CA12 
does not appear to be as tightly regulated by the hy-
poxia/pVHL pathway and as strongly linked to cancer as CA9 
[11,23].  
Apart from hypoxia, very little is known about the mecha-
nisms that regulate CA9 and CA12 expression.  It is possible 
that these cancer-associated enzymes are regulated at 
higher levels of the biosynthetic pathway in a similar man-
ner to some other hypoxia-induced genes.  However, it is 
also possible that CA12 has an unknown role in cancer 
progression, which is not directly linked to the hypoxia-
associated pathway.  In the present study, we examined 
whether different hormones and growth factors affected the 
levels of CA9 and CA12 mRNA in human cancer-derived and 
normal cell lines. 
 
Materials and Methods 
 
Cell lines and treatments 
Caki-1 and A-498 human renal carcinoma cell lines and 
HepG2 human hepatocellular carcinoma cell line were 
obtained from the American Type Culture Collection (Ma-
nassas, VA, USA).  HeLa human cervical carcinoma cell line 
and MCF-7 human breast adenocarcinoma cell line were 
kindly provided by Professor Jorma Isola (Institute of 
Medical Technology, University of Tampere, Tampere, 
Finland).  U373 human glioblastoma cell line and HUVEC 
normal human umbilical vein endothelial cell line were 
purchased from the European Collection of Cell Cultures 
(Porton Down, Salisbury, UK).  
Caki-1, A-498, and HepG2 cells were cultured in Dul-
becco's Modified Eagle's Medium (DMEM; Lonza, Venviers, 
Belgium) supplemented with 10%  (v/v) FBS (Biochrom, 
Cambridge, UK), 2 mM L-glutamine, 100 unit/ml penicillin, 
and 100 µg/ml streptomycin (Lonza).  MCF-7 cells were 
cultured in DMEM supplemented with 10%  FBS, 1 mM 
sodium pyruvate (Lonza), 1%  (v/v) non-essential amino acids 
(Lonza), and 10 µg/ml insulin (Sigma-Aldrich Finland Oy, 
Helsinki, Finland).  HeLa cells were maintained in RPMI-1640 
medium (Lonza) supplemented with 10%  FBS and 2 mM L-
glutamine.  U373 cells were cultured in Alpha MEM (Lonza) 
supplemented with 10%  FBS, 2 mM L-glutamine, 100 unit/ml 
penicillin, and 100 µg/ml streptomycin.  HUVEC cells were 
maintained in Endothelial Cell Basal Medium-2 (EBM®-2) 
supplemented with EGM™-2 SingleQuots® kit (Lonza, 
Walkersville, MD, USA). 
All cell cultures were grown in 75-cm2 flasks in a 37°C 
incubator with humidified 5%  CO2/95%  air.  When the 
cultured cells reached 80-90%  of confluence, they were 
trypsinized and plated in 6-well plates (except for the HUVEC 
cells which were plated in 59-cm2 dishes) at appropriate 
densities to obtain a sufficient quantity of cells for RNA 
extraction.  After 24 h, the cells were changed to fresh 
serum-free medium with the tested hormones and growth 
factors.  Only serum-free medium was added to two control 
wells/dishes.  The cells were incubated for 24 h in the 
presence of different hormones or growth factors.  The 
treatments were performed using recombinant human 
growth hormone (400 ng/ml), hydrocortisone (10 µM), insulin 
(30 nM), tri-iodothyronine (T3; 10 nM), estradiol (E2; 2.5 µM), 
recombinant human insulin-like growth factor-1 (IGF-1; 50 
ng/ml), recombinant human transforming growth factor-
alpha (TGF-α; 10 ng/ml), recombinant human transforming 
growth factor-beta 1 (TGF-β1; 10 ng/ml), recombinant human 
epidermal growth factor (EGF; 10 ng/ml), and deferoxamine 
mesylate (200 µM), an iron chelator commonly used to 
induce the hypoxia regulatory pathway.  Every cell line was 
treated with the same hormones or growth factors except for 
MCF-7, which was not treated with insulin because these 
cells require a high insulin concentration in their culture 
medium.  The growth hormone, IGF-1, TGF-β1 and EGF were 
purchased from ProSpec-Tany TechnoGene Ltd. (Rehovot, 
Israel).  TGF-α  was purchased from PromoCell GmbH 
(Heidelberg, Germany).  The rest of the chemicals were 
obtained from Sigma-Aldrich Finland Oy, and diluted when 
necessary according to the manufacturersʼ instructions.  
 
RNA extraction and first-strand cDNA synthesis 
Total RNA from cultured cells was extracted using the 
RNeasy RNA isolation kit (Qiagen, Valencia, USA).  Residual 
DNA was removed from samples using RNase-free DNase 
(Qiagen).  The RNA concentration and purity was determined 
by measurement of the optical density at 260 and 280 nm.  
Different quantities of RNA (U373, 410 ng; HeLa, 600 ng; A-
498, 850 ng; HepG2, 1000 ng; HUVEC and MCF-7, 1100 ng; 
Caki-1, 1400 ng) were converted into first-strand cDNA using 
the First Strand cDNA synthesis kit (Fermentas, Burlington, 
Canada) using random hexamer primers according to the 
protocol recommended by the manufacturer. 
 
Quantitative real-time PCR 
The levels of human CA9 and CA12 transcripts in the 
different cell lines after indicated treatments were assessed 
by quantitative real-time PCR using the Lightcycler detection 
system (Roche, Rotkreuz, Switzerland).  Real-time PCR 
primers were designed based on the complete cDNA 
sequences deposited in GenBank (accession numbers: 
NM_001216 for CA9, NM_001218 for CA12, and NM_001530 
for HIF-1α).  The house-keeping genes ubiquitin C (UBC) and 
β-2-microglobulin (B2M) were used as internal controls to 
normalize the cDNA samples for possible differences in 
quality and quantity.  The UBC primers were obtained from 
RTprimerDB database (under the identification number 8), 
and the B2M primers were designed on the basis of the 
complete B2M cDNA sequences (accession number: 
NM_004048).  In order to avoid amplification of genomic 
DNA, the primers from each primer pair were located in 
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Table 1: Primer sequences for quantitative real-time PCR used in the study 
 
Gene Forward primer Reverse primer PCR product size Ta (°C)** 
CA9 5’- GGAAGGCTCAGAGACTCA-3’ 5’- CTTAGCACTCAGCATCAC-3’ 160 53 
CA12 5’- CTGCCAGCAACAAGTCAG-3’ 5’- ATATTCAGCGGTCCTCTC-3’ 179 53 
HIF-1α 5’- TCACCTGAGCCTAATAGTCC-3’ 5’- GCTAACATCTCCAAGTCTAA-3’ 161 52 
UBC* 5’- ATTTGGGTCGCGGTTCTTG-3’ 5’- TGCCTTGACATTCTCGATGGT-3’ 133 57 
B2M 5’- GTATGCCTGCCGTGTGAA-3’ 5’- CTCCATGATGCTGCTTAC-3’ 84 52  
 
*obtained from RTprimerDB database (http://medgen.ugent.be/rtprimerdb/index.php) 
**Ta: annealing temperature  
 
 
 
Table 2: CA9 expression in different cell lines after the treatments (fold change values are shown)** 
 
 U373 HeLa MCF-7 Caki-1 A-498 HepG2 HUVEC 
EGF 2.2 0 0 0 0 0 0 
GH -1.3 0 0 0 0 0 0 
HC 1.0 0 0 0 0 0 0 
INS 1.4 0 0 0 0 0 0 
T3 1.4 0 0 0 0 0 0 
DFM 4.2 137.5 0 0 0 0 0 
E2 -1.2 0 0 0 0 0 0 
IGF-1 2.4 0 0 0 0 0 0 
TGF-α 2.6 0 0 0 0 0 0 
TGF-β1 1.7 0 0 0 0 0 0  
 
*EGF, epidermal growth factor; GH, growth hormone; HC, hydrocortisone; INS, insulin; T3, tri-iodothyronine; DFM, deferoxamine mesylate; E2, 
estradiol; IGF-1, insulin-like growth factor-1; TGF-α , transforming growth factor-alpha; TGF-β1, transforming growth factor-beta 1. 
**0 = copy number < 100 
 
 
 
different exons.  The primer sequences used in this study 
are shown in Table 1. 
Each PCR reaction was performed in a total volume of 20 
µ l containing 1.0 µ l of first-strand cDNA, 1×  QuantiTect 
SYBR Green PCR Master Mix (Qiagen, Hilden, Germany), and 
0.5 µM of each primer.  The amplification and detection were 
carried out as follows: after an initial 15 min activation step 
at 95°C, amplification was performed in a three-step cycling 
procedure for 45 cycles: denaturation at 95°C for 15 sec, 
annealing at a temperature determined according to the Tm 
for each primer pair for 20 sec, and elongation at 72°C for 15 
sec (the ramp rate was 20°C per sec for all the steps), and a 
final cooling step.  Melting curve analysis was always 
performed after the amplification to check the specificity of 
the PCR reaction.  To quantify the levels of transcripts in the 
cell lines studied, a standard curve was established for each 
gene using five-fold serial dilutions of known concentrations 
of purified PCR products generated with the same primer 
pairs.  Every cDNA sample was tested in triplicate, and the 
obtained crossing point (Cp) value permitted the levels of 
the starting mRNA to be determined using a specific stan-
dard curve.  The geometric mean of the two internal control 
genes was used as an accurate normalization factor for 
gene expression levels [25].  The final relative mRNA 
expression was indicated as the copy number of the target 
gene divided by the corresponding normalization factor and 
multiplied by 103. 
 
Statistical analyses 
After a statistical consultation, it was decided that the 
obtained results should be presented using descriptive 
methods rather than using extensive statistical compari-
sons.  The median values were calculated from the technical 
triplicates for the quantitative real-time PCR experiments.  
Subsequently, the median values for treatments were 
compared to the median values for negative controls. 
 
Results and Discussion 
 
CA9 had a narrow expression profile and was detected in 
only two out of seven cell lines (Table 2).  In a human 
glioblastoma cell line, U373, the basal level of CA9 expres-
sion was relatively high (Figure 1).  This is in accordance 
with the fact that the strongest CA9 expression among 
different gliomas has been observed in the most malignant 
forms, i.e. glioblastomas [26].  Compared to the control 
sample, CA9 expression increased 4.2-fold after defer-
oxamine mesylate treatment, which was used as a positive 
control to induce a hypoxia-like response (Table 2 and 
Figure 1).  In addition, the IGF-1, TGF-α  and EGF treatments 
notably increased CA9 expression compared to the control 
sample (fold changes of 2.4, 2.6 and 2.2, respectively).  After 
TGF-β1 treatment, CA9 expression was moderately elevated 
(1.7-fold).  
Interestingly, the inhibition of MAPK and PI3K pathways 
has been shown to result in reduced CA9 expression under 
both standard and acidic conditions in human glioblastoma 
8-MG-BA cells [27].  It is also known that HIF-1α  can be up-
regulated under normoxic conditions via the MAPK and 
PI3K/Akt pathways [22].  Furthermore, it has been demon-
strated that EGF up-regulates HIF-1α  protein expression in 
several cell lines, including human embryonic kidney 293 
cells [28] and human prostate cancer TSU cells [29].  IGF-1, 
among other growth factors, also increases the levels of 
HIF-1α  protein [28].  The increase in the level of CA9 mRNA 
induced by EGF and IGF-1 is therefore likely to be mediated 
through the stabilization of HIF-1α  protein rather than via 
increased mRNA levels.  This was supported by our finding, 
confirming that HIF-1α  mRNA expression was not up-
regulated after growth factor treatments in U373 cells (data 
not shown).  This result was expected, as HIF-1α  regulation 
mainly involves post-transcriptional changes [30].  One 
hypothesis is that up-regulation of CA9 by EGF and IGF-1 
treatments is mediated through activation of the MAPK 
and/or PI3K pathway.  In fact, Dorai and co-workers have 
demonstrated that the tyrosine moiety of CA9 present in its 
intracellular domain can be phosphorylated in an EGF-
dependent manner in the renal cell carcinoma cell line 
SKRC-01 [31].  Their results also suggested that tyrosine-
phosphorylated CA9 interacted with the regulatory subunit 
of PI3K, leading to Akt activation.  Similarly, TGF-α  could 
increase the level of CA9 expression via these pathways, 
since TGF-α  is one of the ligands of the EGF receptor [32].  It 
has also been shown that TGF-β1 can contribute to the 
accumulation of HIF-1α  in normoxic conditions.  Stimulation 
with TGF-β1 increased HIF-1α  expression levels and DNA
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Table 3: CA12 expression in different cell lines after the treatments (fold change values are shown)** 
 
 U373 HeLa MCF-7 Caki-1 A-498 HepG2 HUVEC 
EGF 2.9 0 2.4 1.8 2.6 0 -1.3 
GH -1.6 0 1.3 -1.5 -1.3 0 -1.2 
HC 1.0 0 -1.1 1.4 -1.6 0 -2.0 
INS 1.2 0 ND 1.3 -1.3 0 -1.1 
T3 -1.3 0 1.3 1.2 -1.4 0 -1.4 
DFM 3.8 0 -1.3 10.2 -1.3 0 1.3 
E2 1.0 0 1.9 1.5 1.2 0 1.1 
IGF-1 2.0 0 1.3 1.5 1.7 0 -2.2 
TGF-α 3.1 0 -1.1 1.1 2.2 0 -1.8 
TGF-β1 1.6 0 2.8 1.7 2.5 0 -1.6  
 
*EGF, epidermal growth factor; GH, growth hormone; HC, hydrocortisone; INS, insulin; T3, tri-iodothyronine; DFM, deferoxamine mesylate; E2, 
estradiol; IGF-1, insulin-like growth factor-1; TGF-α , transforming growth factor-alpha; TGF-β1, transforming growth factor-beta 1. 
**0 = copy number < 100, ND = not done 
 
 
 
 
 
 
 
 
 
 
Figure 1: Effects of different treatments on 
CA9 and CA12 expression in U373 cells, 
detected by quantitative real-time PCR. The 
treatments included growth hormone (GH), 
hydrocortisone (HC), insulin (INS), tri-
iodothyronine (T3), deferoxamine mesylate 
(DFM), estradiol (E2), insulin-like growth 
factor-1 (IGF-1), transforming growth factor-
alpha (TGF-α), transforming growth factor-
beta 1 (TGF-β1), and epidermal growth factor 
(EGF).  Both CA9 (A) and CA12 (B) expression 
were maximally induced by DFM treatment.  
Likewise, growth factor treatments elevated 
the transcription levels of both isozymes.  The 
normalized values of triplicate experiments 
are shown.  Two control (CTRL) groups were 
included in the study.  The values of the first 
five treatments are compared to control 1 
(squares), and the values of the last five 
treatments are compared to control 2 
(crosses).  
 
 
 
 
 
binding activity in human HT-1080 fibrosarcoma cells and in 
human vascular smooth muscle cells [33,34].  The observed 
induction of CA9 by TGF-β1 may also act through accumula-
tion of HIF-1α , but this remains to be tested. 
In HeLa cells, CA9 was expressed only when stimulated 
with deferoxamine mesylate (Table 2).  This change in 
expression was notable and indicates that hypoxia is an 
important regulator of CA9 expression in this cell line, which 
was already reported [23].  Basal CA9 expression below the 
detection limit (copy number < 100) was observed with MCF-
7, Caki-1, A-498, HUVEC, and HepG2 cell lines (Table 2).  
Furthermore, CA9 expression was not induced by any 
treatment in these cell lines, suggesting that critical ele-
ment(s) necessary to drive its transcription could be missing 
or underrepresented.  The fact that CA9 expression was not 
induced in Caki-1 cells expressing wild-type pVHL after 
deferoxamine mesylate treatment is in line with a previous 
publication showing no CA9 expression in Caki-1 cells with 
or without a hypoxic stimulation [23].  It is unclear why the 
levels of CA9 mRNA were below the detection limit in A-498 
cells.  It was presumed that there were high basal CA9 
expression levels in these cells due to pVHL inactivation.  
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Furthermore, these cells produced CA9 protein under 
standard cell culture conditions [35].  The most plausible 
explanation for this discrepancy is that CA9 transcription 
was decreased due to the absence of serum in the cell 
cultures.  
CA12 mRNA expression was detected in U373, MCF-7, 
Caki-1, A-498 and HUVEC cell lines (Table 3).  In U373 cells, 
the CA12 mRNA levels were not as high as the CA9 levels, 
but the expression patterns were strikingly similar (Table 3 
and Figure 1).  Deferoxamine mesylate treatment markedly 
increased CA12 expression compared to the control sample 
(3.8-fold).  In addition, stimulation with TGF-α  and EGF both 
caused a notable increase in CA12 expression (fold changes 
of 3.1 and 2.9, respectively).  Likewise, IGF-1 treatment 
elevated CA12 levels two-fold and TGF-β1 treatment in-
creased CA12 levels 1.6-fold.  Addition of growth hormone 
slightly decreased the levels of CA12 expression (1.6-fold). 
In MCF-7 cells, CA12 was present at relatively high levels 
with an unusual expression profile (Table 3).  CA12 tran-
scription was clearly induced after TGF-β1 and EGF treat-
ments (fold changes of 2.8 and 2.4, respectively).  Estradiol 
treatment also increased the CA12 mRNA levels (1.9-fold).  A 
similar effect was demonstrated in MCF-7 cells [36].  The 
study showed that CA12 was strongly up-regulated by 
estradiol via the estrogen receptor α  (ERα), and that this 
regulation involved a distal estrogen-responsive enhancer 
region.  We anticipated that the hypoxia pathway would have 
been induced in this cell line by deferoxamine mesylate 
treatment, but this was not the case.  In fact, deferoxamine 
mesylate treatment somewhat decreased the levels of CA12 
mRNA, and CA9 mRNA remained completely absent.  It is 
notable that in invasive breast cancer, CA12-positive tumors 
are associated with positive ERα  status, lower grade dis-
ease, lower relapse rate, and better overall patient survival 
[37].  Since hypoxia is usually linked to poor prognosis, it is 
possible that CA12 is not mainly regulated through the 
hypoxia-induced pathway in breast cancer, but regulation 
may involve an alternative pathway triggered by estradiol 
and certain growth factors. 
Caki-1 and A-498 human renal carcinoma cell lines were 
selected for the study, because the first cell line produces 
wild-type pVHL and the latter represents a VHL-null cell line.  
In Caki-1 cells, CA12 showed the highest signal after defer-
oxamine mesylate treatment (10.2-fold), as expected (Table 
3).  Again, IGF-1, TGF-β1 and EGF also induced a moderate 
increase in CA12 mRNA levels (fold changes of 1.5, 1.7 and 
1.8, respectively).  Moreover, estradiol induced a 1.5-fold 
increase in CA12 expression.  Similar to U373 cells, growth 
hormone treatment caused a decrease in CA12 expression 
(1.5-fold).  In A-498 cells, CA12 transcript was present in 
high levels and, as predicted, deferoxamine mesylate 
treatment had no effect on gene expression (Table 3).  The 
CA12 mRNA levels were also elevated after growth factor 
treatments.  The highest levels of induction were obtained 
with TGF-β1 and EGF (fold changes of 2.5 and 2.6, respec-
tively), while TGF-α  had a slightly weaker effect (2.2-fold).  
Moreover, IGF-1 stimulation elicited a 1.7-fold increase in the 
CA12 mRNA levels.  Addition of hydrocortisone moderately 
decreased the CA12 mRNA levels (1.6-fold).  It is worth 
noticing that the mRNA levels of another hypoxia-induced 
gene, VEGF, have also been demonstrated to be down-
regulated in A-498 cells after hydrocortisone treatment [38].  
Although this effect was suggested to associate with the 
glucocorticoid receptor pathway, the exact mechanism for 
the reduced expression was not reported.  
In HUVEC cells, CA12 was expressed at a low level.  None 
of the treatments markedly increased CA12 expression 
(Table 3).  Interestingly, several treatments reduced CA12 
expression.  Hydrocortisone and IGF-1 caused an approxi-
mately two-fold decrease in CA12 mRNA levels whereas 
TGF-α  and TGF-β1 treatments resulted in minor decreases 
(1.8- and 1.6-fold, respectively).  In HeLa and HepG2 cells, 
the levels of CA12 expression were below the detection limit 
of the quantitative PCR. 
Like CA9, CA12 expression was also elevated in the can-
cer-derived cell lines after IGF-1, TGF-α , TGF-β1, and EGF 
treatments.  Since CA12 is not strongly regulated by hy-
poxia, it is not surprising that it has additional regulators.  It 
is plausible that the main stimulatory effects observed in 
this study are mediated through up-regulation of HIF-1α  
protein, which has been shown to be activated by several 
growth factors under normoxia.  Our data suggests that this 
effect could be specific to cancerous environments, since it 
was not observed in normal HUVEC cells.  However, in 
contrast, some inhibition of CA12 was detectable after 
growth factor treatment.  It is also worth noticing that similar 
to CA9, CA12 expression could not be induced in cell lines 
lacking CA12 expression under control conditions.  
In summary, an understanding of CA9 and CA12 regula-
tion has been mainly confined to hypoxia.  Therefore, the 
object of the present study was to use several hormones 
and growth factors in order to find novel potential regulators 
of CA9 and CA12 transcription.  In conclusion, we have 
shown that CA9 and CA12 are up-regulated by certain 
growth factors in human cancer-derived cell lines.  For CA9, 
this effect was only observed in one cell line.  In contrast, 
CA12 expression was elevated in several cancer-derived cell 
lines after growth factor treatment.  This induction may 
represent a novel regulatory mechanism for CA12 expres-
sion in a cancerous environment and merits further investi-
gation.  The regulation of CA isozymes has been generally 
an understudied research area, and future studies should 
therefore include investigation of the regulation of other 
CAs.  In the present study, insulin and T3 remained the only 
representatives of hormones or growth factors which 
elicited no substantial effects in any of the analyzed cell 
lines. 
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Abstract
Background: Carbonic anhydrases (CAs) are a family of enzymes that regulate pH homeostasis in various tissues. CA IX 
is an exceptional member of this family because in addition to the basic CA function, it has been implicated in several 
other physiological and pathological processes. Functions suggested for CA IX include roles in cell adhesion and 
malignant cell invasion. In addition, CA IX likely regulates cell proliferation and differentiation, which was demonstrated 
in Car9-/- mice. These mice had gastric pit cell hyperplasia and depletion of chief cells; however, the specific molecular 
mechanisms behind the observed phenotypes remain unknown. Therefore, we wanted to study the effect of CA IX 
deficiency on whole-genome gene expression in gastric mucosa. This was done using Illumina Sentrix®Mouse-6 
Expression BeadChip arrays. The expression of several genes with notable fold change values was confirmed by QRT-
PCR.
Results: CA IX deficiency caused the induction of 86 genes and repression of 46 genes in the gastric mucosa. There 
was 92.9% concordance between the results obtained by microarray analysis and QRT-PCR. The differentially expressed 
genes included those involved in developmental processes and cell differentiation. In addition, CA IX deficiency altered 
the expression of genes responsible for immune responses and downregulated the expression of several digestive 
enzymes.
Conclusions: Microarray analysis identified several potential genes whose altered expression could explain the 
disturbed cell lineage phenotype in the Car9-/- gastric mucosa. The results also indicated a novel role for CA IX in the 
regulation of immunologic processes and digestion. These findings reinforce the concept that the main role of CA IX is 
not the regulation of pH in the stomach mucosa. Instead, it is needed for proper function of several physiological 
processes.
Background
The carbonic anhydrases (CAs) are a family of zinc-con-
taining metalloenzymes that catalyze the reversible
hydration of carbon dioxide in the reaction: CO2 + H2O 
H+ + HCO3-. They participate in several physiological
processes, such as acid-base balance, CO2 and HCO3-
transport, respiration, bone resorption, ureagenesis, glu-
coneogenesis, lipogenesis, production of body fluids, and
fertilization [1,2]. The CA family consists of 13 active
isozymes in mammals, 12 of which are expressed and
function in humans [3]. The CA isozymes have diverse
tissue expression patterns, characteristic subcellular
localizations, as well as unique kinetic and inhibitory
properties.
CA IX is a dimeric protein associated with the cell
membrane [4,5]. In its mature form, CA IX is composed
of an N-terminal proteoglycan (PG) domain, a CA cata-
lytic domain, a transmembrane region, and a short intra-
cytoplasmic tail at the C-terminus [6]. CA IX is the only
member of the CA family containing a PG domain in
addition to the CA domain. Consequently, CA IX has
been suggested to participate in cell adhesion processes.
In fact, using MDCK (Madin-Darby canine kidney) epi-
thelial cells, it was shown that CA IX reduces E-cadherin-
mediated cell-cell adhesion by interacting with β-catenin
[7].
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Page 2 of 14CA IX is expressed in only few normal tissues with the
expression being strongest in human, rat, and mouse gas-
tric mucosa, where it is present from the gastric pits to
the deep gastric glands [8,9]. CA IX is confined to the
basolateral surface of epithelial cells and is produced by
all major cell types of the gastric epithelium [8]. CA IX is
an exceptional member of the CA family because it is
expressed in several cancers that arise from CA IX nega-
tive tissues including renal, lung, cervical, ovarian, esoph-
ageal, and breast carcinomas [6]. However, gastric cancer
and premalignant lesions have shown decreased expres-
sion of CA IX [10]. In tumor tissues, CA IX is linked with
the hypoxic phenotype mediated by the hypoxia-induc-
ible transcription factor 1 (HIF-1), which binds to the
hypoxia responsive element, HRE, of the CA9 promoter
[11]. In hypoxic conditions, cancer cells are dependent
mainly on anaerobic metabolism in their energy produc-
tion. This anaerobic tumor metabolism generates
excesses of acidic products, such as lactic acid and H+
that have to be extruded from the cell interior. It has been
shown that CA IX can contribute to the acidification of
the hypoxic extracellular milieu, thus helping tumor cells
to neutralize the intracellular pH [12]. Accordingly, CA
IX overexpression often indicates poor prognosis and
resistance to classical radio- and chemotherapies [13].
However, CA IX is not only confined to the hypoxic
regions of the tumors, indicating that there might be
some other pathways that regulate its expression. In fact,
the expression of CA IX can be induced under normoxic
conditions by high cell density, and this regulation is
mediated by phosphatidylinositol 3-kinase (PI3K) signal-
ing [14]. Moreover, the mitogen-activated protein kinase
(MAPK) pathway is involved in the regulation of CA IX
expression via control of the CA9 promoter by both HIF-
1-dependent and -independent signals [15]. This pathway
is also interrelated with the PI3K pathway and the SP1
(specificity protein 1) transcription factor.
The generation of Car9-/- mice has revealed that in
addition to pH regulation and cell adhesion, CA IX pos-
sesses other functional roles [16]. These Car9 knockout
mice showed no abnormalities in growth, reproductive
potential, and life span. However, CA IX deficiency
resulted in hyperplasia of the gastric mucosa. The hyper-
plastic mucosa contained an increased number and pro-
portion of the mucus-producing pit cells whereas the
number and proportion of chief cells was reduced. The
total number of parietal cells remained unchanged, and
accordingly, CA IX-deficient mice had normal gastric pH,
acid secretion, and serum gastrin levels. Thus, these find-
ings demonstrate that CA IX contributes to the control of
differentiation and proliferation of epithelial cell lineages
in the gastric mucosa. A previous study examined
whether the effects of CA IX deficiency could be modi-
fied by a high-salt diet, a known co-factor of carcinogene-
sis [17]. These results showed that the high-salt diet
slightly increased the glandular atrophy in the body
mucosa in Car9-/- C57BL/6 mice, whereas this effect was
not observed in BALB/c mice. However, no metaplastic
or dysplastic abnormalities were seen in the gastrointesti-
nal epithelium of CA IX-deficient C57BL/6 mice. Thus,
these observations suggest that CA IX deficiency alone
may not be a significant carcinogenic factor but could ini-
tiate a carcinogenic process by affecting cell proliferation
and/or differentiation in the gastric mucosa.
This study was designed to better understand the
hyperplastic phenotype of the stomach mucosa of Car9-/-
mice because the molecular mechanisms behind it are
currently unknown. In addition, we wanted to more spe-
cifically elucidate the functional roles of CA IX, as there is
a growing body of evidence showing that they extend far
beyond pH regulation. For this purpose, a genome-wide
expression analysis was performed. Microarray data anal-
ysis revealed several genes whose expression was changed
due to Car9 gene disruption in the gastric mucosa.
Results
Transcriptional response to Car9 deficiency in the stomach 
wall
Stomach RNA from 6 Car9-/- mice and 6 wild-type mice
was analyzed by microarray. The analysis revealed 86
upregulated genes and 46 downregulated genes, using a
fold change cut-off of ± 1.4 for up- and downregulated
expression, respectively (See additional file 1: List of
genes differentially expressed in the stomach of Car9-/-
mice). This cut-off value has been proposed as an ade-
quate level above which there is a high correlation
between microarray and QRT-PCR data, regardless of
other factors such as spot intensity and cycle threshold
[18]. The fold changes ranged from 10.46 to -12.14.
Herein, a list of genes using a cut-off value of ± 2.5-fold is
shown (Tables 1 and 2). When using these criteria, all the
genes with significantly (p < 0.05) altered expression are
displayed, that is, 14 genes with induced expression and
21 genes with repressed expression. The list of all the reg-
ulated genes was functionally annotated (see additional
file 2: Functional annotation of genes regulated in the
stomach of Car9 knockout mice), showing enrichment of
hydrolase activity, developmental processes, cell differen-
tiation, proteolysis, peptidase activity, structural mole-
cule activity, and immune system process, among others.
The functional annotation categories and gene numbers
in each category are shown in Table 3.
Confirmation of microarray results by QRT-PCR
Changes in the expression levels of selected genes were
confirmed, and microarray results were validated by
QRT-PCR using the same RNA samples as those used for
the microarray. Fourteen genes with notable fold change
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Table 1: Genes with upregulated expression using a cut-off value of 2.5-fold.
Gene symbol Description GenBank number FC QRT-PCR
Cym chymosin NM_001111143 10.46 19.66
Slc9a3 solute carrier family 9 (sodium/hydrogen exchanger), member 3 NM_001081060 8.07 10.72
U46068 cDNA sequence U46068, transcript variant 2 NM_153418 5.95
Dmbt1 deleted in malignant brain tumors 1 NM_007769 5.68 5.29
Il1rl1 interleukin 1 receptor-like 1, transcript variant 2 NM_010743 5.38 8.95
Tm4sf5 transmembrane 4 superfamily member 5 NM_029360 4.26
9130204L05Rik RIKEN cDNA 9130204L05 gene NM_001101461 4.19
Sftpd surfactant associated protein D NM_009160 4.11 3.69
Nccrp1 non-specific cytotoxic cell receptor protein 1 homolog (zebrafish) NM_001081115 3.81
Pkp4 plakophilin 4, transcript variant 1 NM_026361 3.54 1.09
Sprr2d small proline-rich protein 2D NM_011470 3.46
Gm14446 predicted gene 14446, transcript variant 2 NM_001101605 3.45
Sprr3 small proline-rich protein 3 NM_011478 3.39
Sprr2i small proline-rich protein 2I NM_011475 3.31
Sprr1a small proline-rich protein 1A NM_009264 3.30
Ivl involucrin NM_008412 3.08
Serpinb12 serine (or cysteine) peptidase inhibitor, clade B (ovalbumin), member 12 NM_027971 3.02
Krt10 keratin 10 NM_010660 3.01
Gm94 predicted gene 94 NM_001033280 2.94
Krt13 keratin 13 NM_010662 2.94
Gsdmc2 gasdermin C2, transcript variant 2 NM_177912 2.88
Lor loricrin NM_008508 2.84
Dmkn dermokine, transcript variant 2 NM_172899 2.78
Ly6d lymphocyte antigen 6 complex, locus D NM_010742 2.69
Krt1 keratin 1 NM_008473 2.52
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Page 4 of 14Table 2: Genes with downregulated expression using a cut-off value of -2.5-fold.
Gene symbol Description GenBank number FC QRT-PCR
Try4 trypsin 4 NM_011646 -12.14
Prss1 protease, serine, 1 (trypsin 1) NM_053243 -10.57
Amy2a5 amylase 2a5, pancreatic NM_001042711 -9.85
Cela2a chymotrypsin-like elastase family, member 2A NM_007919 -7.59 -16.23
Gm12888 predicted gene 12888 NM_001033791 -7.12
Gdf9 growth differentiation factor 9 NM_008110 -7.04
Blm bloom syndrome homolog (human), transcript variant 1 NM_007550 -6.27
Pnlip pancreatic lipase NM_026925 -6.23 -23.88
Cfd complement factor D (adipsin) NM_013459 -5.35 -27.45
Ctrb1 chymotrypsinogen B1 NM_025583 -5.00
Mug1 murinoglobulin 1 NM_008645 -4.30
Sostdc1 sclerostin domain containing 1 NM_025312 -4.17
Tmed6 transmembrane emp24 protein transport domain 
containing 6
NM_025458 -4.07
Cpa1 carboxypeptidase A1 NM_025350 -3.95
Slc27a2 solute carrier family 27 (fatty acid transporter), member 2 NM_011978 -3.80
Adipoq adiponectin, C1Q and collagen domain containing NM_009605 -3.74 -20.51
Car3 carbonic anhydrase 3 NM_007606 -3.72 -15.39
Egf epidermal growth factor NM_010113 -3.68 -3.71
Abpg androgen binding protein gamma NM_178308 -3.67
Slc38a5 solute carrier family 38, member 5 NM_172479 -3.64
Chia chitinase, acidic NM_023186 -3.52
LOC638418 PREDICTED: similar to Ela3 protein XM_914439 -3.48
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Page 5 of 14values were selected for validation based on the results of
functional annotation. The selected genes involved repre-
sentatives from different functional categories. Thirteen
(92.9%) out of 14 genes showed concordant results
between microarray analysis and QRT-PCR (Tables 1 and
2, Figure 1). The sole discrepant result was Pkp4, which
was upregulated according to the microarray and did not
change according to the QRT-PCR (1.09-fold).
Discussion
A previous study showed a hyperplastic phenotype of
gastric body mucosa in Car9-/- mice [16]. CA IX defi-
ciency led to overproduction of gastric pit cells and
reduction of chief cells. Quite surprisingly, the gastric pH
of CA IX-deficient mice remained unaltered. Based on
these observations, it can be concluded that the main role
of CA IX in the stomach mucosa is not related to pH reg-
ulation but it is required for normal gastric morphogene-
sis and homeostasis within the gastric mucosa. In this
paper, we report alterations in mRNA expression that
might contribute to the phenotypic changes reported in
the stomach of Car9-deficient mice. However, one must
take into consideration that some of these changes can
merely reflect differences in the relative proportions of
various cell types within the gastric mucosa.
As expected, the Car9-/- phenotype changed the expres-
sion of genes involved in developmental processes and
cell differentiation. The depletion of chief cells in Car9-/-
gastric mucosa may be explained by the significant down-
regulation of the basic helix-loop-helix family, member
a15/Mist1 (Bhlha15) gene, which is a class B basic helix-
loop-helix (bHLH) transcription factor that exhibits aci-
nar cell-specific expression [19]. Mist1 gene expression is
observed in a wide array of tissues with serous type secre-
tion including the pancreas, salivary glands, chief cells of
the stomach, Paneth cells of the small intestine, seminal
vesicles, and lacrimal glands [20]. The deletion of Mist1
blocks normal mucous neck cell redifferentiation into
zymogenic chief cells as all basal zymogen-secreting cells
in Mist1-/- mice show multiple structural defects [21].
Another interesting candidate with regard to cell lin-
eage disturbance in the gastric epithelium of CA IX-defi-
LOC100043836 PREDICTED: similar to lacrimal androgen-binding 
protein delta, transcript variant 1
XM_001481113 -3.41
EG640530 PREDICTED: predicted gene, EG640530 XM_917532 -3.37
Nrn1 neuritin 1 NM_153529 -3.36
Cela3b chymotrypsin-like elastase family, member 3B NM_026419 -3.32 -75.74
Spink3 serine peptidase inhibitor, Kazal type 3 NM_009258 -3.32
Scd1 stearoyl-Coenzyme A desaturase 1 NM_009127 -3.27
Ctrl chymotrypsin-like NM_023182 -3.19
Gper G protein-coupled estrogen receptor 1 NM_029771 -2.96
Sycn syncollin NM_026716 -2.91
Bhlha15 basic helix-loop-helix family, member a15 NM_010800 -2.77
Cpb1 carboxypeptidase B1 (tissue) NM_029706 -2.73 -18.22
Slc5a8 solute carrier family 5 (iodide transporter), member 8 NM_145423 -2.68
Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 NM_021282 -2.65
Zg16 zymogen granule protein 16 NM_026918 -2.57
Table 2: Genes with downregulated expression using a cut-off value of -2.5-fold. (Continued)
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Functional category Total regulated genes Upregulated genes Downregulated genes
Developmental processes* 20 13 7
Keratinization and keratinocyte differentiation 8 8 0
Structural molecule activity 13 13 0
Embryo implantation, female pregnancy, and 
menstrual cycle
3 3 0
Rhythmic process 4 3 1
Multi-organism process 5 5 0
Cell differentiation 16 12 4
Serine-type endopeptidase activity, serine hydrolase 
activity, and serine-type peptidase activity
9 3 6
Proteolysis 15 6 9
Peptidase activity 14 5 9
Endopeptidase activity 10 4 6
Trypsin and chymotrypsin activity 4 1 3
Hydrolase activity 22 8 14
Structural constituent of cytoskeleton 5 5 0
Cell communication 4 4 0
Metallocarboxypeptidase activity, carboxypeptidase 
activity, and metalloexopeptidase activity
3 0 3
Serine-type endopeptidase inhibitor activity, 
endopeptidase inhibitor activity, and protease 
inhibitor activity
4 2 2
Taxis and chemotaxis 4 3 1
Response to external stimulus 7 4 3
Immune system process 10 5 5
Defense response 7 5 2
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Page 7 of 14cient mice is epidermal growth factor (Egf), which has an
expression that was significantly decreased when com-
pared to wild-type mice. Among growth factors, the EGF
family includes important agents for gastric mucosa. EGF
is a single-chain polypeptide of 53 amino acid residues,
which is found mainly in the submandibular glands and
Brunner's glands of the gastrointestinal tract [22]. EGF
binds and activates the epidermal growth factor receptor
resulting in cellular proliferation, differentiation, and sur-
vival [23]. Interestingly, several investigators have
reported that EGF receptors are enriched in rodent chief
cells [24,25], suggesting the importance of EGF function
in these cells. Therefore alterations in the expression of
EGF receptor ligands or, in this case, EGF could contrib-
ute to the differentiation and function of chief cells.
One of the most strongly upregulated genes of this
study was deleted in malignant brain tumors 1 (Dmbt1),
which belongs to the scavenger receptor cysteine-rich
(SRCR) superfamily of proteins. This is a superfamily of
secreted and membrane-bound proteins with SRCR
domains that are highly conserved down to sponges
[26,27]. The expression of DMBT1 is the highest in epi-
thelia and is usually observed on the apical cell surface or
in luminal exocrine secretions. In mice, DMBT1 is most
strongly expressed in the gastrointestinal system [28].
DMBT1 is proposed to be a tumor suppressor [26,29,30]
and/or a regulator of epithelial differentiation [31], as well
as having roles in innate immune defense and inflamma-
tion [32,33]. DMBT1 is located in the crypt cells of the
human, mouse, and rabbit small intestine [31,34,35] and
the neck region of normal human gastric mucosa [36],
which are predominantly composed of stem/progenitor
cells. Thus, this gene is potentially involved in the physio-
logical renewing process of gastrointestinal epithelia. A
role for DMBT1 in innate immune defense has been dem-
onstrated in various studies. The human DMBT1 glyco-
protein, expressed in salivary glands, airways, and genital
tract, binds various bacterial pathogens and viruses [37-
40]. Additionally, expression of mouse DMBT1 in the
gastrointestinal tract is regulated by bacteria [41,42], and
its expression is increased during infection [43]. It has
also been shown that there is an association of a Dmbt1
variant allele with Crohn's disease and there is a correla-
tion of expression levels of Dmbt1 with inflammatory
bowel disease severity [44].
Furthermore, DMBT1 binds surfactant proteins SP-D
and SP-A. These are collagen- containing, (C-type) cal-
cium-dependent lectins called collectins which interact
with glycoconjugates and lipids on the surface of micro-
organisms mostly through their carbohydrate recognition
domains (CRDs) [45]. SP-D and SP-A are involved in a
range of immune functions, including viral neutraliza-
tion, aggregation and killing of bacteria and fungi, and
clearance of apoptotic and necrotic cells. In immunologi-
cally naïve lungs, they downregulate inflammatory reac-
tions, but when challenged with LPS or apoptotic cells
they induce phagocytosis by macrophages, pro-inflam-
matory cytokine production, and enhancement of adap-
tive immune responses [46]. It is interesting that in the
present study, in addition to Dmbt1, the expression of
surfactant associated protein D (Sftpd or SP-D) was
highly induced in Car9-/- mice. Thus, the upregulation of
both Dmbt1 and Sftpd suggest that CA IX deficiency
induced an immune process in the gastric mucosa. It
should also be noted that CA IX has been suggested to
bind to dendritic cells in a receptor-mediated manner
and scavenger receptors appear to play an important role
in this process [47]. In addition, CA IX seems to activate
an immune response by a mechanism characteristic to
heat shock proteins. Thus, CA IX could directly interact
with DMBT1 via a scavenger receptor.
In fact, the disruption of Car9 gene caused disregula-
tion of several genes that are involved in immune pro-
cesses. This corroborates the results from a previous
study where gastric submucosal inflammation was
detected in the body region in a majority of C57BL/6
Car9-/- mice [17]. In the present study, Il1rl1/ST2 tran-
script variant 2 mRNA was highly induced due to CA IX
deficiency. The Il1rl1/ST2 gene is a member of the inter-
leukin-1 (IL-1) receptor family and produces a soluble
secreted form (sST2) and a transmembrane form (ST2L),
coded by transcript variants 2 and 1, respectively. The
membrane-bound form is expressed primarily by
hematopoietic cells and the soluble form is predomi-
nantly expressed by fibroblasts [48]. In particular, ST2L is
preferentially expressed in murine and human Th2 cells
Positive regulation of cell differentiation 3 2 1
PPAR signaling pathway 3 0 3
Leukocyte migration 3 2 1
*A representative category for the following overlapping categories: epidermis morphogenesis, tissue morphogenesis, epidermis 
development, ectoderm development, tissue development, organ development, anatomical structure development, anatomical structure 
morphogenesis, cellular developmental process, multicellular organismal development, and epidermal cell differentiation.
Table 3: The functional annotation categories for the genes regulated by CA IX deficiency. (Continued)
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Figure 1 Verification of microarray data from Car9-/- mice by QRT-PCR. The expression of various transcripts in 6 Car9-/- mice was compared to 
that in 6 wild-type controls. The normalized values of triplicate experiments are shown. A, QRT-PCR analysis of 6 genes with induced expression. B, 
QRT-PCR evaluation of 8 genes with repressed expression. Statistically significant differences relative to wild-type mice were determined. *p < 0.05; 
**p < 0.01.
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vitro experiments [49-52]. Therefore, the function of
ST2L has been suggested to correlate with Th2 cell-medi-
ated immunological responses and IL-33, a newly discov-
ered member of the IL-1 cytokine family, has been
reported as a specific ligand for ST2L [53]. Interestingly,
several studies have shown that the level of soluble ST2 in
sera is elevated in asthmatic disease [54,55]. Therefore, it
has been suggested that soluble ST2 may also play a criti-
cal role in Th2 cell-mediated diseases. In fact, it has been
demonstrated that soluble ST2 acts as an antagonistic
decoy receptor for IL-33 using a murine thymoma cell
line, EL-4, which stably expresses ST2L, and a murine
model of asthma [56]. This suggests that soluble ST2 neg-
atively modulates the production of Th2 cytokines
through IL-33 signaling in allergic airway inflammation.
It is interesting to note that in the present study, the
mRNA level of IL-33 was also elevated ~ 2-fold, although
this change was not statistically significant. Thus, it
seems plausible that CA IX is somehow involved in regu-
lation of the Th2 response.
CA IX could also contribute to the development of the
immune system as CA IX deficiency significantly down-
regulated the bloom syndrome homolog (human) gene
(Blm), which encodes an ATP-dependent DNA helicase
that belongs to an evolutionarily conserved family of
RecQ helicases [57]. Mutation of Blm causes a rare
human autosomal recessive disorder called Bloom's syn-
drome (BS), which is characterized by marked genomic
instability. BS is associated with growth retardation, pro-
found susceptibility to most cancer types, and immuno-
deficiency [58], with the latter two features accounting
for early death [59]. The functions of BLM have been only
partially characterized. However, it has been shown that
BLM has a role in the proliferation and survival of both
developing and mature T lymphocytes, and its deletion
leads to defective T-cell immunity [60]. Additionally, the
conditional knockout of Blm contributed to compro-
mised B cell development and maintenance, strongly
impaired T cell-dependent and -independent antibody
responses after immunization, and a propensity for devel-
oping B cell lymphomas [61]. Therefore, it is conceivable
that Car9-/- mice have compromised acquired immunity
responses.
An unexpected finding was that several small proline-
rich proteins (Sprr) were notably upregulated including
Sprr1a, Sprr2d, Sprr2e, Sprr2i, and Sprr3. However, only
the induction of Sprr1a was statistically significant. SPRR
proteins were originally identified as markers for terminal
squamous cell differentiation where they are precursors
of the cornified envelope [62]. Additionally, SPRR pro-
teins are expressed in various nonsquamous tissues, and
their biological function is not restricted to structural
proteins of the cornified envelope [63]. It has been shown
that SPRR proteins participate in the response to various
stresses in many tissues without a stratified epithelium. In
the biliary tract, SPRR2 members appear to contribute to
modification of the biliary barrier under conditions of
stress [64]. Likewise, SPRR1A has been identified as a
novel stress-inducible downstream mediator of gp130
cytokines in cardiomyocytes with a cardioprotective
effect against ischemic stress [65]. Furthermore, in mice,
SPRR2A protein was reported to be highly induced in
gastric mucosa infected by Helicobacter heilmannii [66].
In addition, it has been suggested that SPRR1A is a regen-
eration-associated protein because its induction in neu-
ronal injury correlates with regenerative capacity, with
virtually all injured dorsal root ganglion neurons express-
ing SPRR1A one week after sciatic nerve injury [67].
Therefore, SPRR genes are presumably induced in
response to different stress conditions and contribute to
cell protection, tissue remodeling, and/or tissue regenera-
tion. In the light of these findings it seems plausible that
CA IX deficiency creates a stress condition in the gastric
mucosa, which leads to upregulation of some protective
factors.
Our analysis identified mRNAs from four members of
solute carrier family proteins to be misregulated in the
Car9-/- mice stomach mucosa. These solute carrier pro-
teins are involved in membrane transport of various mol-
ecules. The expression of Slc9a3 was strongly induced,
whereas the expression of Slc27a2, Slc38a5, and Slc5a8
was repressed. The basic function of SLC9A3 or NHE3 is
the exchange of extracellular Na+ for intracellular H+,
thus causing either a rise in intracellular pH or, if coupled
to the action of other transporters, an increase in cell vol-
ume [68]. In the gastrointestinal tract, SLC9A3 is
expressed in the apical membrane and recycling endo-
somes of the ileum, jejunum, colon, and stomach [69].
Further studies are needed to elucidate the possible inter-
play between CA IX and SLC9A3 in the gastric mucosa.
Surprisingly, among the most downregulated genes we
found several genes involved in digestion. These included
trypsin 1, amylase 2a5, chymotrypsin-like elastase family
member 2A, and pancreatic lipase with statistically signif-
icant p-values and others, such as chymotrypsinogen B1,
carboxypeptidase A1, and carboxypeptidase B1 with non-
significant p-values. The implication of this finding
remains unclear. A possible explanation for this might be
that downregulation of these enzymes is a secondary
event. If it is assumed that these enzymes are produced
by chief cells, the reduced number of chief cells in the
Car9-/- mice gastric mucosa can also cause a decrease in
the amount of the enzymes they produce. However, the
exact mechanism behind this phenomenon remains to be
elucidated.
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In conclusion, CA IX deficiency was shown to alter the
expression of various genes in the gastric mucosa. The
number of affected genes and the magnitude of changes
were relatively high, indicating that CA IX has a remark-
able role in gastric functions. Microarray analysis
revealed several genes involved in developmental pro-
cesses and cell differentiation, which could explain the
cell lineage disturbance in the gastric epithelium of Car9-
/- mice. Interestingly, some of the regulated genes identi-
fied in this study are involved in digestion as well as func-
tions of the immune and defense responses. This finding
suggests that CA IX deficiency compromises the immune
system in the gastric epithelium implying yet another role
for this multifunctional enzyme.
Methods
Animal model and tissue preparation
Generation of the targeted disruption of the Car9 gene
has been previously described by Ortova Gut et al. [16].
These Car9-deficient C57BL/6 mice were produced and
maintained in the animal facility of the University of Oulu
and then delivered to the animal facility of the University
of Tampere. Permissions for use of the experimental mice
were obtained from the Animal Care Committees of the
Universities of Oulu and Tampere. Six Car9-/- mice (3
males and 3 females) and six wild-type control mice (3
males and 3 females) were kept under tightly controlled
specific pathogen-free conditions and fed identical diets.
The mice were sacrificed at approximately 11 (SD = ±
1.35) months of age. Tissue specimens from the body of
the stomach were immediately collected, immersed in
RNAlater solution (Ambion, Austin, TX, USA), and fro-
zen at -80°C.
RNA isolation
Total RNA was obtained using the RNeasy RNA isolation
kit (Qiagen, Valencia, USA) following the manufacturer's
instructions. Residual DNA was removed from the sam-
ples using RNase-free DNase (Qiagen). The RNA concen-
tration and purity were determined by measurement of
the optical density (OD) at 260 and 280 nm. All samples
had an OD260/OD280 ratio of 1.95 or higher.
Microarray analysis
All microarray data reported in the present article are
described in accordance with MIAME guidelines, have
been deposited in NCBI's Gene Expression Omnibus
public repository [70], and are accessible through GEO
Series accession number GSE20981 [71]. Microarray
experiments were performed in the Finnish DNA
Microarray Centre at the Turku Centre for Biotechnol-
ogy. Stomach RNA samples from 6 Car9-/- mice were
used. As controls, RNA samples from the stomach of 6
wild-type mice were used. All 12 samples were analyzed
individually. 400 ng of total RNA from each sample was
amplified using the Illumina® TotalPrep RNA Amplifica-
tion kit (Ambion) as recommended by the manufacturer.
The in vitro transcription reaction, which was conducted
for 14.5 h, included labeling of the cRNA by biotinylation.
Hybridization and scanning
Labeled and amplified cRNAs (1.5 μg/array) were hybrid-
ized to Illumina's Sentrix® Mouse-6 Expression Bead
Chips (Illumina, Inc., San Diego, CA) at 58°C for 18 h
according to Illumina® Whole-Genome Gene Expression
with IntelliHyb Seal System Manual. The arrays were
washed and then stained with 1 μg/ml cyanine3-strepta-
vidin (Amersham Biosciences, Buckinghamshire, UK).
The Illumina BeadArray™ Reader was used to scan the
arrays according the manufacturer's instructions. The
numerical results were extracted with the Illumina's
BeadStudio software without any normalization or back-
ground subtraction.
Data analysis
Array data were normalized with Chipster (v1.3.0) using
the quantile normalization method. The data were fil-
tered according to the SD of the probes. The percentage
of data that did not pass through the filter was adjusted to
99.4%, implicating a SD value of almost 3. Statistical anal-
ysis was next performed using the empirical Bayes t-test
for the comparison of two groups. Finally, the probes
were further filtered according to fold change with ± 1.4
as the cut-off for up- and downregulated expression,
respectively. The functional annotation tool DAVID
(Database for Annotation, Visualization and Integrated
Discovery) [72,73] was used to identify enriched biologi-
cal categories among the regulated genes when compared
to all the genes present on Illumina's Sentrix Mouse-6
Expression Bead Chip. The annotation groupings ana-
lyzed were Gene Ontology biological process and molec-
ular functions, SwissProt comments, SwissProt Protein
Information Resources Keywords, Kyoto Encyclopedia of
Genes and Genomes pathway, and Biocarta pathway.
Results were filtered to remove categories with EASE
(Expression Analysis Systematic Explorer) scores greater
than 0.05. Overlapping categories with the same gene
members were removed to yield a single representative
category.
Quantitative real-time PCR
For quantitative real-time PCR (QRT-PCR), the same
samples were used as for the microarray analysis. 5 μg of
each RNA sample was converted into first strand cDNA
using a First Strand cDNA Synthesis Kit (Fermentas, Bur-
lington, Canada) using random hexamer primers follow-
ing the manufacturer's instructions. The relative
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Table 4: Sequences of the QRT-PCR primers used in this study.
Gene symbol Description GenBank number Forward primer (5'-3') Reverse primer (5'-3')
Adipoq adiponectin, C1Q and collagen domain containing NM_009605 TCCTGCTTTGGTCCCTCCAC TCCTTTCTCTCCCTTCTCTCC
Car3 carbonic anhydrase 3 NM_007606 GCTCTGCTAAGACCATCC ATTGGCGAAGTCGGTAGG
Cela2a chymotrypsin-like elastase family, member 2A NM_007919 TGATGTGAGCAGGGTAGTTGG CACTCGGTAGGTCTGATAGTTG
Cela3b chymotrypsin-like elastase family, member 3B NM_026419 TGCCTGTGGTGGACTATGAA CAGCCCAAGGAGGACACAA
Cfd complement factor D (adipsin) NM_013459 AACCGGACAACCTGCAATC CCCACGTAACCACACCTTC
Cpb1 carboxypeptidase B1 (tissue) NM_029706 GGTTTCCACGCAAGAGAG GTTGACCACAGGCAGAACA
Cym chymosin NM_001111143 ATGAGCAGGAATGAGCAG TGACAAGCCACCACTTCACC
Dmbt1 deleted in malignant brain tumors 1 NM_007769 GCACAAGTCCTCCATCATTC AGACAGAGCAGAGCCACAAC
Egf epidermal growth factor NM_010113 GCTCGGTGTTTGTGTCGTG CTGTCCCATCATCGTCTGG
Il1rl1 interleukin 1 receptor-like 1, transcript variant 2 NM_010743 ATTCTCTCCAGCCCTTCATC AAGCCCAAAGTCCCATTCTC
Pkp4 plakophilin 4, transcript variant 1 NM_026361 GAACATAACCAAAGGCAGAGG GGTGGACAGAGAAGGGTGTG
Pnlip pancreatic lipase NM_026925 CCCGCTTTCTCCTCTACACC TCACACTCTCCACTCGGAAC
Sftpd surfactant associated protein D NM_009160 CCAACAAGGAAGCAATCTGAC TCTCCCATCCCGTCCATCAC
Slc9a3 solute carrier family 9 (sodium/hydrogen exchanger), member 3 NM_001081060 TGACTGGCGTGGATTGTGTG ACCAAGGACAGCAGGAAGG
Actb actin, beta NM_007393 AGAGGGAAATCGTGCGTGAC CAATAGTGATGACCTGGCCGT
Hprt hypoxanthine guanine phosphoribosyl transferase NM_013556 AGCTACTGTAATGATCAGTCAACG AGAGGTCCTTTTCACCAGCA
Sdha succinate dehydrogenase complex, subunit A NM_023281 GCTTGCGAGCTGCATTTGG CATCTCCAGTTGTCCTCTTCCA
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were assessed by QRT-PCR using the LightCycler detec-
tion system (Roche, Rotkreuz, Switzerland). The primer
sets for the target genes (Table 4) were designed using
Primer3 [74], based on the complete cDNA sequences
deposited in GenBank. The specificity of the primers was
verified using NCBI Basic Local Alignment Search Tool
(BLAST) [20]. The house-keeping genes β-actin (Actb),
hypoxanthine guanine phosphoribosyl transferase (Hprt),
and succinate dehydrogenase complex, subunit A (Sdha)
were used as internal controls to normalize the cDNA
samples for possible differences in quality and quantity
(Table 4). The Actb and Hprt primers are available in the
public Quantitative PCR Primer Database [75] under the
identification numbers 634 and 10050, respectively. The
Sdha primers were obtained from the public PrimerBank
database [76] with the identification number 15030102a2.
To avoid amplification of genomic DNA, the primers
from each primer pair were located in different exons,
when possible.
Each PCR reaction was performed in a total volume of
20 μl containing 0.5 μl of first strand cDNA, 1x of Quanti-
Tect SYBR Green PCR Master Mix (Qiagen, Hilden, Ger-
many), and 0.5 μM of each primer. Amplification and
detection were carried out as follows: after an initial 15
min activation step at 95°C, amplification was performed
in a three-step cycling procedure for 45 cycles: denatur-
ation at 95°C for 15 s, annealing at a temperature deter-
mined according to the Tm for each primer pair for 20 s,
and elongation at 72°C for 15 s (the ramp rate was 20°C/s
for all the steps), followed by a final cooling step. Melting
curve analysis was always performed after the amplifica-
tion to examine the specificity of the PCR. To quantify
the levels of the target transcripts, a standard curve was
established for each gene using five-fold serial dilutions of
known concentrations of purified PCR products gener-
ated with the same primer pairs. Every cDNA sample was
tested in triplicate. The mean and SD of the 3 crossing
point (Cp) values were calculated for each sample and a
SD cut-off of 0.2 was set. Accordingly, when the SD of the
triplicates of a sample was greater than 0.2, the most out-
lying replicate was excluded and the analysis was contin-
ued with the two remaining replicates. Using a specific
standard curve, the Cp values were then transformed by
the LightCycler software into copy numbers. The expres-
sion value for each sample was the mean of the copy
numbers for the sample's replicates. The geometric mean
of the three internal control genes was used as an accu-
rate normalization factor for gene expression levels [77].
The final relative mRNA expression was given as the
expression value of the sample divided by the corre-
sponding normalization factor and multiplied by 103.
Statistical analyses
Statistical analyses of the microarray were performed
using the empirical Bayes t-test for comparison of the two
groups, and the p-values are shown in Additional file 1.
For the QRT-PCR results, the Mann-Whitney test was
used to evaluate differences in group values for Car9-/-
mice vs. wild-type mice.
List of abbreviations used
CA IX: carbonic anhydrase IX; HIF-1: hypoxia-inducible
transcription factor 1; HRE: hypoxia responsive element;
MAPK: mitogen-activated protein kinase; PI3K: phos-
phatidylinositol 3-kinase; QRT-PCR: quantitative real-
time PCR.
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Abstract
Our previous microarray study showed that the non-specific cytotoxic cell receptor protein 1 (Nccrp1) transcript is
significantly upregulated in the gastric mucosa of carbonic anhydrase IX (CA IX)-deficient (Car92/2) mice. In this paper, we
aimed to characterize human NCCRP1 and to elucidate its relationship to CA IX. Recombinant NCCRP1 protein was
expressed in Escherichia coli, and a novel polyclonal antiserum was raised against the purified full-length protein.
Immunocytochemistry showed that NCCRP1 is expressed intracellularly, even though it has previously been described as a
transmembrane protein. Using bioinformatic analyses, we identified orthologs of NCCRP1 in 35 vertebrate genomes, and up
to five paralogs per genome. These paralogs are FBXO genes whose protein products are components of the E3 ubiquitin
ligase complexes. NCCRP1 proteins have no signal peptides or transmembrane domains. NCCRP1 has mainly been studied
in fish and was thought to be responsible for the cytolytic function of nonspecific cytotoxic cells (NCCs). Our analyses
showed that in humans, NCCRP1 mRNA is expressed in tissues containing squamous epithelium, whereas it shows a more
ubiquitous tissue expression pattern in mice. Neither human nor mouse NCCRP1 expression is specific to immune tissues.
Silencing CA9 using siRNAs did not affect NCCRP1 levels, indicating that its expression is not directly regulated by CA9.
Interestingly, silencing NCCRP1 caused a statistically significant decrease in the growth of HeLa cells. These studies provide
ample evidence that the current name, ‘‘non-specific cytotoxic cell receptor protein 1,’’ is not appropriate. We therefore
propose that the gene name be changed to FBXO50.
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Introduction
Carbonic anhydrase IX (CA IX) belongs to a family of
mammalian a-carbonic anhydrases (CAs), zinc-containing metal-
loenzymes that catalyze the reversible hydration of carbon dioxide
in the reaction CO2+H2O«H++HCO32. CA IX is a dimeric
transmembrane protein that has many unique features that
distinguish it from other CAs [1,2]. First, the expression of CA
IX is limited to a few cell types in normal tissues, but it is highly
expressed in several tumors, especially under hypoxic conditions.
Furthermore, CA IX is involved in the regulation of tumor pH
which makes it an attractive antitumor drug target [3]. Second,
CA IX is the only member of the CA family that has a
proteoglycan (PG) domain, which may contribute to cell adhesion,
in addition to a catalytic CA domain [4]. Third, CA IX has a role
in cell proliferation; this was demonstrated by the generation of
CA IX knockout mice [5]. These mice showed gastric hyperplasia
of the glandular epithelium with numerous cysts. In a recent study,
we investigated the effect of CA IX deficiency on whole-genome
gene expression in gastric mucosa using microarrays [6]. Several
candidate genes were identified whose altered expression could
explain the abnormal cell lineage phenotype in Car92/2 gastric
mucosa. In subsequent studies, we focused on three poorly
characterized genes that have only been the subject of a few
published reports. One of these genes, non-specific cytotoxic cell
receptor protein 1 (Nccrp1), was significantly overexpressed in
Car92/2 gastric mucosa compared with wild-type mice.
NCCRP1 has been predicted to be a type II [7] or type III [8]
membrane protein and has been cloned from catfish, zebrafish,
tilapia, gilthead seabream and carp [7–12]. NCCRP1 is believed
to be a receptor expressed in nonspecific cytotoxic cells (NCCs)
that is responsible for their cytolytic function and has been
suggested to consist of three domains [13].
An interesting feature of the fish NCCRP1 proteins is their
homology with the F-box-only proteins. The zebrafish and catfish
NCCRP1 proteins share approximately 30% identity with this
subset of the F-box superfamily of proteins [12]. The homology is
considered to be restricted to an F-box-associated (FBA) domain
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located in the C terminus, as fish NCCRP1 proteins are thought to
lack the F-box motif in their N-termini. However, our analyses of
its sequence and structure indicate the presence of a shorter
version of the F-box domain in NCCRP1 proteins in mammals
and possibly even in fish. The function of the F-box is to mediate
protein-protein interactions, and F-box proteins are known to bind
protein substrates for ubiquitin-mediated proteolysis [14]. F-box
proteins recognize various substrates, but only members of the
FBXO subfamily have the ability to bind glycoproteins [15].
The tissue distribution of Nccrp1 mRNA has been studied in
several fish species, and its expression was found to be ubiquitous. In
tilapia, Nccrp1 is expressed in all immune and non-immune tissues
[9]. The relative expression level was highest in the liver, followed
by the head, kidney, spleen and intestine. Lower levels were
detected in the brain, gill and heart. Nccrp1 expression was lowest in
the skin. Similarly, constitutive expression of Nccrp1 transcripts was
detected in gilthead seabream [10] and carp [11]. Nccrp1 mRNA
expression has also been studied in the tetrapod animal axolotl [16].
Nccrp1 transcripts were detected in many tissues, including the limb
blastema, normal limb, skin, lung and spleen, but not in the brain or
liver. High mRNA levels were detected in the spleen and
regeneration blastema and in isolated blood cells.
To the best of our knowledge, this is the first study to
characterize human NCCRP1. We expressed this gene in E. coli
and analyzed its structure using biochemical methods. We also
examined the expression of NCCRP1 mRNA in human and mouse
tissues. Furthermore, we have investigated the association between
NCCRP1 and CA IX using siRNA technology. Our experimental
and bioinformatics results contradict the previous prediction that
the NCCRP1 protein is localized to the plasma membrane and
point unambiguously to its function as a protein-binding F-box
component of E3 ubiquitin ligases in the cytoplasm.
Results
Comparison of NCCRP1 and FBXO sequences
An ortholog of NCCRP1 was identified in 35 vertebrate genomes
from Ensembl ortholog tables. In fugu (Takifugu rubripes), two
orthologs were found. We found 21 protein sequences from 20
species to be at least 90% complete. Table 1 shows the Ensembl
gene identifiers for all identified orthologs, with the 20 species used
in further bioinformatic analyses in bold.
Multiple sequence alignment of 21 NCCRP1 proteins in Fig. 1
shows that the mouse and rat sequences in Ensembl are either 25
residues longer at the N-terminus, or the real start codon is the one
corresponding to M26. Mammalian sequences are characterized
by a proline-rich N-terminal domain of approximately 60 residues,
whereas fish sequences show shorter insertions around columns
150 and 190 in the alignment. NCCRP1 from the frog X. tropicalis
has short insertions similar to the fish sequences, but the N-
terminus is incomplete, so the presence of the N-terminal domain
remains inconclusive.
A major portion of the N-terminal domain in mammals is
predicted to be disordered. Prediction analysis of the human,
mouse and wallaby sequences yielded disordered domains of 70,
57 and 49 residues, respectively. These regions are underlined in
Fig. 1, which shows the end point of the disordered regions to be
very close to the end of the additional sequence seen in mammals.
There is an analogous Glu- and Ala-rich N-terminal domain in the
PEST domain of FBXO2 that also seems to be disordered. The N-
terminal 47 residues show no electron density in the crystal
structures of mouse FBXO2 (2E31, 2E32, 2E33) [17], and the
disorder prediction is consistent with the 41 N-terminal residues
predicted to be disordered.
The human paralogs of NCCRP1, as shown by the Ensembl
comparative genomics tools and Blast searches, are the genes
FBXO2, FBXO6, FBXO17, FBXO27 and FBXO44. The protein
products of these five genes are components of E3 ubiquitin ligase
complexes, and they define a lectin subfamily of ubiquitin ligases
[15]. In humans, the genes FBXO2, FBXO6 and FBXO44 are
contiguous genes on chromosome 1 (at 11.70 to 11.74 Mb), and
FBXO17, FBXO27 and NCCRP1 are on chromosome 19 (at 39.4 to
39.7 Mb). The protein sequence identity of NCCRP1 with the
other five lectin-type FBXO proteins ranges from 31% to 36% in
the last 180 residues, and the Blast E values range from 10227 to
10218, clearly indicating that these proteins share homology and
common ancestry.
Table 1. NCCRP1 orthologs found in Ensembl genomes.*
Species Ensembl Gene ID
Anole Lizard (Anolis carolinensis) ENSACAG00000011950
Armadillo (Dasypus novemcinctus) ENSDNOG00000018735
Bushbaby (Otolemur garnettii) ENSOGAG00000012185
Cat (Felis catus) ENSFCAG00000007425
Chimpanzee (Pan troglodytes) ENSPTRG00000010953
Cow (Bos taurus) ENSBTAG00000014296
Dog (Canis familiaris) ENSCAFG00000005593
Dolphin (Tursiops truncatus) ENSTTRG00000014969
Elephant (Loxodonta africana) ENSLAFG00000026532
Fugu (Takifugu rubripes) (1 of 2) ENSTRUG00000006309
Fugu (Takifugu rubripes) (2 of 2) ENSTRUG00000013740
Gibbon (Nomascus leucogenys) ENSNLEG00000014516
Gorilla (Gorilla gorilla) ENSGGOG00000028030
Guinea Pig (Cavia porcellus) ENSCPOG00000009451
Hedgehog (Erinaceus europaeus) ENSEEUG00000015408
Horse (Equus caballus) ENSECAG00000018954
Human (Homo sapiens) ENSG00000188505
Hyrax (Procavia capensis) ENSPCAG00000004015
Kangaroo rat (Dipodomys ordii) ENSDORG00000001051
Macaque (Macaca mulatta) ENSMMUG00000013906
Marmoset (Callithrix jacchus) ENSCJAG00000014055
Medaka (Oryzias latipes) ENSORLG00000000459
Microbat (Myotis lucifugus) ENSMLUG00000002162
Mouse (Mus musculus) ENSMUSG00000047586
Opossum (Monodelphis domestica) ENSMODG00000013456
Orangutan (Pongo abelii) ENSPPYG00000009956
Panda (Ailuropoda melanoleuca) ENSAMEG00000008646
Pika (Ochotona princeps) ENSOPRG00000006693
Platypus (Ornithorhynchus anatinus) ENSOANG00000015297
Rabbit (Oryctolagus cuniculus) ENSOCUG00000011658
Rat (Rattus norvegicus) ENSRNOG00000026244
Stickleback (Gasterosteus aculeatus) ENSGACG00000020167
Tetraodon (Tetraodon nigroviridis) ENSTNIG00000006031
Wallaby (Macropus eugenii) ENSMEUG00000001939
Xenopus tropicalis ENSXETG00000005319
Zebrafish (Danio rerio) ENSDARG00000035326
*Twenty-one genes with at least 90% complete predicted protein products are
shown in boldface.
doi:10.1371/journal.pone.0027152.t001
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In the available fish genomes, we only found orthologs to
FBXO2, FBXO44 and NCCRP1. Interestingly, the zebrafish
genome carries a cluster of ten copies of FBXO44 orthologs on
chromosome 23.
Analysis of protein domains
By Interpro scan, all 21 protein sequences had domain matches
to ‘‘Fbox-associated’’ (FBA, IPR007397) and ‘‘galactose-binding
domain-like’’ (IPR008979) patterns in the ,200 C-terminal
residues in fish and frog species and ,180 residues in mammalian
species. Only the protein products of NCCRP1 and the above five
FBXO gene loci are annotated to contain an FBA domain (InterPro
entry IPR007397), and no other human proteins were found in
Blast searches when NCCRP1 or the FBA domain of FBXO2 were
used as queries. The products of these five human FBXO genes also
contain a cyclin-like F-box domain pattern (InterPro entry
IPR001810) in the N-terminal region that spans 50 residues or
less, but none of the NCCRP1 proteins match this pattern.
Fig. 2 shows the alignment of human NCCRP1 with these five
FBXO proteins and their phylogenetic tree. Although there was
no match to the cyclin-like F-box domain pattern in the NCCRP1
sequence, 12 residues are conserved between human NCCRP1
and at least three other FBXO proteins within the F-box domain
region (lines on top of the alignment in Fig. 2). The main
differences in this region are found in three indels, in which
NCCRP1 has shorter sequences and lacks many conserved
residues, most notably the signature pattern CRxVC. To test
whether these deletions would be compatible with the F-box
domain structure, we visualized them in the known 3D structure of
mouse FBXO2 [17].
Fig. 3 shows the sequences to be deleted in purple. They
constitute one complete helical turn in alpha helix a1 (helices
named as described previously [17]), one helix turn in a2 and part
of the a29 loop, the end of helix a4, and the major part of the
linker before a5, including the flexible residues 104 to 108 that are
missing from the structure between the open ends (purple and
cyan). These deletions could be modeled in a shorter version of the
F-box fold while retaining the positions of a3 and a4 and the
sugar-binding domain (SBD), as in the structure 2E31 in PDB, by
linking a5 to the truncated a4 and shifting the right-hand ends of
helices a1 and a2 to the left. Alternatively, the SBD could be
moved to bring a5 into the position of a4, which would still
maintain the relative orientation between the F-box and the SBD.
Fig. 1 shows the extent of the F-box domain in these two models.
The solid line over the alignment indicates the version in which a4
is truncated, whereas the dotted line indicates the fusion of a5 into
the F-box domain. In conclusion, we believe that the region
preceding the SBD in human and other mammalian NCCRP1
proteins is indeed folded as an F-box domain.
In fish NCCRP1 sequences, the F-box domain is not detected
(by matching to the F-box pattern in InterPro), which is not
surprising because the fish sequences start in the middle of the F-
box region (Fig. 1). However, because the fish sequences only lack
six residues or less from the beginning of the structurally defined F-
box domain (see line at the top of the alignment in Fig. 1), a
version with a shortened initial helix a1 might exist. This remains
speculative because the fish and mammalian sequences are not
highly conserved in the putative F-box region.
TMHMM predicted that there are no transmembrane helices in
any of the studied 21 NCCRP1 ortholog proteins. SignalP
predicted no signal peptides in any of the proteins, and TargetP
predicted a non-mitochondrial, non-secreted localization for all
proteins. The predictions for the mouse and rat sequences were
run with alternative start sites: residue 1, as in Ensembl proteins,
and residue 26, consistent with the translation start site of other
mammalian sequences. All of these results indicate the absence
of transmembrane domains and cytoplasmic localization of
NCCRP1 in all of the studied species.
Jaso-Friedmann et al. [12] reported Box-1 motifs in zebrafish
and catfish NCCRP1 proteins. We did not detect these motifs in
the NCCRP1 proteins we analyzed, and we disagree with their
finding because they took the liberty of reversing the sequences,
which does not make sense for peptides.
Modelling of suggested active peptides
Because the NCCRP1 proteins could not be located on the cell
surface, as would be expected for the proteins to function as
antigen receptors [7], we next asked whether there were any
structural explanations for the previously reported [8,12] cytotox-
icity-inhibiting activity of NCCRP1-derived peptides (a more
potent 16-mer and a less potent 37-mer). The location of these two
overlapping peptides is shown under the alignment in Fig. 1. Fig. 4
shows the location of the 16-mer in yellow and the 37-mer in
yellow plus blue, extrapolated into the structure of mouse FBXO2
based on the sequence alignment. These peptides contain long
beta-strand elements coming from the amphiphilic beta sheets,
which have one side of mainly hydrophobic residues (facing the
protein core). Randomized peptides with same residues would be
highly unlikely to have such an organized amphiphilic surface.
Production, purification and characterization of
recombinant human NCCRP1
The human NCCRP1 cDNA was cloned into the expression
vector pGEX-4T-1 and expressed as a fusion protein with GST.
The recombinant NCCRP1 protein was characterized using SDS-
PAGE based on its apparent size. After purification by affinity
chromatography and digestion with thrombin, NCCRP1 ap-
peared as polypeptide of approximately 30 kDa after SDS-PAGE
(Fig. 5, lane 1). Fig. 5 also shows the 26-kDa GST band (lane 2).
Western blotting was used to confirm the reactivity of the
antibody produced against NCCRP1. Fig. 6 shows a single band
for NCCRP1 in lane 1, whereas the control blot using normal
rabbit serum was negative (Fig. 6, lane 2).
Mass spectrometry
Upon buffer exchange, the NCCRP1 protein sample slightly
precipitated, and therefore, mass analyses were conducted from
both the precipitate and supernatant. A small amount of the
precipitate was dissolved in 100 ml of 10 mM ammonium
bicarbonate buffer, pH 8.5, further diluted with acetonitrile/
water/acetic acid (49.5:49.5:1.0, v/v) mixture and directly analyzed
with ESI FT-ICR mass spectrometry. From this analysis, the
Figure 1. Alignment of 21 NCCRP1 protein sequences from 20 species. Shading indicates conservation, with more strongly conserved
positions shaded in darker colors. Uppercase letters under the alignment give the identity of fully conserved residues, and lowercase letters show the
consensus residue of partially conserved positions. Underlined sequences in the N-terminal region are predicted to be disordered in the three species
studied. The line over the sequence (columns 85 to 123) indicates the predicted F-box domain. The solid line (cols. 85 to 113) indicates an alternative
model (see ‘‘Analysis of protein domains’’). Underlining of the bottom consensus line indicates the location of the peptides discussed in ‘‘Modeling of
suggested active peptides’’ and studied in previous work [8]. Solid line: 16-mer peptide; Solid line plus dotted line: 37-mer peptide.
doi:10.1371/journal.pone.0027152.g001
Characterization of NCCRP1
PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e27152
Figure 2. Alignment of human NCCRP1 with its closest five paralogs and their phylogenetic tree. (A) Shading and consensus lettering
were used as described in Fig. 1. Dotted line over the sequence: F-box domain, cyclin-like, as defined in human FBXO2 by InterPro. Solid line over the
sequence: F-box domain as defined by compact alpha-helical folding in PDB entry 2E31 [17]. Line under the sequence: the sugar-binding domain as
defined previously [17]. (B) Phylogenetic tree with bootstrap support percentages for each node.
doi:10.1371/journal.pone.0027152.g002
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precipitate was found to contain a 27-kDa protein as well as a small
3-kDa peptide (Fig. 7A). The most abundant isotopic mass of the
protein (27743.57 Da) was matched against the NCCRP1 sequence
and a reasonable match was found with the fragment containing
residues 31–275 (theoretically 27743.45 Da), indicating the pres-
ence of one intra-molecular disulfide (Cys158-Cys192) in the
protein structure (see inset in Figure 7A). The monoisotopic mass
of the observed peptide P (3260.51 Da) was also matched against
the NCCRP1 sequence, and it was found to correspond to the first
30 residues of NCCRP1 with an additional Gly-Ser in the N-
terminus (theoretically 3260.52 Da). These amino acids are
attributable to the pGEX-4T-1 expression vector construct (Fig. 7B).
To further identify the produced protein, a database search for
the trypsin-digested protein was performed. An aliquot of 20 ml of
the tryptic digest sample was further diluted with 150 ml of an
acetonitrile/water/acetic acid (49.5:49.5:1.0, v/v) mixture and
analyzed directly. The digestion resulted in 18 identified tryptic
peptides within an average mass error of 6 ppm, covering 75% of
the NCCRP1 sequence. A search against the SwissProt database
gave an unambiguous hit for human NCCRP1 (NCRP1_HU-
MAN) with a Mowse score of 370 (Figure S1).
Figure 3. Structure of mouse FBXO2 (cyan) complexed with SKP1 (yellow). PDB entry 2E31 [17]. The regions of FBXO2 shown in purple
correspond to parts that would be deleted from a model of the F-box domain of human NCCRP1. The first 46 residues and residues 104–108 of
FBXO2 are not resolved in the structure. The sugar-binding site (SBD) is at the extreme right in this image. Alpha helices of FBXO2 are labeled at the
N-end of each helix, as described previously [17].
doi:10.1371/journal.pone.0027152.g003
Figure 4. Structure of the sugar-binding domain of mouse
FBXO2 complexed with an oligosaccharide of bovine ribonu-
clease A. PDB entry 2E33 [17]. Two views rotated 180 degrees vertically
are shown. The protein part of ribonuclease A is omitted. The coloring
indicates the positions homologous to the NCCRP1 peptides discussed
in ‘‘Modeling of suggested active peptides’’ and studied in previous
work [8,13]. Yellow: 16-mer peptide; yellow plus blue: 37-mer peptide.
doi:10.1371/journal.pone.0027152.g004
Figure 5. SDS-PAGE of the human recombinant NCCRP1
protein produced in E. coli. Lane 1 shows the 30-kDa NCCRP1
eluted from the affinity chromatography column after thrombin
treatment. In lane 2, 26-kDa GST is shown.
doi:10.1371/journal.pone.0027152.g005
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Mass spectra measured from the supernatant instead revealed
the same 3-kDa peptide that was detected from the precipitate as
well as a small amount of the NCCRP1 [31–275] fragment. In
addition, small amounts of some larger, currently unidentified 7–
10 kDa polypeptides were detected (data not shown).
Localization of NCCRP1 in HeLa cells
The subcellular localization of NCCRP1 was examined in
HeLa cells by immunocytochemistry. The protein was detected in
the cytoplasm, as shown in green in Fig. 8. In contrast, CA IX was
localized at the cell membrane, as expected (Fig. 8A and C, red).
Interestingly, these two proteins were only rarely detected in the
same cell (Fig. 8A, arrows). Control immunostaining using 30 mg
of blocking NCCRP1 recombinant protein and anti-NCCRP1
serum resulted in only very faint staining, confirming the
specificity of the antiserum (Fig. 8D). A second control using
pre-immune serum instead of the anti-NCCRP1 serum showed
virtually no staining (Fig. 8E).
Figure 6. Western blot analysis of the antibody produced
against NCCRP1. Lane 1 shows a single band confirming the
expected reactivity of the antibody towards NCCRP1 protein. The
control experiment using normal rabbit serum is negative (lane 2).
doi:10.1371/journal.pone.0027152.g006
Figure 7. Mass spectrometry analysis of NCCRP1. (A) ESI FT-ICR mass spectrum of NCCRP1 sample measured in an acetonitrile/water/acetic
acid (49.5:49.5:1.0, v/v) mixture. The sample contained an NCCPR1 [31–275] fragment (charge state 22+ denoted) and a peptide P (charge states 2+
and 3+ denoted), corresponding to the first 30 residues with an additional Gly-Ser in the N-terminus due to the used expression vector construct. The
charge-deconvoluted mass spectrum in the inset shows calculated and experimental isotopic distributions for the NCCRP1 [31–275] fragment (with
the most abundant masses indicated), as well as experimental isotopic distribution for the peptide P with a monoisotopic mass of 3260.15 Da. (B)
Primary sequence of NCCRP1. The residues corresponding to the peptide P are underlined and cysteines (Cys158, Cys192) are marked with asterisks.
doi:10.1371/journal.pone.0027152.g007
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NCCRP1 expression in human tissues
The IST database system developed by MediSapiens Ltd was
used to obtain the data for NCCRP1 mRNA expression in human
normal and cancer-derived tissues (Fig. 9A and B). The expression
pattern of NCCRP1 was relatively narrow in both normal and
cancerous tissues. The normal tissues with the highest signal were
the esophagus, oral cavity, skin, tongue and male and female
reproductive organs. The cancer-derived tissues with high
NCCRP1 expression included the squamous cell carcinoma of
the skin and cancers of the female reproductive organs.
Nccrp1 expression in mouse tissues
Nccrp1 mRNA expression was studied in several mouse tissues
by QRT-PCR. Nccrp1 transcript was expressed in all tissues
studied and the signal was highest in the kidney (Fig. 10). The
expression was moderate in the stomach, colon, duodenum and
prostate. In other tissues, Nccrp1 was expressed to a lesser degree
but signal was still clearly detectable.
The effect of growth factors and deferoxamine mesylate
on NCCRP1 mRNA expression
The influence of growth factors and deferoxamine mesylate on
NCCRP1 transcript levels was studied in HeLa cells using QRT-
PCR. The basal level of NCCRP1 expression was relatively high in
these cells and neither treatment had a major effect on its
expression. After treatment with deferoxamine mesylate, which is
commonly used to induce a hypoxia-like response, the expression
of NCCRP1 decreased moderately (1.4-fold), as shown in Fig. 11.
In contrast, deferoxamine mesylate treatment induced CA9
expression 4-fold, as expected (data not shown). Stimulation with
EGF decreased NCCRP1 expression levels but the decline was
small (1.2-fold). Other treatments did not have any effect on
NCCRP1 mRNA levels.
Expression of NCCRP1 and CA9 in human pancreatic and
breast cancer cell lines
The expression of NCCRP1 and CA9 was measured by QRT-
PCR in 16 pancreatic cancer cell lines and 21 breast cancer cell
lines. NCCRP1 showed the highest expression in the Su.86.86,
Hup-T4 and Hs700T pancreatic cancer cell lines and the MDA-
MB-415, SK-BR-3 and BT-474 breast cancer cell lines (Fig. 12).
In other cell lines, NCCRP1 was expressed at moderate or low
levels. In general, the expression of CA9 was lower than NCCRP1
in the studied cell lines. CA9 had the strongest signal in the
DU4475 breast cancer and AsPC-1 pancreatic cancer cell lines. Its
expression was moderate in a few cell lines and very low in several
others. NCCRP1 and CA9 showed reciprocal expression patterns in
some cell lines; i.e., when NCCRP1 expression was high CA9
expression was low or absent, and vice versa.
NCCRP1 and CA9 silencing
CA9 was silenced in the human glioblastoma cell line, U373,
which has a high basal level of CA9 expression. Efficient
downregulation of mRNA expression (up to 93% reduction
compared with luciferase control siRNA-treated cells) was detected
for the CA9 gene after siRNA treatment (data not shown). Silencing
of CA9 was monitored until 144 h after transfection and remained
efficient at that time point. ThemRNA level ofNCCRP1was studied
in U373 cells after CA9 silencing to examine whether NCCRP1 was
directly regulated by CA9 expression. The expression of NCCRP1
was below the detection limit of QRT-PCR at the basal level in
U373 cells and did not change after the silencing of CA9.
NCCRP1 silencing was performed in two cell lines, HeLa and
Su.86.86, and the effect of silencing on the expression level of CA9
was studied. The silencing of NCCRP1 was efficient in both cell
lines (up to 91% and 83% reduction compared with luciferase
control siRNA-treated cells for HeLa and Su.86.86 cells,
respectively). In HeLa cells, the silencing of NCCRP1 was
monitored until 144 h after transfection and remained efficient.
CA9mRNA levels were not affected by NCCRP1 silencing (Fig. 13).
The expression of CA9 steadily increased until 120 h after
transfection, after which it decreased dramatically. In Su.86.86
cells, CA9 expression was also unaffected by the silencing of
NCCRP1 (data not shown).
Effect of NCCRP1 silencing on cell growth
The effect of NCCRP1 silencing on cell growth was studied in
HeLa cells at 48, 96 and 144 h after transfection, and the analysis
was performed using ImageJ. Silencing of NCCRP1 led to a
Figure 8. Subcellular localization of NCCRP1 in HeLa cells by
immunocytochemistry. (A, B) Staining for NCCRP1 is detected in the
cytosol as shown in green. (A, C) CA IX is expressed on the cell
membrane as shown in red. (A; arrows) Only a few HeLa cells expressed
both proteins at the same time. (D) Control immunostaining using
30 mg of blocking NCCRP1 recombinant protein and anti-NCCRP1
serum together gives only a very faint staining. (E) Other control
staining using pre-immune serum instead of the anti-NCCRP1 serum
shows a barely detectable signal.
doi:10.1371/journal.pone.0027152.g008
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statistically significant decrease in HeLa cell proliferation at every
time point (Fig. 14).
Discussion
According to our previous cDNA microarray analysis, carbonic
anhydrase IX-deficient mice showed significantly upregulated
expression of Nccrp1 in the stomach, which is the most abundant
site of CA IX expression in normal mice. This finding led us to
investigate possible connections between these two genes/proteins
and to further assess the structure, regulation and function of the
NCCRP1 protein. Our bioinformatic analyses clearly linked
NCCRP1 protein to the FBXO gene family. The FBA domain
in the FBXO2, FBXO6, FBXO17 and FBXO27 proteins is a
lectin domain, and these proteins have been experimentally shown
to bind various glycans [15]. The presumed role of these proteins
is to bind misfolded and retrotranslocated glycoproteins in the
cytoplasm for ubiquitin conjugation leading to proteasomal
degradation [15]. The fact that this family of lectin-type F-box
proteins (among the dozens of different F-box proteins found in
ubiquitin ligase complexes) comprises the closest paralogs of
NCCRP1 gives us a strong reason to predict that NCCRP1
functions as a protein-binding component in ubiquitin ligase
complexes. Whether it actually binds glycans, similar to FBXO2,
FBXO6, FBXO17 and FBXO27, or lacks the ability to bind
sugar, like FBXO44 [15], remains to be tested experimentally.
However, sequence alignments and structural interpretations
(Figs. 1, 2, 3) suggest that NCCRP1 is a sixth member of the
lectin-type FBXO gene family, and we therefore propose that the
gene name be changed to FBXO50 (the number may change
based on the decision of the Human Gene Nomenclature
Committee, http://www.genenames.org/).
Jaso-Friedmann et al. [12] stated that NCCRP1 does not
contain an F-box and is therefore an exception in this subfamily.
Figure 9. Data for human NCCRP1mRNA expression from the MediSapiens database. (A) Boxplot analysis of the NCCRP1 expression levels
across healthy human tissues. (B) Boxplot analysis of the NCCRP1 expression levels across a large panel of cancer tissues. Among the normal tissues
with the highest NCCRP1 expression are the esophagus, oral cavity, skin, tongue and reproductive organs. In cancerous tissues, the expression profile
of NCCRP1 is relatively narrow, with the highest expression seen in the squamous cell carcinomas of the skin and cancers of the female reproductive
organs. The number of samples in each category is shown in parenthesis. The box refers to the quartile distribution (25–75%) range, with the median
shown as a black horizontal line. The whiskers extend to 1.5 times the interquartile range from the edges of the box, and any data points beyond this
are considered outliers and marked by open circles.
doi:10.1371/journal.pone.0027152.g009
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However, our analysis points to the existence of an F-box in
mammalian NCCRP1 proteins, and at least the remnants of one
in the fish sequences, so the name FBXO50 would be appropriate.
The ‘‘F-box associated’’ domain occurs in the human proteome
only in the six gene products discussed in this paper. This domain
could also be renamed to reflect its known functions, e.g. F-box
associated lectin(-like) domain or ubiquitin ligase lectin(-like)
domain.
To our surprise, mass spectrometry analysis indicated the
presence of a truncated protein in the NCCRP1 sample after
purification and buffer exchange, which corresponded to the
residues 31–275 of the full-length polypeptide. However, the
peptide corresponding to the first 30 residues was also detected,
which suggests that the N-terminal region had been cleaved after
the protein production, probably during purification or desalting
steps. Protein precipitation was also observed upon buffer-
exchange but it is not known whether this is related to the
observed N-terminal cleavage or change in the buffer conditions.
The reason for the intrinsically weak N-terminal region of the
NCCRP1 protein is unknown and will be investigated further.
Based on our sequence analyses, the N-terminal proline-rich
region of mammalian NCCRP1 proteins is predicted to be
disordered, which might contribute to the N-terminal truncation.
Mass analysis of the NCCRP1 [31–275] fragment also indicated
that there is an intra-molecular disulfide between Cys158 and
Cys192.
None of the NCCRP1 sequences contain any putative signal
sequences or transmembrane domains, which rules out a
membrane location. Accordingly, we showed using immunocyto-
chemistry that recombinant human NCCRP1 is expressed
intracellularly. Jaso-Friedmann, Leary and Evans previously
reported two contradictory predictions of membrane topology
and transmembrane helix location [7,8]. Both papers suggest
unrealistically short and fairly hydrophilic transmembrane helices
but provide no explanation as to how these predictions were made.
Moreover, both predictions locate the transmembrane regions in
the middle of what we now know to be the beta sandwich fold of
the FBA domain.
We speculate that the initial NCCRP1 research [7] was
hampered by an unfortunate incident of purifying and cloning
an incorrect protein with approximately the correct molecular
weight (27.3 kDa) instead of the real antigen they originally
discovered (34 kDa). In any case, our study now clearly
demonstrates that NCCRP1 is an intracellular ubiquitin ligase
protein, not a cell surface protein.
Previous reports provide some indirect results that have been
interpreted as linking fish NCCRP1 proteins with cytotoxicity.
First, NCCRP1 anti-sense oligonucleotides were found to reduce
the cytotoxicity of catfish NCC cells [7]. In our study, we have
demonstrated the anti-proliferative effect of siRNA-mediated
NCCRP1 knockdown in HeLa cells, which may be due to a failure
to degrade misfolded glycoproteins. We hypothesize that similar
disturbances in viability or in protein secretion could account for
the effect of anti-sense oligonucleotides in catfish NCC cells.
Second, peptides derived from catfish and zebrafish NCCRP1
were observed to reduce NCC-mediated cell lysis [8,12]. These
peptides (Figs. 1 and 4) come from the most highly conserved
region of the lectin domain and contain amphiphilic beta strands.
We believe that the hydrophobic patches in these peptides would
have a high degree of nonspecific binding and could interfere with
various cell surface events. The uniform orientation of hydropho-
bic residues is sequence-dependent and would be lost in most
randomized peptides, which may have been the case in a previous
report [12], leading to seemingly specific results for a peptide that
is not derived from a cell-surface receptor.
The human lectin-type F-box-only (FBXO) genes are present in
two clusters in the genome: FBXO2, FBXO6 and FBXO44 on
chromosome 1, and FBXO17 and FBXO27 on chromosome 19.
NCCRP1 is only 150 kb away from FBXO27, separated by two
other genes. The adjacent gene triplet on human chromosome 1
Figure 10. The Nccrp1 mRNA expression in mouse tissues by
QRT-PCR. Nccrp1 is present in all the tissues studied. The expression of
Nccrp1 is highest in the kidney and moderate in the stomach, colon,
duodenum and prostate. In the other tissues Nccrp1 expression is
modest. Normalized median values calculated from the technical
triplicates are shown.
doi:10.1371/journal.pone.0027152.g010
Figure 11. The effect of different treatments on NCCRP1 levels
in HeLa cells. The treatments included deferoxamine mesylate (DFM),
transforming growth factor-alpha (TGF-a), transforming growth factor-
beta 1 (TGF-b1) and epidermal growth factor (EGF). Deferoxamine
mesylate and EGF treatments moderately decreased the expression of
NCCRP1 (1.4-fold and 1.2-fold, respectively). The normalized values of
triplicate experiments as detected by QRT-PCR are shown.
doi:10.1371/journal.pone.0027152.g011
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and the pair on chromosome 19 are likely due to recent gene
duplication events. However, the phylogenetic tree in Fig. 2B
indicates that FBXO17 and FBXO27 share their latest common
ancestor with the triplet of FBXO genes on chromosome 1, and
therefore, their proximity to NCCRP1 may be coincidental. A full
phylogenetic analysis of FBXO proteins and their emergence in
various vertebrate taxa would be an interesting topic for a future
study.
Because there have been no previous reports on the expression
pattern of NCCRP1 in mammals, we examined mRNA levels of
human and mouse NCCRP1. In normal human tissues, NCCRP1 is
strongly confined to the squamous epithelium, mainly being
detected in tissues such as the esophagus, oral cavity, skin and
tongue. The expression pattern is similar in cancerous tissues; the
highest expression was seen in squamous cell carcinomas of the
skin, cervix and vagina/vulva. In mice, the expression of Nccrp1
was highest in the kidney and moderate in the stomach, colon,
duodenum and prostate. Lower levels of the transcript were also
detectable in the other tissues studied, including the parotid and
submandibular glands, lung, jejunum, ileum and testis. These data
suggest that NCCRP1 is relatively ubiquitously expressed, similar
to FBXO6, FBXO27 and FBXO44 [15]. In contrast, FBXO2 is
predominantly expressed in different areas of the brain and only
weakly in some other tissues [15,18], and FBXO17 is expressed in
only a few tissues [15,18]. It should be noted that many tissues
express several FBXO genes. For example, major glycoprotein-
producing tissues include the brain, liver and pancreas, all of
which express multiple FBXO family members [15]. In this
Figure 12. Screening of NCCRP1 and CA9mRNA expression in cancer cell lines. 16 human pancreatic (AsPC-1 to SW 1990) and 21 breast (BT-
474 to ZR-75-30) cancer cell lines were screened using QRT-PCR. The expression of NCCRP1 is highest in the Su.86.86, Hup-T4 and Hs700T pancreatic
cancer cell lines and the MDA-MB-415, SK-BR-3 and BT-474 breast cancer cell lines. CA9 is most highly expressed in the DU4475 breast cancer and
AsPC-1 pancreatic cancer cell lines. The expression levels of these genes typically show a reciprocal pattern: high simultaneous expression is observed
in none of these cell lines. The normalized values are shown.
doi:10.1371/journal.pone.0027152.g012
Figure 13. CA9 expression after silencing of NCCRP1 in HeLa
cells. The mRNA expression of CA9 was monitored for 144 h after the
silencing of NCCRP1. No change was observed in CA9 expression with
NCCRP1 siRNA compared with luciferase (Luc) control siRNA. The
normalized median values calculated from the three replicates are
shown.
doi:10.1371/journal.pone.0027152.g013
Figure 14. The effect of NCCRP1 silencing on cell proliferation in
HeLa cells as analyzed by ImageJ. Cell growth was studied at 48, 96
and 144 h after transfection. The silencing of NCCRP1 caused a
statistically significant decrease in cell proliferation at every time point.
Statistically significant differences relative to luciferase (Luc) control
siRNA were determined. ** p,0.01.
doi:10.1371/journal.pone.0027152.g014
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respect, the expression pattern of NCCRP1 in human tissues is
exceptional because it is almost solely present in tissues containing
squamous epithelium. On the other hand, Nccrp1 is expressed
widely in mouse tissues; this pattern resembles the expression of
other ubiquitously expressed FBXO genes.
Finally, we examined the connection between CA9 and NCCRP1
using several different approaches. Nccrp1 was originally found to
be significantly upregulated in the gastric mucosa of CA IX-
deficient mice [6], which prompted us to explore its role more
closely, but focusing on the human gene. In HeLa cells, we found
that the NCCRP1 and CA IX proteins usually ‘‘avoid’’ each other;
that is, they are only rarely expressed in the same cells (Fig. 8A,
arrows). Furthermore, in a panel of 16 pancreatic cancer cell lines
and 21 breast cancer cell lines, NCCRP1 and CA9 expression were
inversely correlated in certain cell lines; NCCRP1 was weakly
expressed or absent when CA9 mRNA was highly expressed, and
vice versa. These data support the observation in Car9 knockout
mice in which the expression of Nccrp1 was increased in the
absence of Car9. We also determined whether the expression of
NCCRP1 was regulated in a similar manner to CA9 in HeLa cells.
NCCRP1 expression decreased moderately after stimulation with
deferoxamine mesylate, which was used to induce a hypoxia-like
response. On the contrary, CA9 expression increased highly, as
expected. Thus, NCCRP1 does not seem to share a main
regulatory pathway with CA IX.
siRNA-mediated gene silencing was used to study whether CA9
expression directly regulates NCCRP1 expression. Knockdown of
CA9 in U373 cells had no effect on NCCRP1 expression levels,
implying that NCCRP1 is not directly regulated by CA9, at least in
this cell line. Likewise, silencing of NCCRP1 in HeLa and Su.86.86
cells did not affect CA9 expression. Interestingly, we found that
knockdown of NCCRP1 led to a statistically significant decrease in
the growth of HeLa cells, and this effect was still observed at 144 h
after transfection. FBXO6 has also been shown to promote growth
and proliferation of gastric cancer cells compared with control cells
that do not express the protein [19]. One plausible explanation for
these observations is that NCCRP1 and FBXO6 are needed to
target certain glycoproteins that affect the cell cycle for
degradation and that the proliferation of cancer cells is impaired
when this function is inhibited. The results of this study indicate
that NCCRP1 is not directly regulated by CA9, but there are more
complicated regulation events that lead to its upregulation when
CA9 is knocked down.
In conclusion, these studies provide ample evidence that the
present name, ‘‘non-specific cytotoxic cell receptor protein 1,’’
does not fittingly describe the polypeptide known as NCCRP1.
Bioinformatic analyses clearly show that NCCRP1 is a paralog to
five other FBXO genes. We have also shown experimentally that
the human recombinant NCCRP1 protein is expressed in the
cytosol, not on the cell surface. Furthermore, the tissue expression
pattern of NCCRP1 in humans and mice is incompatible with an
immune receptor function.
Materials and Methods
Bioinformatics
Sequences were retrieved from Ensembl release 62 (www.
ensembl.org) [20], UniProt (www.uniprot.org) [21], GenBank
(www.ncbi.nlm.nih.gov/genbank/) [22] and RefSeq (www.ncbi.
nlm.nih.gov/RefSeq/) [23]. BLAST searches were carried out via
NCBI (blast.ncbi.nlm.nih.gov/Blast.cgi) [24]. Multiple sequence
alignments were prepared with ClustalW (www.ebi.ac.uk/Tools/
msa/clustalw2/) [25] and Mafft (www.ebi.ac.uk/Tools/msa/
mafft/) [26] and visualized with GeneDoc (www.nrbsc.org/gfx/
genedoc/). Protein motifs were searched using InterProScan
(www.ebi.ac.uk/Tools/pfa/iprscan/) [27] and transmembrane
domains were predicted with TMHMM v. 2.0 (www.cbs.dtu.dk/
services/TMHMM/) [28]. Signal peptides and other target
peptides were predicted using SignalP 3.0 with eukaryotic
parameters (www.cbs.dtu.dk/services/SignalP/) [28] and TargetP
1.1. with non-plant parameters (www.cbs.dtu.dk/services/Tar-
getP/) [28], respectively. Intrinsic protein disorder was predicted
with DISpro (www.ics.uci.edu/,baldig/dispro.html) [29]. Phylo-
genetic trees were prepared using the MEGA4 software (www.
megasoftware.net/) [30] with maximum parsimony and the
complete deletion option for gapped sites with 1000 bootstrap
replicates. Molecular images were prepared with PyMol 0.99
(DeLano Scientific, South San Francisco, CA).
Construction of recombinant human NCCRP1
The full-length protein-coding cDNA sequence for human
NCCRP1 was obtained from the Mammalian Gene Collection,
and the cDNA clone (IMAGE ID: 30348184) was purchased from
Source BioScience LifeSciences (Cambridge, United Kingdom).
Plasmid DNA was isolated from an overnight culture using a
QIAprep Spin Miniprep Kit (Qiagen, Hilden, Germany). NCCRP1
cDNA was amplified by PCR using PhusionTM Hot Start High
Fidelity DNA Polymerase (Finnzymes, Espoo, Finland). Primers
were ordered from Biomers (Ulm, Germany). The forward primer
sequence was 59-CCG CGG ATC CAT GGA GGA GGT GCG
TGA GGG A-39 and the reverse primer was 59-CGC CGT CGA
CTC ACT CCC GGA GCT GCA CAG-39, with the restriction
sites for BamHI and SalI underlined, respectively. PCR was
performed in an XP Thermal Cycler (Bioer Technology,
Hangzhou, China) with a program consisting of a single 98uC
denaturation step for 30 s followed by 35 cycles of denaturation at
98uC for 10 s, annealing at 64uC for 30 s and extension at 72uC
for 30 s, and a final extension at 72uC for 5 min. The PCR
product band was separated from agarose gel and dissolved using
an IllustraTM GFX PCR DNA and GEL Band Purification Kit
(GE Healthcare Life Sciences, Buckinghamshire, UK). The
purified PCR product and pGEX-4T-1 vector (Invitrogen,
Carlsbad, CA) were digested at 37uC for 2 hours with the BamHI
and SalI restriction enzymes (New England Biolabs, Ipswich, MA,
USA). The digested plasmid and NCCRP1 construct were purified
and ligated overnight at 4uC using T4 DNA ligase (New England
Biolabs). The ligated product was transformed into E. coli
BL21(DE3)pLysS bacteria (Promega, Madison, WI, USA).
Overnight cultures (5 ml) were grown from colonies, and plasmids
were purified using a QIAprep Spin Miniprep KitTM (Qiagen).
Sequencing was performed to verify the sequence of the NCCRP1
construct. This purification method was based on a glutathione S-
transferase (GST) gene fusion system. Expression of pGEX-4T-1
in E. coli yielded fusion proteins with the GST moiety at the amino
terminus and NCCRP1 recombinant protein at the carboxyl
terminus. The construct also contained a thrombin protease site
between the GST tag and NCCRP1. This vector construct codes
additional Gly and Ser residues to the N-terminus of the
recombinant protein.
Production and purification of recombinant human
NCCRP1
A single BL21(DE3)pLysS transformant colony was grown in
5 ml LB medium containing 50 mg/ml ampicillin at room
temperature with shaking (200 rpm) overnight and used to
inoculate 500 ml of LB/amp medium. This culture was grown
until the optical density (OD) at 600 nm reached 0.6. Expression
of NCCRP1 protein was induced by adding isopropyl b-D-1-
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thiogalactopyranoside (IPTG) (Fermentas, Ontario, Canada) at a
final concentration of 0.25 mM, and the culture was grown at
room temperature overnight. The cells were harvested by
centrifugation (Sorvall RC 28S) at 5,000 rpm for 5 min at room
temperature. The cell pellet was suspended in 10 ml Tris-buffer
containing 0.1 M Tris-Cl, pH 8, 0.05% Triton X-100, 200 mg
lysozyme, 200 U DNase (Roche, Penzberg, Germany) and the
protease inhibitors phenylmethanesulfonylfluoride (0.2 mg; Sig-
ma-Aldrich, Helsinki, Finland) and leupeptin (0.1 mg) (Santa
Cruz, Heidelberg, Germany). After a 30-min incubation at room
temperature, the cell suspension was placed on ice and sonicated
for 1 min. The suspension was clarified by centrifugation at
10,000 rpm for 30 min at 4uC, and the clear supernatant was
affinity purified using Glutathione Sepharose 4B medium (GE
Healthcare, Buckinghamshire, UK). Recombinant NCCRP1
protein was isolated under native conditions according to the
manufacturer’s protocol. A site-specific thrombin (GE Healthcare)
was used for specific cleavage of the GST under shaking at room
temperature overnight. Finally, the protein was eluted using the
glutathione elution method (GE Healthcare) recommended by the
manufacturer. The size of the expressed NCCRP1 protein was
determined under reducing conditions by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) analysis.
Production of a polyclonal antibody and western blotting
Anti-human NCCRP1 serum was raised in a rabbit against the
purified full-length NCCRP1 by Innovagen AB (Lund, Sweden).
Western blotting was used to confirm the reactivity of the antibody
with NCCRP1.
Recombinant NCCRP1 proteins were subjected to SDS-PAGE
under reducing conditions and transferred to polyvinylidene
fluoride (PVDF) membranes. The membranes were treated with
blocking solution (Santa Cruz, Heidelberg, Germany) for 30 min.
After blocking, the membrane was incubated with the primary
antibody (rabbit anti-NCCRP1) diluted 1:2,000, or normal rabbit
serum as a control, and washed. The membrane was incubated
with the secondary antibody diluted 1:25,000 (anti-rabbit Ig,
horseradish-peroxidase-linked whole antibody from donkey,
Amersham Biosciences, Buckinghamshire, England) and washed,
and protein bands were visualized by electrochemiluminescence
(ECL) using Amersham ECLTM Western Blotting Detection
Reagents (GE Healthcare) according to the manufacturer’s
instructions.
Mass spectrometry
All experiments were performed on a 4.7-T Fourier transform
ion cyclotron resonance (FT-ICR) mass spectrometer (APEX-Qe;
Bruker Daltonics, Billerica, MA, USA) equipped with an Apollo-II
ion source and a mass-selective quadrupole front-end. This
instrument has been described in detail elsewhere [31]. The
protein samples were buffer exchanged into 10 mM ammonium
acetate buffer, pH 6.9, on PD-10 columns (Amersham Bioscienc-
es, Billingham, UK) and directly electrosprayed at a flow rate of
1.5 mL/min. ESI-generated ions were externally accumulated for
1 s in a hexapole ion trap and transmitted to the ICR for trapping,
excitation and detection. For each spectrum, 1,000 co-added 512-
kWord time-domain transients were recorded, zero-filled twice,
Gaussian multiplied and fast Fourier transformed before magni-
tude calculation and external mass calibration with respect to the
ions of an ES Tuning Mix (Agilent Technologies, Santa Clara,
CA, USA). All data were acquired and processed using Bruker
XMASS 6.0.2 software. Mass spectra were further charge
deconvoluted using a standard deconvolution macro implemented
in the XMASS software. Tryptic digests were obtained by
dissolving a small amount of the protein precipitate in 100 ml of
a 10 mM ammonium bicarbonate buffer, pH 8.5, and 15 mg of
sequencing grade trypsin (Promega GmbH, Mannheim, Germany)
in 15 ml of water was added. The digest sample was incubated at
37uC for 1.5 hours, after which no precipitate was observed, and
the sample was directly analyzed without chromatographic
separation. The resulting protein or peptide masses were matched
against the protein sequence using the GPMAW 8.11 software,
and tryptic peptide masses were further subjected to database
search using the Mascot search engine (www.matrixscience.com).
Cell lines
A panel of 16 established pancreatic cancer cell lines was used in
this study. Thirteen of these (AsPC-1, BxPC-3, Capan-1, Capan-2,
CFPAC-1, HPAC, HPAF-II, Hs 700T, Hs 766T, MIA PaCa-2,
PANC-1, Su.86.86, and SW 1990) were purchased from the
American Type Culture Collection (ATCC, Manassas, VA, USA),
and three (DanG, Hup-T3, and Hup-T4) were purchased from the
German Collection of Microorganisms and Cell Cultures
(Braunschweig, Germany). The 21 breast cancer cell lines used
in this study (BT-474, CAMA-1, DU4475, HCC38, HCC1419,
HCC1954, MCF7,MDA-MB-134-VI, MDA-MB-231, MDA-MB-
361, MDA-MB-415, MDA-MB-436, MDA-MB-453, SK-BR-3,
T-47D, UACC-732, UACC-812, UACC-893, UACC-3133, ZR-
75-1, and ZR-75-30) were obtained from the ATCC. The U373
human glioblastoma astrocytoma cell line was purchased from the
European Collection of Cell Cultures. The HeLa human cervical
carcinoma cell line was from the laboratory of Professor Jorma
Isola (Institute of Biomedical Technology, University of Tampere,
Tampere, Finland). Cells were grown under the recommended
culture conditions.
Immunocytochemistry
Rabbit anti-human NCCRP1 serum (Innovagen) and the M75
antibody specific for the PG region of CA IX were used for
immunocytochemistry [32]. Non-immune normal rabbit serum
was used as a control.
HeLa cells were fixed with 4% (vol/vol) neutral-buffered
formaldehyde for 30 min. The cells were then rinsed with PBS
and subjected to immunofluorescence staining using the following
protocol: (a) pre-treatment with 0.1% BSA in PBS (BSA-PBS) for
30 min; (b) incubation for 1 h with rabbit NCCRP1 antiserum or
normal rabbit serum diluted 1:100 in 0.1% BSA-PBS or mouse
CA IX antiserum diluted 1:10 in 0.1% BSA-PBS; (c) rinsing three
times for 5 min with BSA-PBS; (d) incubation for 1 h with 1:100
diluted Alexa Fluor 488 goat anti-rabbit IgG antibodies or Alexa
Fluor 568 goat anti-mouse IgG antibodies (both from Molecular
Probes, Eugene, Oregon, USA) in 0.1% BSA-PBS; (e) rinsing two
times for 5 min with BSA-PBS and once with PBS. All incubations
and washings were performed in the presence of 0.05% saponin.
Immunostained cells were analyzed and photographed using a
Zeiss LSM 700 confocal laser scanning microscope.
NCCRP1 expression in human and mouse tissues
NCCRP1 mRNA expression levels across a large number of
human tissues were retrieved from the IST database system
developed by MediSapiens Ltd. The current version of the IST
database (4.3) contains 20,218 human tissue and cell line samples
analyzed by Affymetrix gene expression microarrays. The
database was constructed and validated using methods similar to
those described by Kilpinen et al. [33] and Autio et al. [34] for the
construction of the GeneSapiens database. The database contains
expression data that is fully integrated in terms of both the
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annotation and numerical compatibility, allowing for analysis of
the expression levels of 19,123 genes across 228 distinct tissues.
Mouse tissues were obtained from C57BL/6 mice that were
maintained in the animal facility of the University of Oulu. A total
of six mice (3 males and 3 females) were sacrificed at two months
of age. Tissue specimens were taken from the following areas:
parotid gland, submandibular gland, stomach, duodenum, jeju-
num, ileum, colon, lung, kidney, prostate and testis. The tissue
samples were immediately immersed in RNAlater solution
(Ambion, Austin, TX, USA) and frozen at 280uC.
Total RNA was extracted from the mouse tissues using an
RNeasy RNA isolation kit (Qiagen, Valencia, USA) following the
manufacturer’s instructions. Residual DNA was removed from the
samples using RNase-free DNase (Qiagen). The RNA concentra-
tion and purity was determined by measuring the optical density at
260 and 280 nm. Different quantities of RNA (lung and prostate:
200 ng, ileum: 900 ng, all other tissues: 2,000 ng) were converted
into first strand cDNA using a First Strand cDNA synthesis kit
(Fermentas, Burlington, Canada) with random hexamer primers
according to the manufacturer’s protocol.
The relative expression levels of the mouse Nccrp1 gene in
several tissues were assessed by quantitative real-time PCR (QRT-
PCR) using the LightCycler detection system (Roche, Rotkreuz,
Switzerland). The primers (Table 2) were designed using Primer3
(http://frodo.wi.mit.edu/primer3/) and based on the complete
cDNA sequence deposited in GenBank. The specificity of the
primers was verified using NCBI Basic Local Alignment Search
Tool (BLAST) (http://blast.ncbi.nlm.nih.gov/Blast.cgi). The
housekeeping gene b-actin (Actb) was used as internal control to
normalize the cDNA samples for possible differences in quality
and quantity (Table 2).
Each PCR reaction was performed in a total volume of 20 ml
containing 1.0 ml of first strand cDNA, 16 QuantiTect SYBR
Green PCRMaster Mix (Qiagen, Hilden, Germany) and 0.5 mM of
each primer. Amplification and detection were conducted as
follows: after an initial 15 min activation step at 95uC, amplification
was performed in a three-step cycling procedure for 45 cycles
consisting of denaturation at 95uC for 15 s, annealing at a
temperature determined according to the Tm for each primer pair
for 20 s, and elongation at 72uC for 15 s (the ramp rate was 20uC/s
for all the steps), and a final cooling step was performed. Melting
curve analysis was always performed after the amplification to check
the specificity of the PCR reaction. To quantify the levels of
transcripts in the cell lines studied, a standard curve was established
for each gene using five-fold serial dilutions of known concentrations
of purified PCR products generated with the same primer pairs.
Each cDNA sample was tested in triplicate, and the crossing point
(Cp) value obtained allowed the levels of the starting mRNA to be
determined using a specific standard curve. The relative mRNA
expression was calculated as the copy number of the target gene
divided by the corresponding normalization factor and multiplied
by 103. Median values were calculated from the technical triplicates.
The effect of growth factors and deferoxamine mesylate
on mRNA expression of NCCRP1
HeLa cells were grown in 75 cm2 flasks in a 37uC incubator
with humidified 5% CO2/95% air. When the cultured cells
reached 80–90% confluence, they were trypsinized and plated in
58 cm2 dishes at a density of 1 million cells per dish. After
24 hours, the medium was replaced with fresh medium containing
recombinant human transforming growth factor-alpha (TGF-a;
10 ng/ml), recombinant human transforming growth factor-beta 1
(TGF-b1; 10 ng/ml), recombinant human epidermal growth
factor (EGF; 10 ng/ml), or deferoxamine mesylate (200 mM), an
iron chelator commonly used to induce the hypoxia regulatory
pathway. Normal medium was added to control plates. TGF-b1
and EGF were purchased from ProSpec-Tany TechnoGene Ltd.
(Rehovot, Israel). TGF-a was purchased from PromoCell GmbH
(Heidelberg, Germany). Deferoxamine mesylate was obtained
from Sigma-Aldrich Finland Oy (Helsinki, Finland). The chem-
icals were diluted as necessary according to the manufacturers’
instructions. The cells were incubated for 72 hours, after which
they were harvested and total RNA was extracted using an
RNeasy RNA isolation kit. For each sample, 850 ng of RNA
was converted into first strand cDNA by reverse transcription
and QRT-PCR was performed as described above. The primers
for human NCCRP1 and CA9 were designed using Primer3 and
the primers for the housekeeping gene ubiquitin C (UBC)
were obtained from the RTprimerDB database (http://www.
rtprimerdb.org/) under the identification number 8 (Table 2). The
median values were calculated from the technical triplicates for the
QRT-PCR experiments. Subsequently, the median values for
treatments were compared to the median values for negative
controls.
Table 2. QRT-PCR primer sequences used in this study.
Gene symbol Description GenBank number Forward primer (59-39) Reverse primer (59-39)
Nccrp1 Mus musculus non-specific
cytotoxic cell receptor
protein 1
homolog(zebrafish)
NM_001081115 GCTGCATGTCTGGCTGTTAG ATGCGGTTCTTAGCCTTGTG
Actb Mus musculus actin, beta NM_007393 AGAGGGAAATCGTGCGTGAC CAATAGTGATGACCTGGCCGT
NCCRP1 Homo sapiens non-specific
cytotoxic cell receptor
protein 1
homolog(zebrafish)
NM_001001414 TTCCGTGGCTGGTACATTAG ATGGCTGGTTGTTCGTCATC
CA9 Homo sapiens carbonic
anhydrase IX
NM_001216 ATGAGAAGGCAGCACAGAAG TAATGAGCAGGACAGGACAG
UBC Homo sapiens ubiquitin C NM_021009 ATTTGGGTCGCGGTTCTTG TGCCTTGACATTCTCGATGGT
GAPDH Homo sapiens
glyceraldehyde-3-
phosphate dehydrogenase
NM_002046 TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG
doi:10.1371/journal.pone.0027152.t002
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Expression of CA9 and NCCRP1 in human pancreatic and
breast cancer cell lines
To examine the co-expression of human CA9 and NCCRP1 in
tumor cells, transcript levels were measured in 16 pancreatic and
21 breast cancer cell lines using QRT-PCR. Total RNA was
isolated from the cell lines using TRIzol reagent (Invitrogen,
Carlsbad, CA), and 5 mg of each RNA sample was converted into
first strand cDNA using SuperScript III First-Strand Synthesis kit
(Invitrogen) according to the manufacturer’s instructions. QRT-
PCR reactions were performed as described above, with the
exception that each cDNA sample was tested only once. The
housekeeping gene glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used as a reference (Table 2). The final relative
mRNA expression was calculated as the copy number of the target
gene divided by the corresponding normalization factor, multi-
plied by 104.
NCCRP1 and CA9 silencing
The human NCCRP1 and CA9 genes were silenced using specific
ON-TARGETplus SMARTpool small interfering RNAs (siRNAs)
(Thermo Fisher Scientific, Lafayette, CO). The catalog numbers
for NCCRP1 and CA9 SMARTpools are L-032307-01-0005 and L-
005244-00-0005, respectively. U373 cells, HeLa cells and
Su.86.86 cells were transfected with the siRNAs using INTER-
FERinTM reagent (PolyPlus-transfection, Illkirch, France) accord-
ing to the manufacturer’s instructions. Transfections were
performed in 24-well plates with the desired cell density (25,000
cells per well for U373 and HeLa cells and 50,000 cells per well for
Su.86.86 cells). Final concentrations of 10 nM for CA9 siRNA and
30 nM for NCCRP1 siRNA were used. Parallel control experi-
ments using siRNA targeting the firefly luciferase (PPYLUC) gene
were also performed. The sequence of the PPYLUC siRNA was 59-
GAUUUCGAGUCGUCUUAAUTT-39. All siRNA experiments
were performed in triplicate and repeated twice. Gene silencing
was verified each time using QRT-PCR as described above. The
housekeeping gene glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used as a reference (Table 2). Median values were
calculated from the triplicate QRT-PCR experiments, and the
median values for NCCRP1 or CA9 siRNA-treated cells were
compared to the median values for luciferase control siRNA-treated
cells to estimate the efficacy of silencing.
Cell growth analyses
For cell growth analyses, 15,000 HeLa cells per well were
transfected with NCCRP1 SMARTpool siRNAs or luciferase control
siRNA as described above. Cell growth was analyzed at 48, 96,
and 144 hours after transfection.
From each well, 464 fields were photographed using Olympus
IX71 microscope with a 1006 objective. Quantitative analysis of
the captured images was performed using the public domain
image processing software ImageJ (http://rsbweb.nih.gov/ij/). A
custom-made algorithm was developed for the analysis; it first
identified the cellular area of the sample image at each time point
and then measured the relative change in the cellular area
percentage over the sample-specific time course.
Statistical analyses
For the cell growth analyses, the Mann-Whitney test was used to
evaluate differences in group values for NCCRP1 SMARTpool
siRNA-treated HeLa cells vs. luciferase control siRNA-treated HeLa
cells.
Ethics statement
The animal protocols were approved by the Animal Care and
Use Committee of the University of Oulu (Permit Number: 085/
07).
Supporting Information
Figure S1 A search result against the SwissProt data-
base for trypsin digestion of recombinant human
NCCRP1. A search against the SwissProt database gave an
unambiguous hit for human NCCRP1 (NCRP1_HUMAN) with a
Mowse score of 370.
(PDF)
Acknowledgments
The authors thank Mrs. Ritva Romppanen for her skillful technical
assistance.
Author Contributions
Conceived and designed the experiments: HK PP EL AK JV S. Parkkila.
Performed the experiments: HK MT JJ. Analyzed the data: HK MT JJ.
Contributed reagents/materials/analysis tools: SK VJT JI S. Pastorekova
JP. Wrote the paper: HK MT JJ.
References
1. Hilvo M, Baranauskiene L, Salzano AM, Scaloni A, Matulis D, et al. (2008)
Biochemical characterization of CA IX, one of the most active carbonic
anhydrase isozymes. J Biol Chem 283: 27799–27809.
2. Alterio V, Hilvo M, Di Fiore A, Supuran CT, Pan P, et al. (2009) Crystal
structure of the catalytic domain of the tumor-associated human carbonic
anhydrase IX. Proc Natl Acad Sci U S A 106: 16233–16238.
3. Neri D, Supuran CT (2011) Interfering with pH regulation in tumours as a
therapeutic strategy. Nat Rev Drug Discov 10: 767–777.
4. Pastorekova S, Zavada J (2004) Carbonic anhydrase IX (CA IX) as a potential
target for cancer therapy. Cancer Therapy 2: 245–262.
5. Ortova Gut MO, Parkkila S, Vernerova Z, Rohde E, Zavada J, et al. (2002)
Gastric hyperplasia in mice with targeted disruption of the carbonic anhydrase
gene Car9. Gastroenterology 123: 1889–1903.
6. Kallio H, Hilvo M, Rodriguez A, Lappalainen EH, Lappalainen AM, et al.
(2010) Global transcriptional response to carbonic anhydrase IX deficiency in
the mouse stomach. BMC Genomics 11: 397.
7. Jaso-Friedmann L, Leary JH, 3rd, Evans DL (1997) NCCRP-1: a novel receptor
protein sequenced fromteleost nonspecific cytotoxic cells.Mol Immunol 34: 955–965.
8. Evans DL, Leary JH, 3rd, Jaso-Friedmann L (1998) Nonspecific cytotoxic cell
receptor protein-1: a novel (predicted) type III membrane receptor on the teleost
equivalent of natural killer cells recognizes conventional antigen. Cell Immunol 187:
19–26.
9. Ishimoto Y, Savan R, Endo M, Sakai M (2004) Non-specific cytotoxic cell
receptor (NCCRP)-1 type gene in tilapia (Oreochromis niloticus): its cloning and
analysis. Fish Shellfish Immunol 16: 163–172.
10. Cuesta A, Esteban MA, Meseguer J (2005) Molecular characterization of the
nonspecific cytotoxic cell receptor (NCCRP-1) demonstrates gilthead seabream
NCC heterogeneity. Dev Comp Immunol 29: 637–650.
11. Sakata H, Savan R, Sogabe R, Kono T, Taniguchi K, et al. (2005) Cloning
and analysis of non-specific cytotoxic cell receptor (NCCRP)-1 from common
carp Cyprinus carpio L. Comp Biochem Physiol C Toxicol Pharmacol 140:
287–294.
12. Jaso-Friedmann L, Peterson DS, Gonzalez DS, Evans DL (2002) The antigen
receptor (NCCRP-1) on catfish and zebrafish nonspecific cytotoxic cells belongs
to a new gene family characterized by an F-box-associated domain. J Mol Evol
54: 386–395.
13. Jaso-Friedmann L, Leary JH, 3rd, Evans DL (2001) The non-specific cytotoxic
cell receptor (NCCRP-1): molecular organization and signaling properties. Dev
Comp Immunol 25: 701–711.
14. Kipreos ET, Pagano M (2000) The F-box protein family. Genome Biol 1:
REVIEWS3002.
15. Glenn KA, Nelson RF, Wen HM, Mallinger AJ, Paulson HL (2008) Diversity in
tissue expression, substrate binding, and SCF complex formation for a lectin
family of ubiquitin ligases. J Biol Chem 283: 12717–12729.
Characterization of NCCRP1
PLoS ONE | www.plosone.org 15 November 2011 | Volume 6 | Issue 11 | e27152
16. Reimers K, Abu Qarn M, Allmeling C, Bucan V, Vogt PM (2006) Identification
of the non-specific cytotoxic cell receptor protein 1 (NCCRP1) in regenerating
axolotl limbs. J Comp Physiol B 176: 599–605.
17. Mizushima T, Yoshida Y, Kumanomidou T, Hasegawa Y, Suzuki A, et al.
(2007) Structural basis for the selection of glycosylated substrates by SCF(Fbs1)
ubiquitin ligase. Proc Natl Acad Sci U S A 104: 5777–5781.
18. Yoshida Y (2007) F-box proteins that contain sugar-binding domains. Biosci
Biotechnol Biochem 71: 2623–2631.
19. Zhang L, Hou Y, Wang M, Wu B, Li N (2009) A study on the functions of
ubiquitin metabolic system related gene FBG2 in gastric cancer cell line. J Exp
Clin Cancer Res 28: 78.
20. Flicek P, Aken BL, Ballester B, Beal K, Bragin E, et al. (2010) Ensembl’s 10th
year. Nucleic Acids Res 38: D557–562.
21. Jain E, Bairoch A, Duvaud S, Phan I, Redaschi N, et al. (2009) Infrastructure for
the life sciences: design and implementation of the UniProt website. BMC
Bioinformatics 10: 136.
22. Benson DA, Karsch-Mizrachi I, Lipman DJ, Ostell J, Sayers EW (2011)
GenBank. Nucleic Acids Res 39: D32–37.
23. Pruitt KD, Tatusova T, Klimke W, Maglott DR (2009) NCBI Reference
Sequences: current status, policy and new initiatives. Nucleic Acids Res 37:
D32–36.
24. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, et al. (1997) Gapped
BLAST and PSI-BLAST: a new generation of protein database search
programs. Nucleic Acids Res 25: 3389–3402.
25. Thompson JD, Higgins DG, Gibson TJ (1994) CLUSTAL W: improving the
sensitivity of progressive multiple sequence alignment through sequence
weighting, position-specific gap penalties and weight matrix choice. Nucleic
Acids Res 22: 4673–4680.
26. Katoh K, Kuma K, Toh H, Miyata T (2005) MAFFT version 5: improvement in
accuracy of multiple sequence alignment. Nucleic Acids Res 33: 511–518.
27. Hunter S, Apweiler R, Attwood TK, Bairoch A, Bateman A, et al. (2009)
InterPro: the integrative protein signature database. Nucleic Acids Res 37:
D211–215.
28. Emanuelsson O, Brunak S, von Heijne G, Nielsen H (2007) Locating proteins in
the cell using TargetP, SignalP and related tools. Nat Protoc 2: 953–971.
29. Cheng J, Sweredoski M, Baldi P (2005) Accurate Prediction of Protein
Disordered Regions by Mining Protein Structure Data. Data Mining and
Knowledge Discovery 11: 213–222.
30. Tamura K, Dudley J, Nei M, Kumar S (2007) MEGA4: Molecular Evolutionary
Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 24: 1596–1599.
31. Bootorabi F, Janis J, Valjakka J, Isoniemi S, Vainiotalo P, et al. (2008)
Modification of carbonic anhydrase II with acetaldehyde, the first metabolite of
ethanol, leads to decreased enzyme activity. BMC Biochem 9: 32.
32. Pastorekova S, Zavadova Z, Kostal M, Babusikova O, Zavada J (1992) A novel
quasi-viral agent, MaTu, is a two-component system. Virology 187: 620–626.
33. Kilpinen S, Autio R, Ojala K, Iljin K, Bucher E, et al. (2008) Systematic
bioinformatic analysis of expression levels of 17,330 human genes across 9,783
samples from 175 types of healthy and pathological tissues. Genome Biol 9:
R139.
34. Autio R, Kilpinen S, Saarela M, Kallioniemi O, Hautaniemi S, et al. (2009)
Comparison of Affymetrix data normalization methods using 6,926 experiments
across five array generations. BMC Bioinformatics 10 Suppl 1: S24.
Characterization of NCCRP1
PLoS ONE | www.plosone.org 16 November 2011 | Volume 6 | Issue 11 | e27152
